Cover Page
Cover Page - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Feb. 20, 2023 | Jun. 30, 2022 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2022 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Transition Report | false | ||
Entity File Number | 001-35092 | ||
Entity Registrant Name | EXACT SCIENCES CORPORATION | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Address, Address Line One | 5505 Endeavor Lane | ||
Entity Address, City or Town | Madison | ||
Entity Address, State or Province | WI | ||
Entity Tax Identification Number | 02-0478229 | ||
Entity Address, Postal Zip Code | 53719 | ||
City Area Code | 608 | ||
Local Phone Number | 284‑5700 | ||
Title of 12(b) Security | Common Stock, $0.01 Par Value | ||
Trading Symbol | EXAS | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Entity Shell Company | false | ||
Entity Public Float | $ 6,905,065,031 | ||
Entity Common Stock, Shares Outstanding | 178,217,142 | ||
Documents Incorporated by Reference | The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days after the end of the fiscal year ended December 31, 2022. Portions of such proxy statement are incorporated by reference into Part III of this Form 10‑K. | ||
Entity Central Index Key | 0001124140 | ||
Amendment Flag | false | ||
Document Fiscal Year Focus | 2021 | ||
Document Fiscal Period Focus | FY |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2022 | |
Audit Information [Abstract] | |
Auditor Firm ID | 238 |
Auditor Name | PricewaterhouseCoopers LLP |
Auditor Location | Chicago, Illinois |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 242,493 | $ 315,471 |
Marketable securities | 389,564 | 715,005 |
Accounts receivable, net | 158,043 | 216,645 |
Inventory | 118,259 | 104,994 |
Prepaid expenses and other current assets | 73,898 | 74,122 |
Total current assets | 982,257 | 1,426,237 |
Long-term assets: | ||
Property, plant and equipment, net | 684,756 | 580,248 |
Operating lease right-of-use assets | 167,003 | 174,225 |
Goodwill | 2,346,040 | 2,335,172 |
Intangible assets, net | 1,956,240 | 2,094,411 |
Other long-term assets, net | 90,577 | 74,591 |
Total assets | 6,226,873 | 6,684,884 |
Current liabilities: | ||
Accounts payable | 74,916 | 67,829 |
Accrued liabilities | 299,216 | 398,556 |
Operating lease liabilities, current portion | 28,366 | 19,710 |
Other current liabilities | 10,249 | 30,973 |
Total current liabilities | 412,747 | 517,068 |
Convertible notes, net | 2,186,106 | 2,180,232 |
Long-term debt | 50,000 | 0 |
Other long-term liabilities | 352,459 | 417,782 |
Operating lease liabilities, less current portion | 182,399 | 182,166 |
Total liabilities | 3,183,711 | 3,297,248 |
3183711000 | ||
Stockholders’ equity: | ||
Preferred stock, $0.01 par value Authorized—5,000,000 shares issued and outstanding—no shares at December 31, 2022 and December 31, 2021 | 0 | 0 |
Common stock, $0.01 par value Authorized—400,000,000 shares issued and outstanding—177,925,631 and 173,674,067 shares at December 31, 2022 and December 31, 2021 | 1,780 | 1,738 |
Additional paid-in capital | 6,311,644 | 6,028,861 |
Accumulated other comprehensive loss | (5,236) | (1,443) |
Accumulated deficit | (3,265,026) | (2,641,520) |
Total stockholders’ equity | 3,043,162 | 3,387,636 |
Total liabilities and stockholders’ equity | $ 6,226,873 | $ 6,684,884 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, authorized shares (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, issued shares (in shares) | 0 | 0 |
Preferred stock, outstanding shares (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, authorized shares (in shares) | 400,000,000 | 400,000,000 |
Common stock, issued shares (in shares) | 177,925,631 | 173,674,067 |
Common stock, outstanding shares (in shares) | 177,925,631 | 173,674,067 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | |||
Revenue | $ 2,084,279 | $ 1,767,087 | $ 1,491,391 |
Operating expenses: | |||
Cost of sales (exclusive of amortization of acquired intangible assets) | 574,394 | 458,757 | 354,324 |
Research and development | 393,418 | 385,646 | 554,052 |
Sales and marketing | 846,011 | 861,889 | 589,919 |
General and administrative | 737,304 | 801,262 | 481,393 |
Amortization of acquired intangible assets | 97,450 | 95,001 | 93,398 |
Impairment of long-lived assets | 15,969 | 20,210 | 209,666 |
Total operating expenses | 2,664,546 | 2,622,765 | 2,282,752 |
Other operating income (loss) | (13,244) | 0 | 23,665 |
Loss from operations | (593,511) | (855,678) | (767,696) |
Other income (expense) | |||
Investment income (loss), net | (19,425) | 31,778 | 6,574 |
Interest expense | (19,634) | (18,606) | (67,941) |
Total other income (expense) | (39,059) | 13,172 | (61,367) |
Net loss before tax | (632,570) | (842,506) | (829,063) |
Income tax benefit | 9,064 | 246,881 | 5,458 |
Net loss | $ (623,506) | $ (595,625) | $ (823,605) |
Net loss per share - basic (in dollars per share) | $ (3.54) | $ (3.48) | $ (5.45) |
Net loss per share - diluted (in dollars per share) | $ (3.54) | $ (3.48) | $ (5.45) |
Weighted average common shares outstanding - basic (in shares) | 176,351 | 171,348 | 151,137 |
Weighted average common shares outstanding - diluted (in shares) | 176,351 | 171,348 | 151,137 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Statement of Comprehensive Income [Abstract] | |||
Net loss | $ (623,506) | $ (595,625) | $ (823,605) |
Other comprehensive loss, before tax: | |||
Unrealized gain (loss) on available-for-sale investments | (3,823) | (2,162) | 771 |
Foreign currency adjustment | 30 | 23 | 25 |
Comprehensive loss, before tax | (627,299) | (597,764) | (822,809) |
Income tax benefit (expense) related to items of other comprehensive loss | 0 | 170 | (170) |
Comprehensive loss, net of tax | $ (627,299) | $ (597,594) | $ (822,979) |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands | Total | Common Stock | Additional Paid In Capital | Accumulated Other Comprehensive Income (Loss) | Accumulated Deficit |
Beginning balance (in shares) at Dec. 31, 2019 | 147,625,696 | ||||
Beginning balance at Dec. 31, 2019 | $ 1,957,639 | $ 1,477 | $ 3,178,552 | $ (100) | $ (1,222,290) |
Increase (Decrease) in Stockholders' Equity | |||||
Exercise of common stock options (in shares) | 702,907 | ||||
Exercise of common stock options | 27,077 | $ 7 | 27,070 | ||
Issuance of common stock to fund the Company's 401(k) match (in shares) | 136,559 | ||||
Issuance of common stock to fund the Company’s 2019 401(k) match | 12,007 | $ 1 | 12,006 | ||
Compensation expense related to issuance of stock options and restricted stock awards (in shares) | 1,665,408 | ||||
Compensation expense related to issuance of stock options and restricted stock awards | 152,906 | $ 17 | 152,889 | ||
Purchase of employee stock purchase plan shares (in shares) | 301,064 | ||||
Purchase of employee stock purchase plan shares | 18,355 | $ 3 | 18,352 | ||
Issuance of common stock to fund business combinations (in shares) | 386,293 | ||||
Issuance of common stock for business combinations and asset acquisitions | 28,847 | $ 4 | 28,843 | ||
Issuance of common stock for registered direct offering (in shares) | 8,605,483 | ||||
Issuance of common stock for registered direct offering | 861,701 | $ 86 | 861,615 | ||
Net loss | (823,605) | (823,605) | |||
Other comprehensive income | 626 | 626 | |||
Ending balance (in shares) at Dec. 31, 2020 | 159,423,410 | ||||
Ending balance at Dec. 31, 2020 | 2,235,553 | $ 1,595 | 4,279,327 | 526 | (2,045,895) |
Increase (Decrease) in Stockholders' Equity | |||||
Conversion of convertible notes, net of tax (in shares) | 580 | ||||
Conversion of convertible notes, net of tax | 43 | 43 | |||
Exercise of common stock options (in shares) | 1,295,104 | ||||
Exercise of common stock options | 14,437 | $ 13 | 14,424 | ||
Issuance of common stock to fund the Company's 401(k) match (in shares) | 162,606 | ||||
Issuance of common stock to fund the Company’s 2019 401(k) match | 22,934 | $ 2 | 22,932 | ||
Compensation expense related to issuance of stock options and restricted stock awards (in shares) | 1,879,169 | ||||
Compensation expense related to issuance of stock options and restricted stock awards | 334,023 | $ 19 | 334,004 | ||
Purchase of employee stock purchase plan shares (in shares) | 331,769 | ||||
Purchase of employee stock purchase plan shares | 23,070 | $ 3 | 23,067 | ||
Issuance of common stock to fund business combinations (in shares) | 10,581,429 | ||||
Issuance of common stock for business combinations and asset acquisitions | 1,355,170 | $ 106 | 1,355,064 | ||
Net loss | (595,625) | (595,625) | |||
Other comprehensive income | $ (1,969) | (1,969) | |||
Ending balance (in shares) at Dec. 31, 2021 | 173,674,067 | 173,674,067 | |||
Ending balance at Dec. 31, 2021 | $ 3,387,636 | $ 1,738 | 6,028,861 | (1,443) | (2,641,520) |
Increase (Decrease) in Stockholders' Equity | |||||
Exercise of common stock options (in shares) | 706,593 | 706,134 | |||
Exercise of common stock options | $ 6,524 | $ 6 | 6,518 | ||
Issuance of common stock to fund the Company's 401(k) match (in shares) | 391,129 | ||||
Issuance of common stock to fund the Company’s 2019 401(k) match | 29,202 | $ 4 | 29,198 | ||
Compensation expense related to issuance of stock options and restricted stock awards (in shares) | 2,220,510 | ||||
Compensation expense related to issuance of stock options and restricted stock awards | 206,823 | $ 22 | 206,801 | ||
Purchase of employee stock purchase plan shares (in shares) | 668,605 | ||||
Purchase of employee stock purchase plan shares | 25,491 | $ 7 | 25,484 | ||
Issuance of common stock to fund business combinations (in shares) | 265,186 | ||||
Issuance of common stock for business combinations and asset acquisitions | 14,792 | $ 3 | 14,789 | ||
Other | (7) | (7) | |||
Net loss | (623,506) | (623,506) | |||
Other comprehensive income | $ (3,793) | (3,793) | |||
Ending balance (in shares) at Dec. 31, 2022 | 177,925,631 | 177,925,631 | |||
Ending balance at Dec. 31, 2022 | $ 3,043,162 | $ 1,780 | $ 6,311,644 | $ (5,236) | $ (3,265,026) |
Consolidated Statements of St_2
Consolidated Statements of Stockholders Equity (Parenthetical) - $ / shares | Dec. 31, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Cash flows from operating activities: | |||
Net loss | $ (623,506) | $ (595,625) | $ (823,605) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||
Depreciation | 100,108 | 85,345 | 69,964 |
Loss on disposal of property, plant and equipment | 1,863 | 1,055 | 2,470 |
Unrealized (gain) loss on equity investments | 11,774 | 1,492 | (1,179) |
Deferred tax benefit | (11,901) | (253,169) | (6,748) |
Stock-based compensation | 206,823 | 253,063 | 152,906 |
Post-combination expense for acceleration of unvested equity | 0 | 80,960 | 0 |
Realized (gain) loss on non-marketable investments | 10,000 | (30,500) | 0 |
Loss on settlement of convertible notes | 0 | 0 | 50,819 |
Amortization of deferred financing costs, convertible note debt discount and issuance costs, and other liabilities | 7,127 | 6,683 | 1,546 |
Amortization of premium on short-term investments | 1,845 | 4,618 | 1,549 |
Amortization of acquired intangible assets | 97,450 | 95,001 | 93,398 |
Asset acquisition IPR&D expense | 0 | 85,337 | 412,568 |
Loss on sale of asset | 13,244 | 0 | 0 |
Impairment of long-lived assets | 15,969 | 20,210 | 209,666 |
Remeasurement of contingent consideration | (56,617) | 6,360 | (323) |
Non-cash lease expense | 28,639 | 25,825 | 15,720 |
Changes in assets and liabilities, net of effects of acquisition: | |||
Accounts receivable, net | 61,088 | 25,150 | (100,526) |
Inventory, net | (13,231) | (9,221) | (30,310) |
Operating lease liabilities | (20,646) | (16,685) | (8,784) |
Accounts payable and accrued liabilities | (52,180) | 169,800 | 55,165 |
Other assets and liabilities | (1,408) | (57,935) | 42,186 |
Net cash provided by (used in) operating activities | (223,559) | (102,236) | 136,482 |
Cash flows from investing activities: | |||
Purchases of marketable securities | (131,486) | (1,164,050) | (1,089,953) |
Maturities of marketable securities | 453,072 | 794,322 | 886,675 |
Purchases of property, plant and equipment | (214,462) | (135,766) | (65,078) |
Proceeds from Sale of Productive Assets | 25,000 | 0 | 0 |
Investment in privately held companies | (42,823) | (18,044) | (15,947) |
Business combination, net of cash acquired and issuance costs | (14,686) | (499,730) | (6,658) |
Asset acquisitions, net of cash acquired | 0 | (58,073) | (411,421) |
Other investing activities | (549) | (744) | 345 |
Net cash provided by (used in) investing activities | 74,066 | (1,082,085) | (702,037) |
Cash flows from financing activities: | |||
Proceeds from issuance of convertible notes, net | 0 | 0 | 1,125,547 |
Proceeds from exercise of common stock options | 6,524 | 14,437 | 27,077 |
Proceeds from sale of common stock, net of issuance costs | 0 | 0 | 861,701 |
Proceeds in connection with the Company's employee stock purchase plan | 25,491 | 23,070 | 18,355 |
Payments on settlement of convertible notes | 0 | 0 | (150,054) |
Payments on construction loan | 0 | (23,749) | (1,250) |
Other financing activities | (5,530) | (5,286) | (1,755) |
Net cash provided by financing activities | 76,485 | 8,472 | 1,879,621 |
Effects of exchange rate changes on cash and cash equivalents | 30 | 23 | 0 |
Net increase (decrease) in cash, cash equivalents and restricted cash | (72,978) | (1,175,826) | 1,314,066 |
Cash, cash equivalents and restricted cash at the beginning of period | 315,768 | 1,491,594 | 177,528 |
Cash, cash equivalents and restricted cash at the end of period | 242,790 | 315,768 | 1,491,594 |
Supplemental disclosure of non-cash investing and financing activities: | |||
Property, plant and equipment acquired but not paid | 15,943 | 33,177 | 2,685 |
Business acquisition contingent consideration liability | 4,600 | 350,348 | 0 |
Supplemental disclosure of cash flow information: | |||
Interest paid | 11,519 | 10,735 | 9,384 |
Reconciliation of cash, cash equivalents and restricted cash: | |||
Cash and cash equivalents | 242,493 | 315,471 | 1,491,288 |
Restricted cash — included in prepaid expenses and other current assets as of December 31, 2022, and other long-term assets, net as of December 31, 2021 and 2020 | 297 | 297 | 306 |
Total cash, cash equivalents and restricted cash | 242,790 | 315,768 | 1,491,594 |
Proceeds from Accounts Receivable Securitization | $ 50,000 | $ 0 | $ 0 |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Exact Sciences Corporation (together with its subsidiaries, “Exact” or the “Company”) was incorporated in February 1995. Exact is a leading global cancer diagnostics company. It has developed some of the most impactful tests in cancer screening and diagnostics, including Cologuard ® and Oncotype DX ® . Exact is currently working on the development of additional tests, with the goal of bringing new innovative cancer tests to patients throughout the world. Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements include the accounts of Exact Sciences Corporation and those of its wholly-owned subsidiaries and variable interest entities. All intercompany transactions and balances have been eliminated upon consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company's financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, and accounting for income taxes among others. The spread of the coronavirus (“COVID-19”) has affected many segments of the global economy, including the cancer screening and diagnostics industry. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of December 31, 2021 and through the date of the filing of this Annual Report on Form 10-K. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, marketable and non-marketable investments, and the carrying value of the goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods. The pandemic and related precautionary measures began to materially disrupt the Company's operations in March 2020 and may continue to disrupt the business for an unknown period of time. As a result, the pandemic had an impact on the Company's revenues and operating results. The ultimate impact of COVID-19 depends on factors beyond the Company’s knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, the Company is unable to estimate the extent to which COVID-19 will negatively impact its financial results or liquidity. Cash and Cash Equivalents The Company considers cash on hand, demand deposits in a bank, money market funds, and all highly liquid investments with an original maturity of 90 days or less to be cash and cash equivalents. Marketable Securities Management determines the appropriate classification of debt securities at the time of purchase and re-evaluates such designation as of each balance sheet date. Debt securities carried at amortized cost are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities not classified as held-to-maturity are classified as available-for-sale. Available-for-sale securities are carried at fair value. The unrealized gains and losses, net of tax, on the Company's debt securities are reported in other comprehensive income. Marketable equity securities are measured at fair value and the unrealized gains and losses, net of tax, are recognized in other income (expense) in the consolidated statements of operations. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest rate method. Such amortization is included in investment income, net. Realized gains and losses and declines in value as a result of credit losses on available-for-sale securities are included in the consolidated statements of operations as investment income, net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in the consolidated statements of operations as investment income, net. The Company’s investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support its current operations (including those with a contractual term greater than one year from the date of purchase) are classified as current. The Company periodically evaluates its available-for-sale debt securities in unrealized loss positions to determine whether any impairment is a result of a credit loss or other factors. This evaluation includes, but is not limited to, significant quantitative and qualitative assessments and estimates regarding credit ratings, significance of a security’s loss position, adverse conditions specifically related to the security, and the payment structure of the security. Allowance for Doubtful Accounts The Company estimates an allowance for doubtful accounts against accounts receivable using historical collection trends, aging of accounts, current and future implications surrounding the ability to collect such as economic conditions, and regulatory changes. The allowance for doubtful accounts is evaluated on a regular basis and adjusted when trends, significant events, or other substantive evidence such as an adverse change in a payer's ability to pay indicate that expected collections will be less than previously estimated. At December 31, 2022 and 2021, the allowance for doubtful accounts recorded was not material to the Company's consolidated balance sheets. For the years ended December 31, 2022, 2021 and 2020, there was an immaterial amount of bad debt expense written off against the allowance and charged to operating expense. Inventory Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first out method (“FIFO”). The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale, no longer meet quality specifications, or has a cost basis in excess of its estimated realizable value and records a charge to cost of sales for such inventory as appropriate. Direct and indirect manufacturing costs incurred during process validation with probable future economic benefit are capitalized. Validation costs incurred for other research and development activities, which are not permitted to be sold, are expensed to research and development in the Company’s consolidated statements of operations. Property, Plant and Equipment Property, plant and equipment are stated at cost and depreciated using the straight-line method over the assets’ estimated useful lives. Land is stated at cost and does not depreciate. Additions and improvements are capitalized, including direct and indirect costs incurred to validate equipment and bring to working conditions. Revalidation costs, including maintenance and repairs are expensed when incurred. Software Development Costs Costs related to internal use software, including hosted arrangements, are incurred in three stages: the preliminary project stage, the application development stage, and the post-implementation stage. Costs incurred during the preliminary project and post-implementation stages are expensed as incurred. Costs incurred during the application development stage that meet the criteria for capitalization are capitalized and amortized, when the software is ready for its intended use, using the straight‑line method over the estimated useful life of the software, or the duration of the hosting agreement. Investments in Privately Held Companies The Company determines whether its investments in privately held companies are debt or equity based on their characteristics. The Company also evaluates the investee to determine if the entity is a variable interest entity (“VIE”) and, if so, whether the Company is the primary beneficiary of the VIE, in order to determine whether consolidation of the VIE is required. If consolidation is not required and the Company does not have voting control of the entity, the investment is evaluated to determine if the equity method of accounting should be applied. The equity method applies to investments in common stock or in substance common stock where the Company exercises significant influence over the investee. Investments in privately held companies determined to be equity securities are accounted for as non-marketable securities. The Company adjusts the carrying value of its non-marketable equity securities for changes from observable transactions for identical or similar investments of the same issuer, less impairment. All gains and losses on non-marketable equity securities, realized and unrealized, are recognized in investment income, net in the consolidated statements of operations. Investments in privately held companies determined to be debt securities are accounted for as available-for-sale or held-to-maturity securities unless the fair value option is elected. Derivative Financial Instruments The Company hedges a portion of its foreign currency exposures related to outstanding monetary assets and liabilities using foreign currency forward contracts. The foreign currency forward contracts are included in prepaid expenses and other current assets or in accrued liabilities in the consolidated balance sheets, depending on the contracts’ net position. These contracts are not designated as hedges, and as a result, changes in their fair value are recorded in other income (expense) in the consolidated statements of operations. Business Combinations and Asset Acquisitions Business Combinations are accounted for under the acquisition method in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations. The acquisition method requires identifiable assets acquired and liabilities assumed and any non-controlling interest in the business acquired be recognized and measured at fair value on the acquisition date, which is the date that the acquirer obtains control of the acquired business. The amount by which the fair value of consideration transferred as the purchase price exceeds the net fair value of assets acquired and liabilities assumed is recorded as goodwill. Acquisitions that do not meet the definition of a business combination under ASC 805 are accounted for as asset acquisitions. Asset acquisitions are accounted for by allocating the cost of the acquisition to the individual assets acquired and liabilities assumed on a relative fair value basis. Goodwill is not recognized in an asset acquisition with any consideration in excess of net assets acquired allocated to acquired assets on a relative fair value basis. Transaction costs are expensed in a business combination and are considered a component of the cost of the acquisition in an asset acquisition. Intangible Assets Purchased intangible assets are recorded at fair value. The Company uses a discounted cash flow model to value intangible assets. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital, terminal values and market participants. Patent costs are capitalized as incurred, only if the Company determines that there is some probable future economic benefit derived from the transaction. A capitalized patent is amortized over its estimated useful life, beginning when such patent is approved. Capitalized patent costs are expensed upon disapproval, upon a decision by the Company to no longer pursue the patent or when the related intellectual property is either sold or deemed to be no longer of value to the Company. The Company determined that all patent costs incurred during the years ended December 31, 2022, 2021 and 2020 should be expensed and not capitalized as the future economic benefit derived from the patent costs incurred cannot be determined. Acquired In-process Research and Development (“IPR&D”) Acquired IPR&D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and cost projections used to value acquired IPR&D are, as applicable, reduced based on the probability of success. IPR&D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development (“R&D”) efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. There are often major risks and uncertainties associated with IPR&D projects as the Company is required to obtain regulatory approvals in order to market the resulting products. Such approvals require completing clinical trials that demonstrate the product's effectiveness. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. Capitalized IPR&D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company considers various factors for potential impairment, including the current legal and regulatory environment, current and future strategic initiatives and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors' products could result in partial or full impairment of the related intangible assets. Contingent Consideration Liabilities Certain of the Company’s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain regulatory and product development milestones being achieved. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected probabilities of success, projected payment dates, present value-factors, and projected revenues (for revenue-based considerations). Changes in probabilities of success, present-value factors, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within general and administrative expenses on the Company’s consolidated statements of operations. Cash contingent consideration payments up to the acquisition date fair value of the contingent consideration liability are classified as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are classified as operating activities in the consolidated statements of cash flows. Collateralized Debt Instruments Debt instruments that are collateralized by security interests in financial assets held by the Company are accounted for as a secured borrowing and therefore: (i) the asset balances pledged as collateral are included within the applicable balance sheet line item and the borrowings are included within long-term debt in the consolidated balance sheet; (ii) interest expense is included within the consolidated statements of operations; and (iii) in the case of collateralized accounts receivable, receipts from customers related to the underlying accounts receivable are reflected as operating cash flows, and (iv) borrowings and repayments under the collateralized loans are reflected as financing cash flows within the consolidated statements of cash flows. Goodwill The Company evaluates goodwill for possible impairment at the reporting unit level on an annual basis during the fourth quarter, or more frequently if events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting the Company's business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Impairment of Long-Lived Assets The Company evaluates the fair value of long-lived assets, which include property, plant and equipment, leases, finite-lived intangible assets, and investments in privately held companies, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. Accounting for Government Assistance There is no GAAP that specifically addresses the accounting by business entities for government assistance and tax credits. Absent authoritative accounting standards, interpretative guidance issued and commonly applied by financial statement preparers allows for the selection of accounting policies amongst acceptable alternatives. Based on the facts and circumstances of the government assistance and tax credits received by the Company as discussed below, the Company determined it most appropriate to account for the these transactions by analogy to International Accounting Standards 20 (“IAS 20”), Accounting for Government Grants and Disclosure of Government Assistance. IAS 20 permits for the recognition in earnings either separately under a general heading such as other income, or as a reduction of the related expenses. In April 2020, the Company received $23.7 million from the United States Department of Health and Human Services (“HHS”) as a distribution from the Public Health and Social Services Emergency Fund provided for in the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The fund payments are grants, not loans, and HHS will not require repayment provided the funds are utilized to offset expenses incurred to address COVID-19 or to replace lost revenues. The Company accepted the terms and conditions of the grant in May 2020 and recognized the entire $23.7 million during the year ended December 31, 2020, due to lost revenue attributable to COVID-19. The Company has elected to recognize government grant income separately to present a clearer distinction in its consolidated financial statements between its operating income and the amount of income resulting from the CARES Act grant received. The Company believes this presentation method promotes greater comparability amongst all periods presented. Accordingly, the $23.7 million grant recognized during the year ended December 31, 2020 was reflected in other operating income in the consolidated statement of operations and as an operating activity in the consolidated statement of cash flows. In December 2021 the Company entered into an amended agreement with the Wisconsin Economic Development Corporation (“WEDC”) to earn refundable tax credits on the condition of certain capital investment and job creation requirements. The Company has elected to recognize the tax credits as a reduction of the related expenses, as they are earned through the performance of the Company’s ongoing operating activities. Net Loss Per Share Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share is the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive as a result of the Company’s losses. The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period: December 31, (In thousands) 2022 2021 2020 Shares issuable in connection with acquisitions — 45 157 Shares issuable upon exercise of stock options 1,518 2,284 2,231 Shares issuable upon the release of restricted stock awards 5,255 4,321 3,968 Shares issuable upon the release of performance share units 968 878 619 Shares issuable upon conversion of convertible notes 20,309 20,309 20,309 28,050 27,837 27,284 Accounting for Stock-Based Compensation The Company requires all share-based payments to employees, including grants of employee stock options, restricted stock, restricted stock units, shares purchased under an employee stock purchase plan (if certain parameters are not met), and performance share units to be recognized in the financial statements based on their grant date fair values. Forfeitures of any share-based awards are recognized as they occur. The fair values and recognition of the Company's share-based payment awards are determined as follows: The fair value of each service-based option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions: Expected Term —Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants. Expected Volatility —Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards. Risk-Free Interest Rate —The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent expected term. The estimated fair value of these awards is recognized to expense using the straight-line method over the requisite service period. The fair value of service-based awards for each restricted stock unit award is determined on the date of grant using the closing stock price on that day. The estimated fair value of these awards is recognized to expense using the straight-line method over the vesting period. The fair value of performance-based equity awards that do not include a market condition is determined on the date of grant using the closing stock price on that day. The fair value of performance-based equity awards that include a market condition is determined on the date of grant using a Monte Carlo valuation technique. The expense recognized each period is also dependent on the probability of what performance conditions will be met which is determined by management's evaluation of internal and external factors. Determining the appropriate amount to expense based on the anticipated achievement of the stated goals requires judgment, including forecasting future financial results. The estimate of the timing of the expense recognition is revised periodically based on the probability of achieving the goals and adjustments are made as appropriate. The cumulative impact of any revision is reflected in the period of the change. If the financial performance targets and operational milestones are not achieved, the award would not vest resulting in no stock-based compensation being recognized and any previously recognized stock-based compensation expense being reversed. Research and Development Costs Research and development costs are expensed as incurred. These expenses include the costs of the Company's proprietary research and development efforts, as well as costs of IPR&D projects acquired as part of an asset acquisition that have no alternative future use. Upfront and milestone payments due to third parties in connection with research and development collaborations prior to regulatory approval are expensed as incurred. Milestone payments due to third parties upon, or subsequent to, regulatory approval are capitalized and amortized into research and development costs over the shorter of the remaining license or product patent life, when there are no corresponding revenues related to the license or product. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received, rather than when the payment is made. The Company incurred research and development expenses of $393.4 million, $385.6 million, and $554.1 million during the years ended December 31, 2022, 2021, and 2020, respectively, including IPR&D of $85.3 million and $412.6 million that was acquired in asset acquisitions that had no alternative future use during the years ended December 31, 2021 and 2020, respectively. The value of the acquired IPR&D that was expensed was determined by identifying those acquired specific IPR&D projects that would be continued and which (a) were incomplete and (b) had no alternative future use. Acquired IPR&D assets that are acquired in an asset acquisition and which have no alternative future use are classified as an investing cash outflow in the consolidated statements of cash flows. Advertising Costs The Company expenses the costs of media advertising at the time the advertising takes place. The Company expensed approximately $170.3 million, $144.0 million, and $97.6 million of media advertising during the years ended December 31, 2022, 2021, and 2020, respectively, which is recorded in sales and marketing expenses on the Company's consolidated statements of operations. Fair Value Measurements The Financial Accounting Standards Board (“FASB”) has issued authoritative guidance that requires fair value to be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. Under that standard, fair value measurements are separately disclosed by level within the fair value hierarchy. The fair value hierarchy establishes and prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs. Observable inputs are inputs that reflect the assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. Leases The Company acts as lessee in its lease agreements, which include operating leases for corporate offices, laboratory space, warehouse space, vehicles, and certain laboratory and office equipment, and finance leases for certain equipment and vehicles. The Company determines whether an arrangement is, or contains, a lease at inception. At the beginning of fiscal year 2019, the company adopted ASC 842. The Company records the present value of lease payments as right-of-use (“ROU”) assets and lease liabilities on the consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company’s obligations. As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the US. Treasury rate and an indicative Moody's rating for operating leases or finance leases. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. “Reasonably certain” is assessed internally based on economic, industry, company, strategic and contractual factors. The leases have remaining lease terms of 1 year to 15 years, some of which include options to extend the lease for up to 10 years, and some of which include options to terminate the lease within 1 year. Operating lease expense and amortization of finance lease ROU assets are recognized on a straight-line basis over the lease term as an operating expense. Finance lease interest expense is recorded as interest expense on the Company’s consolidated statements of operations. The Company accounts for leases acquired in business combinations by measuring the lease liability at the present value of the remaining lease payments as if the acquired lease were a new lease for the Company. This measurement includes recognition of a lease intangible for any below-market terms present in the leases acquired. The below-market lease intangible is included in the ROU asset on the consolidated balance sheets and are amortized over the remaining lease term. The Company has not acquired any leases with above-market terms. The Company has taken advantage of certain practical expedients offered to registrants at adoption of ASC 842. The Company does not apply the recognition requirements of ASC 842 to short-term leases. Instead, those lease payments are recognized in profit or loss on a straight-line basis over the lease term. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract. Revenue Recognition Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard, Oncotype, PreventionGenetics, and COVID-19 tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider. To determine reve |
REVENUE
REVENUE | 12 Months Ended |
Dec. 31, 2022 | |
Revenue from Contract with Customer [Abstract] | |
REVENUE | REVENUE The following table presents the Company's revenues disaggregated by revenue source: Year Ended December 31, (In thousands) 2022 2021 2020 Screening Medicare Parts B & C $ 545,458 $ 438,646 $ 365,471 Commercial 743,238 569,944 409,671 Other 136,007 53,718 39,925 Total Screening 1,424,703 1,062,308 815,067 Precision Oncology Medicare Parts B & C $ 197,327 $ 197,394 $ 165,799 Commercial 177,518 180,177 153,410 International 117,738 109,913 77,484 Other 108,905 74,192 43,800 Total Precision Oncology 601,488 561,676 440,493 COVID-19 Testing $ 58,088 $ 143,103 $ 235,831 Total $ 2,084,279 $ 1,767,087 $ 1,491,391 Screening revenue primarily includes laboratory service revenue from Cologuard and PreventionGenetics, LLC (“PreventionGenetics”) tests while Precision Oncology revenue includes laboratory service revenue from global Oncotype products and therapy selection products. At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. The Company recognized revenue from a change in transaction price of $20.3 million for the year ended December 31, 2022. The Company recorded a downward adjustment to revenue from a change in transaction price of $11.8 million for the year ended December 31, 2021. The Company recognized revenue from a change in transaction price of $9.6 million for the year ended December 31, 2020. The Company had deferred revenue of $3.1 million and $1.0 million as of December 31, 2022 and 2021, respectively. Deferred revenue is reported in other current liabilities in the Company’s consolidated balance sheets. |
MARKETABLE SECURITIES
MARKETABLE SECURITIES | 12 Months Ended |
Dec. 31, 2022 | |
Cash and Cash Equivalents [Abstract] | |
MARKETABLE SECURITIES | MARKETABLE SECURITIES The following table sets forth the Company’s cash, cash equivalents, and marketable securities at December 31, 2022 and 2021: December 31, (In thousands) 2022 2021 Cash and cash equivalents Cash and money market $ 178,168 $ 247,335 Cash equivalents 64,325 68,136 Total cash and cash equivalents 242,493 315,471 Marketable securities Available-for-sale debt securities $ 384,415 $ 711,669 Equity securities 5,149 3,336 Total marketable securities 389,564 715,005 Total cash, cash equivalents, and marketable securities $ 632,057 $ 1,030,476 Available-for-sale debt securities, including the classification within the consolidated balance sheet at December 31, 2022, consisted of the following: (In thousands) Amortized Cost Gains in Accumulated Other Comprehensive Income (Loss) (1) Losses in Accumulated Other Comprehensive Income (Loss) (1) Estimated Fair Value Cash equivalents Commercial paper $ 63,021 $ — $ — $ 63,021 U.S. government agency securities 1,304 — — 1,304 Total cash equivalents 64,325 — — 64,325 Marketable securities U.S. government agency securities $ 228,012 $ — $ (2,789) $ 225,223 Corporate bonds 116,318 20 (1,667) 114,671 Asset backed securities 45,374 2 (855) 44,521 Total marketable securities 389,704 22 (5,311) 384,415 Total available-for-sale debt securities $ 454,029 $ 22 $ (5,311) $ 448,740 _________________________________ (1) Gains and losses in accumulated other comprehensive loss (“AOCI”) are reported before tax impact. Available-for-sale debt securities, including the classification within the consolidated balance sheet at December 31, 2021, consisted of the following: (In thousands) Amortized Cost Gains in Accumulated Other Comprehensive Income (Loss) (1) Losses in Accumulated Other Comprehensive Income (Loss) (1) Estimated Fair Value Cash equivalents Commercial paper $ 64,593 $ — $ — $ 64,593 U.S. government agency securities 3,543 — — 3,543 Total cash equivalents 68,136 — — 68,136 Marketable securities Corporate bonds $ 313,634 $ 13 $ (493) $ 313,154 U.S. government agency securities 250,793 — (873) 249,920 Asset backed securities 94,565 2 (107) 94,460 Certificates of deposit 47,147 2 (10) 47,139 Commercial paper 6,996 — — 6,996 Total marketable securities 713,135 17 (1,483) 711,669 Total available-for-sale debt securities $ 781,271 $ 17 $ (1,483) $ 779,805 _________________________________ (1) Gains and losses in AOCI are reported before tax impact. The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at December 31, 2022: Due one year or less Due after one year through five years (In thousands) Cost Fair Value Cost Fair Value Cash equivalents Commercial paper $ 63,021 $ 63,021 $ — $ — U.S. government agency securities 1,304 1,304 — — Total cash equivalents 64,325 64,325 — — Marketable securities U.S. government agency securities $ 218,364 $ 215,620 $ 9,648 $ 9,603 Corporate bonds 90,368 89,102 25,950 25,569 Asset backed securities — — 45,374 44,521 Total marketable securities 308,732 304,722 80,972 79,693 Total available-for-sale securities $ 373,057 $ 369,047 $ 80,972 $ 79,693 The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of December 31, 2022, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position: Less than 12 months 12 months or greater Total (In thousands) Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Marketable securities U.S. government agency securities $ 37,458 $ (337) $ 187,766 $ (2,452) $ 225,224 $ (2,789) Corporate bonds 35,055 (575) 73,702 (1,092) 108,757 (1,667) Asset backed securities 27,984 (735) 15,536 (120) 43,520 (855) Total available-for-sale securities $ 100,497 $ (1,647) $ 277,004 $ (3,664) $ 377,501 $ (5,311) The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of December 31, 2021, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position: Less than 12 months 12 months or greater Total (In thousands) Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Marketable securities Corporate bonds $ 299,448 $ (493) $ — $ — $ 299,448 $ (493) U.S. government agency securities 249,921 (873) — — 249,921 (873) Asset backed securities 89,990 (107) — — 89,990 (107) Certificates of deposit 24,137 (10) — — 24,137 (10) Total available-for-sale securities $ 663,496 $ (1,483) $ — $ — $ 663,496 $ (1,483) The Company evaluates investments that are in an unrealized loss position for impairment as a result of credit loss. It was determined that no credit losses exist as of December 31, 2022 and 2021 because the change in market value for those securities in an unrealized loss position has resulted from fluctuating interest rates rather than a deterioration of the credit worthiness of the issuers. The gains and losses recorded on available-for-sale debt securities and equity securities are included in investment income, net in the Company’s consolidated statements of operations. The gains and losses recorded were not significant for the years ended December 31, 2022, 2021, and 2020. |
INVENTORY
INVENTORY | 12 Months Ended |
Dec. 31, 2022 | |
Inventory Disclosure [Abstract] | |
INVENTORY | INVENTORY Inventory consisted of the following: December 31, (In thousands) 2022 2021 Raw materials $ 61,207 $ 51,321 Semi-finished and finished goods 57,052 53,673 Total inventory $ 118,259 $ 104,994 |
PROPERTY, PLANT AND EQUIPMENT
PROPERTY, PLANT AND EQUIPMENT | 12 Months Ended |
Dec. 31, 2022 | |
Property, Plant and Equipment [Abstract] | |
PROPERTY, PLANT AND EQUIPMENT | PROPERTY, PLANT AND EQUIPMENT The carrying value and estimated useful lives of property, plant and equipment are as follows: December 31, (In thousands) Estimated Useful Life 2022 2021 Property, plant and equipment Land n/a $ 4,716 $ 4,716 Leasehold and building improvements (1) 200,588 147,083 Land improvements 15 years 6,417 5,206 Buildings 30 - 40 years 288,941 210,560 Computer equipment and computer software 3 years 142,896 109,119 Laboratory equipment 3 - 10 years 246,344 189,748 Furniture and fixtures 3 - 10 years 34,047 28,293 Assets under construction n/a 68,398 100,339 Property, plant and equipment, at cost 992,347 795,064 Accumulated depreciation (307,591) (214,816) Property, plant and equipment, net $ 684,756 $ 580,248 _________________________________ (1) Lesser of remaining lease term, building life, or estimated useful life. Depreciation expense for the years ended December 31, 2022, 2021, and 2020 was $100.1 million, $85.3 million, and $70.0 million, respectively. |
INTANGIBLE ASSETS AND GOODWILL
INTANGIBLE ASSETS AND GOODWILL | 12 Months Ended |
Dec. 31, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
INTANGIBLE ASSETS AND GOODWILL | INTANGIBLE ASSETS AND GOODWILL Intangible Assets The following table summarizes the net-book-value and estimated remaining life of the Company's intangible assets as of December 31, 2022: (In thousands) Weighted Average Remaining Life (Years) Cost Accumulated Amortization Net Balance at December 31, 2022 Finite-lived intangible assets Trade name 12.5 $ 104,000 $ (20,653) $ 83,347 Customer relationships 8.0 4,000 (444) 3,556 Patents and licenses 4.2 11,542 (8,152) 3,390 Acquired developed technology (1) 7.8 861,474 (245,527) 615,948 Total finite-lived intangible assets 981,016 (274,776) 706,240 In-process research and development n/a 1,250,000 — 1,250,000 Total intangible assets $ 2,231,016 $ (274,776) $ 1,956,240 _________________________________ (1) The gross carrying amount includes an immaterial foreign currency translation adjustment related to the intangible assets acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”), whose functional currency is also its local currency. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income. The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2021: (In thousands) Weighted Average Remaining Life (Years) Cost Accumulated Amortization Net Balance at December 31, 2021 Finite-lived intangible assets Trade name 13.4 $ 104,700 $ (13,554) $ 91,146 Customer relationships 9.6 6,700 (1,577) 5,123 Patents and licenses 3.6 10,942 (6,763) 4,179 Supply agreement 5.4 2,295 (101) 2,194 Acquired developed technology 8.6 918,171 (176,402) 741,769 Total finite-lived intangible assets 1,042,808 (198,397) 844,411 In-process research and development n/a 1,250,000 — 1,250,000 Total intangible assets $ 2,292,808 $ (198,397) $ 2,094,411 As of December 31, 2022, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows: (In thousands) 2023 $ 91,713 2024 91,379 2025 90,331 2026 89,271 2027 89,271 Thereafter 254,275 Total $ 706,240 The Company’s acquired intangible assets are being amortized on a straight-line basis over the estimated useful life. On August 2, 2022, the Company completed a sale of the developed technology intangible asset related to the Oncotype DX Genomic Prostate Score test (“GPS test”) to MDxHealth SA (“MDxHealth”), which was measured using the income approach to determine the fair value. The gross value of the intangible asset was $59.0 million with accumulated amortization of $16.1 million as of the closing date, resulting in a carrying value of $42.9 million, which was derecognized from intangible assets, net in the consolidated balance sheets upon completion of the divestiture. Refer to Note 18 for further information on this sale. During the third quarter of 2022, the remaining carrying value of $2.0 million related to the supply agreement intangible asset acquired as part of the combination with Genomic Health, Inc. (“Genomic Health”) was recorded as a non-cash, pre-tax impairment loss due to the termination of the agreement. The Company previously recorded a non-cash, pre-tax impairment loss of $20.2 million during the third quarter of 2021 due to lower than anticipated performance of the underlying product. During the second quarter of 2022, the remaining carrying value of $6.6 million related to the developed technology intangible asset acquired as a result of the acquisition of Paradigm Diagnostics, Inc. was recorded a non-cash, pre-tax impairment loss due to lower than anticipated performance of the underlying product. During the third quarter of 2020, the carrying value of $200.0 million related to the IPR&D intangible asset acquired as a result of the acquisition of Genomic Health was recorded a non-cash, pre-tax impairment loss. The Company began discussions with Biocartis during the third quarter of 2020 regarding the termination of its agreements with Biocartis related to the development of an in vitro diagnostic (“IVD”) version of the Oncotype DX Breast Recurrence Score ® test, and the agreements were ultimately terminated in November 2020. During the third quarter of 2020, the remaining carrying value of $9.7 million related to certain research and development assets acquired in 2017 through an asset purchase agreement with Armune Biosciences, Inc. was recorded a non-cash, pre-tax impairment loss These assets were expected to complement the Company’s product pipeline and were expected to have alternative future uses at the time of acquisition; however, due to changes in strategic priorities and efforts during the third quarter of 2020, these assets are no longer expected to be utilized to advance the Company’s product pipeline. The Company utilized the income approach to measure the fair value of the impaired intangible assets, which involved significant unobservable inputs (Level 3 inputs), including revenue projections, cash flow projections, and discount rates. The impairment charges recorded are included in impairment of long-lived assets in the consolidated statements of operations. Goodwill The change in the carrying amount of goodwill for the years ended December 31, 2022 and 2021 is as follows: (In thousands) Balance, January 1, 2021 $ 1,237,672 Thrive Earlier Detection Corporation (“Thrive”) acquisition 948,105 Ashion Analytics, LLC (“Ashion”) acquisition 56,758 PreventionGenetics acquisition 92,637 Balance, December 31, 2021 2,335,172 OmicEra Acquisition 10,809 PreventionGenetics acquisition adjustment (58) Effects of changes in foreign currency exchange rates (1) 117 Balance, December 31, 2022 $ 2,346,040 _________________________________ (1) Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra. Goodwill balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income. |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 12 Months Ended |
Dec. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
FAIR VALUE MEASUREMENTS | FAIR VALUE MEASUREMENTS The three levels of the fair value hierarchy established are as follows: Level 1 Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3 Unobservable inputs that reflect the Company’s assumptions about the assumptions that market participants would use in pricing the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available. The following table presents the Company’s fair value measurements as of December 31, 2022 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall. (In thousands) Fair value at December 31, 2022 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash, cash equivalents, and restricted cash Cash and money market $ 178,168 $ 178,168 $ — $ — Commercial paper 63,021 — 63,021 — U.S. government agency securities 1,304 — 1,304 — Restricted cash 297 297 — — Marketable securities U.S. government agency securities $ 225,223 $ — $ 225,223 $ — Corporate bonds 114,671 — 114,671 — Asset backed securities 44,521 — 44,521 — Equity securities (1) 5,149 5,149 — — Non-marketable securities $ 10,065 $ — $ — $ 10,065 Liabilities Contingent consideration $ (306,927) $ — $ — $ (306,927) Total $ 335,492 $ 183,614 $ 448,740 $ (296,862) _________________________________ (1) Inclusive of the American Depository Shares of MDxHealth received as part of the sale of the Company’s GPS test, which are restricted to a holding period of six months after the date of the sale of August 2, 2022. The shares have a fair value of $4.6 million as of December 31, 2022. The following table presents the Company’s fair value measurements as of December 31, 2021 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall. (In thousands) Fair Value at December 31, 2021 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash and cash equivalents Cash and money market $ 247,335 $ 247,335 $ — $ — Commercial paper 64,593 — 64,593 — U.S. government agency securities 3,543 — 3,543 — Restricted cash 297 297 — — Marketable securities Corporate bonds $ 313,154 $ — $ 313,154 $ — U.S. government agency securities 249,920 — 249,920 — Asset backed securities 94,460 — 94,460 — Certificates of deposit 47,139 — 47,139 — Commercial paper 6,996 — 6,996 — Equity securities 3,336 3,336 — — Non-marketable securities $ 3,090 $ — $ — $ 3,090 Liabilities Contingent consideration $ (359,021) $ — $ — $ (359,021) Total $ 674,842 $ 250,968 $ 779,805 $ (355,931) There have been no changes in valuation techniques or transfers between fair value measurement levels during the year ended December 31, 2022. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities are valued using a third-party pricing agency where the valuation is based on observable inputs including pricing for similar assets and other observable market factors. Contingent Consideration Liabilities The fair value of contingent consideration as of December 31, 2022 and 2021 was $306.9 million and $359.0 million, respectively, which was recorded in other long-term liabilities in the consolidated balance sheets. The following table provides a reconciliation of the beginning and ending balances of contingent consideration: (In thousands) Contingent consideration Balance, January 1, 2021 (1) $ 2,477 Purchase price contingent consideration (2) 350,348 Changes in fair value 6,359 Payments (163) Balance, December 31, 2021 359,021 Purchase price contingent consideration (3) 4,600 Changes in fair value (56,617) Payments (77) Balance, December 31, 2022 $ 306,927 _________________________________ (1) The change in fair value of the contingent consideration liability during the year ended December 31, 2020 was not material to the consolidated financial statements. (2) The increase in the contingent consideration liability is due to the contingent consideration associated with the acquisitions of Ashion and Thrive. Refer to Note 18 for further information. (3) The increase in contingent consideration liability is due to the contingent consideration associated with the acquisition of OmicEra. Refer to Note 18 for further information. This fair value measurement of contingent consideration is categorized as a Level 3 liability, as the measurement amount is based primarily on significant inputs not observable in the market. The fair value of the contingent consideration liability recorded from our acquisitions of Thrive, Ashion, and OmicEra related to regulatory and product development milestones was $306.8 million and $357.8 million as of December 31, 2022 and 2021, respectively. The Company evaluates the fair value of the expected contingent consideration and the corresponding liability related to the regulatory and product development milestones using the probability-weighted scenario based discounted cash flow model, which is consistent with the initial measurement of the expected contingent consideration liabilities. Probabilities of success are applied to each potential scenario and the resulting values are discounted using a present-value factor. The passage of time in addition to changes in projected milestone achievement timing, present-value factor, the degree of achievement if applicable, and probabilities of success may result in adjustments to the fair value measurement. The fair value of the contingent consideration liability recorded related to regulatory and product development milestones was determined using a weighted average probability of success of 91% as of December 31, 2022 and 2021, and a weighted average present-value factor of 6.2% and 2.3% as of December 31, 2022 and 2021, respectively. The projected fiscal year of payment range is from 2023 to 2028. Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. The fair value of the contingent consideration earnout liability related to certain revenue milestones associated with the Biomatrica acquisition was not material as of December 31, 2022 and 2021, respectively. The revenue milestone associated with the Ashion acquisition is not expected to be achieved and therefore no liability has been recorded for this milestone. Non-Marketable Equity Investments As of December 31, 2022 and 2021, the aggregate carrying amounts of the Company’s non-marketable equity securities without readily determinable fair values were $39.8 million and $25.3 million, respectively, which are classified as a component of other long-term assets, net in the Company’s consolidated balance sheets. Since initial recognition of these investments, there have been no material upward or downward adjustments as a result of observable price changes. The Company recorded impairments during the third and fourth quarters of 2022 of $10.0 million and $8.6 million respectively, related to adverse changes in the market and the investees' ability to continue as a going concern. The Company has committed capital to venture capital investment funds (the “Funds”) of $17.5 million, of which $13.7 million remained callable through 2033 as of December 31, 2022. The aggregate carrying amount of the Funds, which are classified as a component of other long-term assets, net in the Company's consolidated balance sheets, were $3.9 million and $1.5 million as of December 31, 2022 and 2021, respectively. Derivative Financial Instruments |
ACCRUED LIABILITIES
ACCRUED LIABILITIES | 12 Months Ended |
Dec. 31, 2022 | |
Payables and Accruals [Abstract] | |
ACCRUED LIABILITIES | ACCRUED LIABILITIES Accrued liabilities at December 31, 2022 and 2021 consisted of the following: December 31, (In thousands) 2022 2021 Compensation $ 201,252 $ 183,517 Pfizer, Inc. (“Pfizer”) Promotion Agreement related costs — 91,436 Professional fees 43,715 50,077 Other 22,329 32,116 Assets under construction 10,462 22,611 Research and trial related expenses 17,455 15,534 Licenses 4,003 3,265 Total $ 299,216 $ 398,556 |
LONG-TERM DEBT
LONG-TERM DEBT | 12 Months Ended |
Dec. 31, 2022 | |
Debt Disclosure [Abstract] | |
LONG-TERM DEBT | LONG-TERM DEBT Accounts Receivable Securitization Facility On June 29, 2022, the Company, through a wholly-owned special purpose entity, Exact Receivables LLC (“Exact Receivables”) entered into an accounts receivable securitization program (the “Securitization Facility”) with PNC Bank, National Association (“PNC”), with a scheduled maturity date of June 29, 2024. The Securitization Facility provides Exact Receivables with a revolving line-of-credit of up to $150.0 million of borrowing capacity, subject to certain borrowing base requirements, by collateralizing a security interest in the domestic customer accounts receivable of certain wholly-owned subsidiaries of the Company. The amount available under the Securitization Facility fluctuates over time based on the total amount of eligible customer accounts receivable generated by the Company during the normal course of operations. The Securitization Facility requires the Company to maintain minimum borrowings under the facility of $50.0 million. The debt issuance costs incurred related to the Securitization Facility were not material and are being amortized over the life of the Securitization Facility through interest expense within the consolidated statements of operations. In connection with the Securitization Facility, the Company also entered into two Receivables Purchase Agreements (“Receivable Purchase Agreements”) on June 29, 2022. The Receivable Purchase Agreements are among the Company and certain wholly-owned subsidiaries of the Company, and between the Company and Exact Receivables. Under the agreements, the wholly-owned subsidiaries sell all of their right, title and interest of their accounts receivable to Exact Receivables. The receivables are used to collateralize borrowings made under the Securitization Facility. The Company retains the responsibility of servicing the accounts receivable balances pledged as collateral under the Securitization Facility and provides a performance guaranty. As of December 31, 2022, the eligible borrowing base under the Securitization Facility was $107.2 million of which the Company elected to collateralize $50.0 million. As of December 31, 2022, the Company had an outstanding balance of $50.0 million, which is recorded to long-term debt on the Company’s consolidated balance sheets. The outstanding balance accrues interest at a rate equal to a daily secured overnight financing rate (“SOFR”) rate plus a SOFR adjustment and an applicable margin. The interest rate was 5.91% at December 31, 2022. Revolving Loan Agreement During November 2021, the Company entered into the Revolving Loan Agreement with PNC. The Revolving Loan Agreement provides the Company with a revolving line of credit of up to $150.0 million (the “Revolver”). The Revolver is collateralized by the Company’s marketable securities held by PNC, which must continue to maintain a minimum market value of $150.0 million. The Revolver is available for general working capital purposes and all other lawful corporate purposes. In addition, the Company may request, in lieu of cash advances, letters of credit with an aggregate stated amount outstanding not to exceed $20.0 million. The availability of advances under the line of credit will be reduced by the stated amount of each letter of credit issued and outstanding. Borrowings under the Revolving Loan Agreement accrue interest at an annual rate equal to the sum of the daily Bloomberg Short-Term Bank Yield Index Rate plus the applicable margin of 0.60%. Loans under the Revolving Loan Agreement may be prepaid at any time without penalty. In October 2022 the Revolving Loan Agreement was amended to extend the maturity date from November 5, 2023 to November 5, 2025. There were no other amendments to the Revolver. The Company has agreed to various financial covenants under the Revolving Loan Agreement, and as of December 31, 2022, the Company is in compliance with all covenants. During the fourth quarter of 2021, PNC issued a letter of credit of $2.9 million, which reduced the amount available for cash advances under the line of credit to $147.1 million as of December 31, 2022. As of December 31, 2022, the Company has not drawn funds from, nor are any amounts outstanding under, the Revolving Loan Agreement. Construction Loan Agreement During December 2017, the Company entered into a loan agreement with Fifth Third Bank (formerly MB Financial Bank, N.A.) (the “Construction Loan Agreement”), which provided the Company with a non-revolving construction loan (the “Construction Loan”) of $25.6 million. The Company used the Construction Loan proceeds to finance the construction of an additional clinical laboratory and related facilities in Madison, Wisconsin. The Construction Loan was collateralized by the additional clinical laboratory and related facilities. As part of the Revolving Loan Agreement discussed above, the Company agreed to repay in full all outstanding debt owed to Fifth Third Bank under the Construction Loan Agreement, and as of December 31, 2021, the remaining outstanding balance had been fully repaid in connection with the termination of the Construction Loan Agreement. Prior to the repayment, the Construction Loan Agreement bore interest at a rate equal to the sum of the 1-month LIBOR rate plus 2.25%. Regular monthly payments were interest-only for the first 24 months, with further payments based on a 20-year amortization schedule. Amounts borrowed pursuant to the Construction Loan Agreement could be prepaid at any time without penalty, and the maturity date of the Construction Loan Agreement would have been December 10, 2022. The Company made its first draw on the Construction Loan in June 2018. In December 2019, the Company began making monthly payments towards the outstanding principal balance plus accrued interest. The interest incurred on the Construction Loan was not material, and was capitalized to the construction project. The Company also incurred minimal debt issuance costs which were recorded as a direct deduction from the liability, and amortized over the life of the Construction Loan. Any unamortized issuance costs were recorded as a loss as of the date of the repayment of the loan in November 2021. The carrying amount of the Construction Loan approximated fair value due to the short maturity of this instrument. The Construction Loan was privately held with no public market for this debt and therefore was classified as a Level 3 fair value measurement. The change in the fair value during the year ended December 31, 2021 was due to payments made on the loan resulting in a decrease in the liability. |
CONVERTIBLE NOTES
CONVERTIBLE NOTES | 12 Months Ended |
Dec. 31, 2022 | |
CONVERTIBLE DEBT | |
CONVERTIBLE NOTES | CONVERTIBLE NOTES Convertible note obligations included in the consolidated balance sheet consisted of the following as of December 31, 2022: Fair Value (1) (In thousands) Principal Amount Unamortized Debt Discount and Issuance Costs Net Carrying Amount Amount Leveling 2028 Convertible notes - 0.375% $ 1,150,000 $ (15,775) $ 1,134,225 $ 908,500 2 2027 Convertible notes - 0.375% 747,500 (9,445) 738,055 612,950 2 2025 Convertible notes - 1.000% 315,005 (1,179) 313,826 326,808 2 Convertible note obligations included in the consolidated balance sheet consisted of the following as of December 31, 2021: Fair Value (1) (In thousands) Principal Amount Unamortized Debt Discount and Issuance Costs Net Carrying Amount Amount Leveling 2028 Convertible notes - 0.375% $ 1,150,000 $ (18,826) $ 1,131,174 $ 1,139,650 2 2027 Convertible notes - 0.375% 747,500 (11,691) 735,809 771,794 2 2025 Convertible notes - 1.000% 315,005 (1,756) 313,249 415,473 2 ____________________________ (1) The fair values are based on observable market prices for this debt, which is traded in less active markets and therefore is classified as a Level 2 fair value measurement. Issuances and Settlements In January 2018, the Company issued and sold $690.0 million in aggregate principal amount of 1.0% Convertible Notes (the “January 2025 Notes”) with a maturity date of January 15, 2025. The January 2025 Notes accrue interest at a fixed rate of 1.0% per year, payable semi-annually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The net proceeds from the issuance of the January 2025 Notes were approximately $671.1 million, after deducting underwriting discounts and commissions and the offering expenses payable by the Company. In June 2018, the Company issued and sold an additional $218.5 million in aggregate principal amount of 1.0% Convertible Notes (the “June 2025 Notes”). The June 2025 Notes were issued under the same indenture pursuant to which the Company previously issued the January 2025 Notes (the “Indenture”). The January 2025 Notes and the June 2025 Notes (collectively, the “2025 Notes”) have identical terms (including the same January 15, 2025 maturity date) and are treated as a single series of securities. The net proceeds from the issuance of the June 2025 Notes were approximately $225.3 million, after deducting underwriting discounts and commissions and the offering expenses payable by the Company. In March 2019, the Company issued and sold $747.5 million in aggregate principal amount of 0.375% Convertible Notes (the “2027 Notes”) with a maturity date of March 15, 2027. The 2027 Notes accrue interest at a fixed rate of 0.375% per year, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2019. The net proceeds from the issuance of the 2027 Notes were approximately $729.5 million, after deducting underwriting discounts and commissions and the offering expenses payable by the Company. The Company utilized a portion of the proceeds from the issuance of the 2027 Notes to settle a portion of the 2025 Notes in privately negotiated transactions. In March 2019, the Company used cash of $494.1 million and an aggregate of 2.2 million shares of the Company’s common stock valued at $182.4 million for total consideration of $676.5 million to settle $493.4 million of the 2025 Notes, of which $0.7 million was used to pay off interest accrued on the 2025 Notes. The transaction resulted in a loss on settlement of convertible notes of $187.7 million, which is reflected in interest expense in the Company’s consolidated statement of operations. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of repurchase. In February 2020, the Company issued and sold $1.15 billion in aggregate principal amount of 0.375% Convertible Notes (the “2028 Notes” and, collectively with the 2025 Notes and the 2027 Notes, the “Notes”) with a maturity date of March 1, 2028. The 2028 Notes accrue interest at a fixed rate of 0.375% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2020. The net proceeds from the issuance of the 2028 Notes were approximately $1.13 billion, after deducting underwriting discounts and commissions and the offering expenses payable by the Company. In February 2020, the Company used $150.1 million of the proceeds from the issuance of the 2028 Notes to settle $100.0 million of the 2025 Notes, of which $0.1 million was used to pay off interest accrued on the 2025 Notes. The transaction resulted in a loss on settlement of convertible notes of $50.8 million, which is recorded in interest expense in the Company’s consolidated statement of operations. The loss represents the difference between (i) the fair value of the consideration transferred and (ii) the carrying value of the debt at the time of repurchase. Summary of Conversion Features Until the six-months immediately preceding the maturity date of the applicable series of Notes, each series of Notes is convertible only upon the occurrence of certain events and during certain periods, as set forth in the Indentures filed at the time of the original offerings. On or after the date that is six-months immediately preceding the maturity date of the applicable series of Notes until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert such Notes at any time. The Notes will be convertible into cash, shares of the Company’s common stock (plus, if applicable, cash in lieu of any fractional share), or a combination of cash and shares of the Company’s common stock, at the Company’s election. It is the Company’s intent and policy to settle all conversions through combination settlement. The initial conversion rate is 13.26, 8.96, and 8.21 shares of common stock per $1,000 principal amount for the 2025 Notes, 2027 Notes, and 2028 Notes, respectively, which is equivalent to an initial conversion price of approximately $75.43, $111.66, and $121.84 per share of the Company’s common stock for the 2025 Notes, 2027 Notes, and 2028 Notes, respectively. The 2025 Notes, 2027 Notes, and 2028 Notes are potentially convertible into up to 4.2 million, 6.7 million, and 9.4 million shares, respectively. The conversion rate is subject to adjustment upon the occurrence of certain specified events as set forth in the Indentures filed at the time of the original offerings but will not be adjusted for accrued and unpaid interest. In addition, holders of the Notes who convert their Notes in connection with a “make-whole fundamental change” (as defined in the Indenture), will, under certain circumstances, be entitled to an increase in the conversion rate. If the Company undergoes a “fundamental change” (as defined in the Indenture), holders of the Notes may require the Company to repurchase for cash all or part of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest. Based on the closing price of the Company's common stock of $49.51 on December 31, 2022, the if-converted values on the Notes do not exceed the principal amount. The Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by the Company. Ranking of Convertible Notes The Notes are the Company’s senior unsecured obligations and (i) rank senior in right of payment to all of its future indebtedness that is expressly subordinated in right of payment to the Notes; (ii) rank equal in right of payment to each outstanding series thereof and to all of the Company’s future liabilities that are not so subordinated, unsecured indebtedness; (iii) are effectively junior to all of the Company's existing and future secured indebtedness and other secured obligations, to the extent of the value of the assets securing that indebtedness and other secured obligations; and (iv) are structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries. Issuance Costs Issuance costs are amortized to interest expense over the term of the Notes. The following table summarizes the original issuance costs at the time of issuance for each set of Notes: (In thousands) January 2025 Notes $ 10,284 June 2025 Notes 7,362 2027 Notes 14,285 2028 Notes 24,453 Interest Expense Interest expense includes the following: Year Ended December 31, (In thousands) 2022 2021 2020 Debt issuance costs amortization $ 5,727 $ 5,727 $ 5,303 Debt discount amortization 147 147 131 Loss on settlement of convertible notes — — 50,819 Coupon interest expense 10,266 10,266 9,631 Total interest expense on convertible notes $ 16,140 $ 16,140 $ 65,884 The following table summarizes the effective interest rates of the Notes: Year Ended December 31, 2022 2021 2020 2025 Convertible Notes 1.18 % 1.18 % 1.20 % 2027 Convertible Notes 0.68 % 0.68 % 0.68 % 2028 Convertible Notes 0.64 % 0.64 % 0.54 % |
LICENSE AND COLLABORATION AGREE
LICENSE AND COLLABORATION AGREEMENTS | 12 Months Ended |
Dec. 31, 2022 | |
LICENSE AGREEMENTS [Abstract] | |
LICENSE AND COLLABORATION AGREEMENTS | LICENSE AND COLLABORATION AGREEMENTS The Company licenses certain technologies that are, or may be, incorporated into its technology under several license agreements, as well as the rights to commercialize certain diagnostic tests through collaboration agreements. Generally, the license agreements require the Company to pay single-digit royalties based on net revenues received using the technologies and may require minimum royalty amounts, milestone payments, or maintenance fees. Mayo In June 2009, the Company entered into a license agreement with the Mayo Foundation for Medical Education and Research (“Mayo”). The Company’s license agreement with Mayo was most recently amended and restated in September 2020. Under the license agreement, Mayo granted the Company an exclusive, worldwide license to certain Mayo patents and patent applications, as well as a non-exclusive, worldwide license with regard to certain Mayo know-how. The scope of the license covers any screening, surveillance or diagnostic test or tool for use in connection with any type of cancer, pre-cancer, disease or condition. The licensed Mayo patents and patent applications contain both method and composition claims that relate to sample processing, analytical testing and data analysis associated with nucleic acid screening for cancers and other diseases. The jurisdictions covered by these patents and patent applications include the U.S., Australia, Canada, the European Union, China, Japan and Korea. Under the license agreement, the Company assumed the obligation and expense of prosecuting and maintaining the licensed Mayo patents and is obligated to make commercially reasonable efforts to bring to market products using the licensed Mayo intellectual property. Pursuant to the Company’s agreement with Mayo, the Company is required to pay Mayo a low-single-digit royalty on the Company’s net sales of current and future products using the licensed Mayo intellectual property each year during the term of the Mayo agreement. In addition to the royalties described above, the Company is required to pay Mayo cash of $0.2 million, $0.8 million and $2.0 million upon each product using the licensed Mayo intellectual property reaching $5.0 million, $20.0 million and $50.0 million in cumulative net sales, respectively. As part of the most recent amendment, the Company agreed to pay Mayo an additional $6.3 million, payable in five equal annual installments, through 2024. The annual installments are recorded in research and development expenses in the Company's consolidated statements of operations. The license agreement will remain in effect, unless earlier terminated by the parties in accordance with the agreement, until the last of the licensed patents expires in 2039 (or later, if certain licensed patent applications are issued). However, if the Company is still using the licensed Mayo know-how or certain Mayo-provided biological specimens or their derivatives on such expiration date, the term shall continue until the earlier of the date the Company stops using such know-how and materials and the date that is five years after the last licensed patent expires. The license agreement contains customary termination provisions and permits Mayo to terminate the license agreement if the Company sues Mayo or its affiliates, other than any such suit claiming an uncured material breach by Mayo of the license agreement. In addition to granting the Company a license to the covered Mayo intellectual property, Mayo provides the Company with product development and research and development assistance pursuant to the license agreement and other collaborative arrangements. In September 2020, Mayo also agreed to make available certain personnel to provide such assistance through January 2025. In connection with this collaboration, the Company incurred charges of $5.3 million, $5.0 million, and $3.9 million for the years ended December 31, 2022, 2021, and 2020, respectively. The charges incurred in connection with this collaboration are recorded in research and development expenses in the Company's consolidated statements of operations. Johns Hopkins University (“JHU”) Through the acquisition of Thrive, the Company acquired a worldwide exclusive license agreement with JHU for use of several JHU patents and licensed know-how. The license is designed to enable the Company to leverage JHU proprietary data in the development and commercialization of a blood-based, multi-cancer early detection test. The agreement terms include single-digit sales-based royalties and sales-based milestone payments of $10.0 million, $15.0 million, and $20.0 million upon achieving calendar year licensed product revenue using JHU proprietary data of $0.50 billion, $1.00 billion, and $1.50 billion, respectively. |
PFIZER PROMOTION AGREEMENT
PFIZER PROMOTION AGREEMENT | 12 Months Ended |
Dec. 31, 2022 | |
PFIZER PROMOTION AGREEMENT | |
PFIZER PROMOTION AGREEMENT | PFIZER PROMOTION AGREEMENTIn August 2018, the Company entered into a Promotion Agreement (the “Original Promotion Agreement”) with Pfizer, Inc., which was amended and restated in October 2020 (the “Restated Promotion Agreement”). The Restated Promotion Agreement extended the relationship between the Company and Pfizer and restructured the manner in which the Company compensates Pfizer for promotion of the Cologuard test through a service fee, and provision of certain other sales and marketing services related to the Cologuard test. The Restated Promotion Agreement included fixed and performance-related fees, some of which retroactively went into effect on April 1, 2020. In November 2021, the Company and Pfizer entered into an amendment to the Restated Promotion Agreement (the “November 2021 Amendment”), which provided that after November 30, 2021, Pfizer will no longer promote the Cologuard test to healthcare providers. The November 2021 Amendment provided that the Company pay Pfizer a total of $35.9 million in three installments, which occurred during the second, third, and fourth quarters of 2022. The November 2021 Amendment eliminated the Company's obligation to pay Pfizer royalties or other fees except for certain media fees, advertising fees, and any detail fees owed to Pfizer for promoting the Cologuard test prior to November 30, 2021. The $35.9 million fee incurred as a result of the November 2021 Amendment was recognized in full during the fourth quarter of 2021. All payments to Pfizer are recorded in sales and marketing expenses in the Company's consolidated statements of operations.Under the Original Promotion Agreement, the service fee was calculated based on incremental gross profits over specified baselines during the term. Under the Restated Promotion Agreement (and prior to giving effect to the November 2021 Amendment), the service fee provided a fee-for-service model that included certain fixed fees and performance-related bonuses. The performance-related bonuses were contingent upon the achievement of certain annual performance criteria with any applicable expense being recognized ratably upon achievement of the payment becoming probable. The Company incurred charges of $7.5 million, $81.3 million, and $51.2 million for the service fee during the years ended December 31, 2022, 2021 and 2020, respectively. The Company incurred charges of $85.8 million, $121.0 million, and $85.3 million for promotion, sales and marketing services performed by Pfizer on behalf of the Company during the years ended December 31, 2022, 2021 and 2020, respectively. |
STOCKHOLDERS' EQUITY
STOCKHOLDERS' EQUITY | 12 Months Ended |
Dec. 31, 2022 | |
Equity [Abstract] | |
STOCKHOLDERS' EQUITY | STOCKHOLDERS' EQUITY Stock Issuances When the Company completes a business combination or asset acquisition, which are further described in Note 18, the Company may issue shares of the Company's common stock. Stock issuances in relation to acquisitions during the years ended December 31, 2022, 2021 and 2020 were as follows: (In millions) Period of Acquisition Shares Issued Fair Value of Shares Issued OmicEra May 2022 0.3 $ 14.8 PreventionGenetics December 2021 1.1 84.2 Ashion April 2021 0.1 16.2 Thrive January 2021 9.3 1,190.0 Targeted Digital Sequencing (“TARDIS”) license January 2021 0.2 27.3 Paradigm Diagnostics, Inc. (“Paradigm”) and Viomics, Inc. (“Viomics”) March 2020 0.4 28.8 Registered Direct Offering In October 2020, the Company entered into securities purchase agreements with a limited number of institutional investors for the registered direct offering of 8.6 million shares of common stock at a price of $101.00 per share. The Company received, in the aggregate, approximately $861.7 million of net proceeds from the offering, after deducting $7.5 million for the offering expenses and other stock issuance costs paid by the Company. Changes in Accumulated Other Comprehensive Loss The amount recognized in AOCI for the years ended December 31, 2022, 2021 and 2020 were as follows: (In thousands) Cumulative Translation Adjustment Unrealized Gain (Loss) on Securities Accumulated Other Comprehensive Income (Loss) Balance at January 1, 2020 $ (25) $ (75) $ (100) Other comprehensive income before reclassifications — 771 771 Amounts reclassified from accumulated other comprehensive loss 25 — 25 Net current period change in accumulated other comprehensive loss 25 771 796 Income tax expense related to items of other comprehensive loss — (170) (170) Balance at December 31, 2020 $ — $ 526 $ 526 Other comprehensive income (loss) before reclassifications 23 (1,648) (1,625) Amounts reclassified from accumulated other comprehensive loss — (514) (514) Net current period change in accumulated other comprehensive loss 23 (2,162) (2,139) Income tax benefit related to items of other comprehensive loss — 170 170 Balance at December 31, 2021 $ 23 $ (1,466) $ (1,443) Other comprehensive income (loss) before reclassifications 30 (4,049) (4,019) Amounts reclassified from accumulated other comprehensive loss — 226 226 Net current period change in accumulated other comprehensive loss 30 (3,823) (3,793) Balance at December 31, 2022 $ 53 $ (5,289) $ (5,236) _________________________________ (1) There was no tax impact from the amounts recognized in AOCI for the year ended December 31, 2022. Amounts reclassified from AOCI for the years ended December 31, 2022, 2021 and 2020 were as follows: Year Ended December 31, Details about AOCI Components (In thousands) Affected Line Item in the 2022 2021 2020 Change in value of available-for-sale investments Sales and maturities of available-for-sale investments Investment income $ 226 $ (514) $ — Foreign currency adjustment General and administrative — — 25 Total reclassifications $ 226 $ (514) $ 25 |
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION | 12 Months Ended |
Dec. 31, 2022 | |
Share-based Payment Arrangement [Abstract] | |
STOCK-BASED COMPENSATION | STOCK-BASED COMPENSATION Stock-Based Compensation Plans The Company maintains the following plans for which awards were granted from or had shares outstanding in 2022: the 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective July 27, 2017), the 2019 Omnibus Long-Term Incentive Plan, and the 2010 Employee Stock Purchase Plan. These plans are collectively referred to as the “Stock Plans.” The Stock Plans are administered by the Human Capital Committee of the Company’s Board of Directors (“Human Capital Committee”). The 2019 Omnibus Long-Term Incentive Plan provides that upon an acquisition of the Company, all equity will accelerate by a period of one year. In addition, upon the termination of an employee without cause or for good reason prior to the first anniversary of the completion of the acquisition, all equity awards then outstanding under the respective plan held by that employee will immediately vest. 2019 Omnibus Long-Term Incentive Plan. The Company adopted the 2019 Omnibus Long-Term Incentive Plan (the “2019 Stock Plan”) on July 25, 2019 to grant share-based awards to employees, officers, directors, consultants and advisors. Awards granted under the 2019 Stock Plan may include incentive stock options, as defined under the Internal Revenue Code, non-qualified options, restricted stock awards and other stock awards in amounts and with terms and conditions determined by the Human Capital Committee, subject to the provisions of the 2019 Stock Plan. The 2019 Stock Plan will expire on July 25, 2029 and after such date no further awards may be granted under the plan. Options granted under the 2019 Stock Plan expire ten years from the date of grant. Grants made from the 2019 Stock Plan generally vest over a period of three 2010 Omnibus Long-Term Incentive Plan. The Company adopted the 2010 Omnibus Long-Term Incentive Plan (the “2010 Stock Plan”) on July 16, 2010 to grant share-based awards to employees, officers, directors, consultants and advisors. Awards granted under the 2010 Stock Plan may include incentive stock options, as defined under the Internal Revenue Code, non-qualified options, restricted stock awards and other stock awards in amounts and with terms and conditions determined by the Human Capital Committee, subject to the provisions of the 2010 Stock Plan. The 2010 Stock Plan expired on July 16, 2020 and after such date no further awards may be granted under the plan. Options granted under the 2010 Stock Plan expire ten years from the date of grant. Grants made from the 2010 Stock Plan generally vest over a period of three 2010 Employee Stock Purchase Plan. The 2010 Employee Stock Purchase Plan (the “2010 Purchase Plan”) was adopted by the Company on July 16, 2010 to provide participating employees the right to purchase shares of common stock at a discount through a series of offering periods. The 2010 Purchase Plan will expire on October 31, 2030. The Company’s stockholders approved amendments to the 2010 Employee Stock Purchase Plan to increase the number of shares available for purchase thereunder by 500,000 shares, 2,000,000 shares, and 3,000,000 shares on July 24, 2014, July 28, 2016, and June 9, 2022, respectively. At December 31, 2022, there were 2,758,641 shares of common stock available for purchase by participating employees under the 2010 Purchase Plan. Generally, all employees whose customary employment is more than 20 hours per week and more than five months in any calendar year are eligible to participate in the 2010 Purchase Plan. Participating employees authorize an amount, between 1% and 15% of the employee’s compensation, to be deducted from the employee’s pay during the offering period. On the last day of the offering period, the employee is deemed to have exercised the employee’s option to purchase shares of Company common stock, at the option exercise price, to the extent of accumulated payroll deductions. Under the terms of the 2010 Purchase Plan, the option exercise price is an amount equal to 85% of the fair market value, as defined under the 2010 Purchase Plan, and no employee can purchase more than $25,000 of Company common stock under the 2010 Purchase Plan in any calendar year. Rights granted under the 2010 Purchase Plan terminate upon an employee’s voluntary withdrawal from the 2010 Purchase Plan at any time or upon termination of employment. At December 31, 2022, there were 3,041,359 cumulative shares issued under the 2010 Purchase Plan. Stock-Based Compensation Expense The Company records stock-based compensation expense in connection with the amortization of restricted stock and restricted stock unit awards (“RSUs”), stock purchase rights granted under the Company’s employee stock purchase plan and stock options granted to employees, non-employee consultants and non-employee directors. A summary of non-cash stock-based compensation expense by expense category included in the Company's consolidated statements of operations for the years ended December 31, 2022, 2021, and 2020 is as follows: Year Ended December 31, (In thousands) 2022 2021 2020 Cost of sales $ 19,218 $ 16,835 $ 12,852 Research and development 33,825 49,723 19,976 Sales and marketing 62,568 55,716 44,079 General and administrative 91,212 216,952 75,999 Total stock-based compensation $ 206,823 $ 339,226 $ 152,906 As of December 31, 2022, there was approximately $345.5 million of expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under all equity compensation plans. The Company expects to recognize that cost over a weighted average period of 2.33 years. In connection with the acquisition of Thrive, the Company accelerated the vesting of shares of previously unvested stock options and restricted stock units for employees with qualifying termination events. During the year ended December 31, 2021, the Company accelerated 139,096 shares of previously unvested stock options and 58,171 shares of previously unvested restricted stock awards and restricted stock units and recorded $19.0 million of non-cash stock-based compensation for the accelerated awards. As further discussed in Note 18, the Company also recorded $86.2 million in stock-based compensation related to accelerated vesting of awards held by Thrive employees in connection with the acquisition. In connection with the combination with Genomic Health, the Company accelerated the vesting of shares of previously unvested stock options and restricted stock units for employees with qualifying termination events. During the year ended December 31, 2020, the Company accelerated 83,593 shares of previously unvested stock options and 93,770 shares of previously unvested restricted stock units and recorded $9.7 million of non-cash stock-based compensation for the accelerated awards. There was an immaterial amount of accelerated unvested stock options and restricted stock during the year ended December 31, 2021. Stock Options The Company determines the fair value of each service-based option award on the date of grant using the Black-Scholes option-pricing model, which utilizes several key assumptions which are disclosed in the following table: Year Ended December 31 2022 2021 2020 Risk-free interest rates (1) (1) 1.26% - 1.47% Expected term (in years) (1) (1) 6.15 Expected volatility (1) (1) 65.67% - 65.71% Dividend yield (1) (1) 0% _________________________________ (1) The Company did not grant stock options under its 2010 Omnibus Long-Term Incentive Plan or 2019 Omnibus Long-Term Incentive Plan during the period. A summary of stock option activity under the Stock Plans is as follows: Options Shares Weighted Average Exercise Price (1) Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (2) (Aggregate intrinsic value in thousands) Outstanding, January 1, 2022 2,284,276 $ 34.65 5.5 Granted — — Exercised (706,593) 9.27 Forfeited (59,807) 78.63 Outstanding, December 31, 2022 1,517,876 $ 44.82 4.7 $ 28,204 Vested and expected to vest, December 31, 2022 1,517,876 $ 44.82 4.7 $ 28,204 Exercisable, December 31, 2022 1,345,998 $ 38.69 4.4 $ 27,932 _________________________________ (1) The weighted average grant date fair value of options granted during the year ended December 31, 2020 was $58.57. (2) The total intrinsic value of options exercised during the years ended December 31, 2022, 2021, and 2020 was $36.4 million, $155.8 million, and $40.6 million, respectively, determined as of the date of exercise. The Company received approximately $6.5 million, $14.4 million, and $27.1 million from stock option exercises during the years ended December 31, 2022, 2021 and 2020, respectively. Restricted Stock and Restricted Stock Units The fair value of restricted stock and restricted stock units is determined on the date of grant using the closing stock price on that day. A summary of restricted stock and restricted stock unit activity is as follows: Restricted Shares Weighted Average Grant Date Fair Value (1) Outstanding, January 1, 2022 4,320,910 $ 108.84 Granted 3,954,761 68.18 Released (2) (1,896,223) 91.22 Forfeited (1,124,739) 86.89 Outstanding, December 31, 2022 5,254,709 $ 89.29 _________________________________ (1) The weighted average grant date fair value of the restricted stock units granted during the years ended December 31, 2021 and 2020 was $129.16 and $92.55, respectively. (2) The fair value of restricted stock units vested and converted to shares of the Company's common stock was $117.6 million, $219.4 million, and $152.4 million for the years ended December 31, 2022, 2021, and 2020, respectively. Performance Share Units The Company has issued performance-based equity awards to certain employees which vest upon the achievement of certain performance goals, including financial performance targets and operational milestones. In June 2020 and December 2020, the Company modified certain of the operational milestones and financial performance targets, respectively, within the outstanding performance-based equity awards, which were not deemed to have an impact on vesting and no incremental stock-based compensation expense was recorded. This modification impacted awards held by 36 employees. A summary of performance share unit activity is as follows: Performance Share Units (1) Weighted Average Grant Date Fair Value (2) Outstanding, January 1, 2022 878,114 $ 107.18 Granted 805,782 89.43 Released (3) (292,134) 93.22 Forfeited (423,916) 92.02 Outstanding, December 31, 2022 967,846 $ 102.58 _________________________________ (1) The performance share units listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding performance share units as of December 31, 2022 was 146,134. (2) The weighted average grant date fair value of the performance share units granted during the years ended December 31, 2021 and 2020 was $138.09 and $90.17, respectively. (3) The fair value of performance share units vested and converted to shares of the Company's common stock was $27.2 million for the year ended December 31, 2022. There were no performance share units vested and converted to shares of the Company's common stock during the years ended December 31, 2021 and 2020. Employee Stock Purchase Plan (“ESPP”) A summary of ESPP activity is as follows: Year Ended December 31, (in thousands, except share and per share amounts) 2022 2021 2020 Shares issued under the 2010 Purchase Plan 668,605 331,769 301,064 Cash received under the 2010 Purchase Plan $ 25,491 $ 23,070 $ 18,355 Weighted average fair value per share of stock purchase rights granted during the period $ 17.52 $ 34.93 $ 32.57 The 668,605 shares issued during the year ended December 31, 2022 were as follows: Offering period ended Number of Shares Weighted Average price per Share April 30, 2022 326,138 $ 47.41 November 1, 2022 342,467 $ 29.33 The fair value of ESPP shares is based on the assumptions in the following table: Year Ended December 31, 2022 2021 2020 Risk-free interest rates 1.49% - 4.71% 0.04% - 0.16% 0.11% - 0.20% Expected term (in years) 0.5 - 2 0.5 - 2 0.5 - 2 Expected volatility 50.94% - 63.13% 43% - 68.51% 61.59% - 89.00% Dividend yield 0% 0% 0% Shares Reserved for Issuance The Company has reserved shares of its authorized common stock for issuance pursuant to its employee stock purchase and equity plans, including all outstanding stock option grants noted above at December 31, 2022, as follows: Shares reserved for issuance 2019 Stock Plan 17,323,264 2010 Purchase Plan 2,758,641 20,081,905 |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES Leases The components of lease expense were as follows: Year Ended December 31, (In thousands) 2022 2021 2020 Finance lease cost Amortization of right-of-use assets $ 4,612 $ 5,731 $ 1,935 Interest on lease liabilities 808 1,018 383 Operating lease cost 36,291 31,730 22,551 Short-term lease cost 476 628 356 Variable lease cost 7,985 5,212 2,703 Total lease Cost $ 50,172 $ 44,319 $ 27,928 Supplemental disclosure of cash flow information related to the Company's cash and non-cash activities with its leases are as follows: Year Ended December 31, (In thousands) 2022 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 33,448 $ 27,461 $ 17,531 Operating cash flows from finance leases 699 938 381 Finance cash flows from finance leases 4,345 5,290 1,756 Non-cash investing and financing activities: Right-of-use assets obtained in exchange for new operating lease liabilities (1) 24,572 74,369 13,261 Right-of-use assets obtained in exchange for new finance lease liabilities 11,276 5,460 20,349 Weighted-average remaining lease term - operating leases (in years) 7.43 8.33 8.75 Weighted-average remaining lease term - finance leases (in years) 3.27 2.95 3.68 Weighted-average discount rate - operating leases 6.37 % 6.11 % 6.80 % Weighted-average discount rate - finance leases 6.60 % 5.36 % 5.67 % _________________________________ (1) This includes an immaterial amount of right-of-use assets acquired as part of the business combinations described in Note 18 for the year ended December 31, 2022, and $39.6 million for the year ended December 31, 2021. As of December 31, 2022 and 2021, the Company’s right-of-use assets from operating leases are $167.0 million and $174.2 million, respectively, which are reported in operating lease right-of-use assets in the Company’s consolidated balance sheets. As of December 31, 2022, the Company has outstanding operating lease obligations of $210.8 million, of which $28.4 million is reported in operating lease liabilities, current portion and $182.4 million is reported in operating lease liabilities, less current portion in the Company’s consolidated balance sheets. As of December 31, 2021, the Company had outstanding operating lease obligations of $201.9 million, of which $19.7 million is reported in operating lease liabilities, current portion and $182.2 million is reported in operating lease liabilities, less current portion in the Company’s consolidated balance sheets. As of December 31, 2022 and 2021, the Company’s right-of-use assets from finance leases are $10.2 million and $18.2 million, respectively, which are reported in other long-term assets other current liabilities other long-term liabilities On June 1, 2022, certain of the Company’s vehicle leases were amended. The Company determined that this amendment was a lease modification, effective June 1, 2022. Under the lease modification guidance within ASC 842, the Company reassessed the lease classification and remeasured the corresponding right-of-use assets and lease liabilities. The Company determined that a portion of the modified leases are to be accounted for as operating leases, and therefore derecognized the previous finance lease right-of-use asset finance lease liability Maturities of operating lease liabilities on an annual basis as of December 31, 2022 were as follows: (In thousands) 2023 $ 38,321 2024 39,122 2025 34,952 2026 33,322 2027 32,528 Thereafter 89,098 Total minimum lease payments 267,343 Imputed interest (56,578) Total $ 210,765 Maturities of finance lease liabilities on an annual basis as of December 31, 2022 were as follows (amounts in thousands): (In thousands) 2023 $ 3,692 2024 3,632 2025 3,111 2026 1,278 2027 16 Thereafter — Total minimum lease payments 11,729 Imputed interest (1,150) Total $ 10,579 Legal Matters The Company records reserves and accrues costs for certain legal proceedings and regulatory matters to the extent that it determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. While such reserves and accrued costs reflect the Company’s best estimate of the probable loss for such matters, the recorded amounts may differ materially from the actual amount of any such losses. In some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal and regulatory proceedings, which may be exacerbated by various factors, including but not limited to, they may involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; involve a large number of parties, claimants or regulatory bodies; are in the early stages of the proceedings; involve a number of separate proceedings and/or a wide range of potential outcomes; or result in a change of business practices. As of the date of this Annual Report on Form 10-K, amounts accrued for legal proceedings and regulatory matters were not material except for the amounts accrued related to the Medicare Date of Service Rule Investigation discussed below. However, it is possible that in a particular quarter or annual period the Company’s financial condition, results of operations, cash flow and/or liquidity could be materially adversely affected by an ultimate unfavorable resolution of, or development in, legal and/or regulatory proceedings, including as described below. Except for the proceedings discussed below, the Company believes that the ultimate outcome of any of the regulatory and legal proceedings that are currently pending against it should not have a material adverse effect on financial condition, results of operations, cash flow or liquidity. The Company is currently responding to civil investigative demands and administrative subpoenas issued pursuant to the Health Insurance Portability and Accountability Act of 1996 by the United States Department of Justice (“DOJ”) concerning Genomic Health’s compliance with the Medicare Date of Service billing regulations (the “DOS Rule Investigation”). The Company has been cooperating with these inquiries and has produced documents in response thereto. During the second quarter of 2021, as part of ongoing discussions between the DOJ and the Company regarding the DOS Rule Investigation, the DOJ presented an initial estimate of civil damages in the amount of $48.2 million relating to alleged non-compliance with the Medicare Date of Service billing regulations from 2007 to 2020. The initial civil damages estimate did not include potential treble damages, civil or criminal penalties or other remedies that the DOJ could seek against the Company. In December 2021, the DOJ presented a total adjusted demand of $53.8 million for civil damages, which includes a multiplier and penalties. On January 19, 2023, the Company was informed that the DOJ has closed its criminal investigation without taking any action. Based on the Company’s review and analysis of the DOJ presentation, ongoing discussions held with the DOJ, the civil damages estimate, and range of potential exposure, the Company recorded an accrual of approximately $10 million as of December 31, 2022. As noted above, litigation outcomes are difficult to predict, and the estimation of probable losses requires an analysis of multiple possible outcomes that often depend on judgments about potential actions by third parties. Accordingly, the recorded accrual of approximately $10 million as of December 31, 2022 is based on several factors, considerations, and judgments, and the ultimate resolution of this matter could result in a material loss in excess of the recorded accrual. On June 24, 2019, Niles Rosen M.D. filed a sealed ex parte qui tam lawsuit against the Company in the United States District Court for the Middle District of Florida, that alleged a violation of the Federal Anti-Kickback Statute and False Claims Act for offering gift cards to patients in exchange for returning the Cologuard screening test (the “Qui Tam Suit”). Dr. Rosen seeks on behalf of the U.S. government and himself an award of civil penalties, treble damages and fees and costs. On February 25, 2020, the Company received a civil investigative demand by the DOJ related to the Company’s gift card program. The Company produced documents in response thereto. On March 25, 2021, the DOJ filed a notice of its election to decline intervention in the Qui Tam Suit. This election does not prevent Dr. Rosen from continuing the Qui Tam Suit. On April 12, 2021, Dr. Rosen filed an amended complaint against the Company, alleging violations of the Federal Anti-Kickback Statute and False Claims Act. The Company first learned of the Qui Tam Suit and the DOJ’s election to decline intervention in July 2021. The Company intends to vigorously defend itself against Dr. Rosen's claims and seek, among other things, the Company’s attorneys' fees and costs incurred in defending this action. Although the Company denies Dr. Rosen's allegations and believes that it has meritorious defenses to his False Claims Act claims, neither the outcome of the litigation nor can a reasonable estimate or an estimated range of loss associated with the litigation be determined at this time. |
EMPLOYEE BENEFIT PLAN
EMPLOYEE BENEFIT PLAN | 12 Months Ended |
Dec. 31, 2022 | |
Retirement Benefits [Abstract] | |
EMPLOYEE BENEFIT PLAN | EMPLOYEE BENEFIT PLAN The Company maintains a qualified 401(k) retirement savings plan for Exact Sciences employees (the “401(k) Plan”). The Company also maintains additional retirement savings plans that are acquired as a result of business combinations. These plans are maintained for a period of time before being merged into the 401(k) Plan. Under the terms of the 401(k) Plan, participants may elect to defer a portion of their compensation into the 401(k) Plan, subject to certain limitations. Company matching contributions may be made at the discretion of the Company's Human Capital Committee. The Human Capital Committee approved 401(k) Plan matching contributions for the years ended December 31, 2022, 2021, and 2020 in the form of Company common stock equal to 100% of a participant's elective deferrals up to 6% of the participant’s eligible compensation for that year. The Company recorded compensation expense of approximately $36.5 million, $30.0 million, and $22.8 million, respectively, in the statements of operations for the years ended December 31, 2022, 2021, and 2020. |
WISCONSIN ECONOMIC DEVELOPMENT
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS | 12 Months Ended |
Dec. 31, 2022 | |
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS. | |
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS | WISCONSIN ECONOMIC DEVELOPMENT TAX CREDITS During February 2015, the Company entered into an agreement with the WEDC (“Original WEDC Agreement”) to earn $9.0 million in refundable tax credits on the condition that the Company expends $26.3 million in capital investments and establishes and maintains 758 full-time positions over a seven-year period. During December 2021, the Company amended its agreement with the WEDC (“Amended WEDC Agreement”) to earn an additional $18.5 million in refundable tax credits on the condition that the Company expends $350.0 million in capital investments and establishes and maintains 1,300 additional full-time positions over a five-year period. The capital investment credits are earned at a rate of 10% of eligible capital investments up to a maximum of $7.0 million, while the jobs creation credits are earned annually pursuant to the agreement. The tax credits earned are first applied against the tax liability otherwise due, and if there is no such liability present, the claim for tax credits will be reimbursed in cash to the Company. The maximum amount of the refundable tax credit to be earned for each year is fixed, and the Company earns the credits by meeting certain capital investment and job creation thresholds over the term of the agreement. Should the Company earn and receive the job creation tax credits but not maintain those full-time positions through the end of the agreement, the Company may be required to pay those credits back to the WEDC. Under the Original WEDC Agreement, the Company recorded the earned tax credits as job creation and capital investments occurred. The tax credits earned from capital investment are being recognized as an offset to depreciation expense over the expected life of the acquired capital assets. The tax credits earned related to job creation were recognized as an offset to operational expenses through December 31, 2020 and were not material. As of December 31, 2020, the Company had earned all $9.0 million of the refundable tax credits, and as of December 31, 2022, the Company has received payment of $9.0 million from the WEDC under the Original WEDC Agreement. Under the Amended WEDC Agreement, the Company records the earned tax credits as job creation and capital investments occurs. The tax credits earned from capital investment are recognized as a reduction to capital expenditures at the time the costs are incurred, and then as an offset to depreciation expense over the expected life of the acquired capital assets. The tax credits earned related to job creation are recognized as an offset to operational expenses in the period in which the credits are earned. The credits recognized will be required to be repaid if the Company does not maintain minimum cumulative job requirements. As of December 31, 2022, the Company has earned $9.0 million of the refundable tax credits under the Amended WEDC Agreement. As of December 31, 2022, $5.5 million is reported in prepaid expenses and other current assets and $3.5 million is reported in other long-term assets, net in the Company's consolidated balance sheets reflecting when collection of the refundable tax credits is expected to occur. |
BUSINESS COMBINATIONS AND ASSET
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS | 12 Months Ended |
Dec. 31, 2022 | |
Business Combination and Asset Acquisition [Abstract] | |
Business Combination, Divestiture, And Asset Acquisition | ACQUISITIONS AND DIVESTITURES Business Combinations OmicEra Diagnostics, GmbH On May 2, 2022, the Company completed the acquisition (the “OmicEra Acquisition”) of all of the outstanding equity interests of OmicEra Diagnostics GmbH. The OmicEra Acquisition provided the Company a state-of-the-art proteomics lab based in Planegg, Germany. OmicEra combines its mass spectrometry-based proteome analysis technology with its in-house proteomics scientific expertise to discover more reliable and valuable protein biomarkers, which will expand the Company’s research and development capabilities. The Company has included the financial results of OmicEra in the consolidated financial statements from the date of the acquisition. The acquisition date fair value of the consideration transferred for OmicEra was approximately $19.4 million, which consisted of the following: (In thousands) Common stock issued $ 14,792 Contingent consideration 4,600 Cash paid related to working capital adjustment 16 Total purchase price $ 19,408 The fair value of the 265,186 common shares issued as part of the consideration transferred was determined on the basis of the average of the high and low market price of the Company’s shares on the acquisition date, which was $55.78. The purchase agreement requires the Company to pay a maximum of $6.0 million of additional cash consideration to OmicEra upon the achievement of certain earnout conditions related to the identification of protein biomarkers, as well as the growth of the proteomics research and development team. The fair value of the contingent consideration at the acquisition date was $4.6 million. The fair value of the contingent consideration was estimated using a probability-weighted scenario-based discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The key assumptions are described in Note 7. The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including immaterial measurement period adjustments as follows: (In thousands) Net operating assets $ 2,586 Developed technology 10,000 Total identifiable assets acquired 12,586 Net operating liabilities (3,987) Net identifiable assets acquired 8,599 Goodwill 10,809 Net assets acquired $ 19,408 The Company recorded $10.0 million of identifiable intangible assets related to the developed technology associated with OmicEra’s proteome analysis platform. Developed technology represents purchased technology that had reached technological feasibility and for which OmicEra had substantially completed development as of the date of acquisition. The fair value of the developed technology has been determined using the income approach multi-period excess earnings method, which involves significant unobservable inputs (Level 3 inputs). These inputs include projected sales, margin, obsolescence factor, required rate of return, and tax rate. Cash flows were discounted to their present value as of the closing date. The developed technology intangible asset is amortized on a straight-line basis over its estimated useful life of 16 years. The calculation of the excess purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill, which is primarily attributed to the acquired workforce expertise, the potential to enhance the capabilities of current and future products, and expected research and development synergies. The total goodwill related to this acquisition is not deductible for tax purposes. The total purchase price allocation is preliminary and based upon estimates and assumptions that are subject to change within the measurement period as additional information for the estimates is obtained. The measurement period remains open pending the completion of valuation procedures related to certain acquired assets and liabilities assumed, primarily in connection with the developed technology intangible asset. Pro forma impact and results of operations disclosures have not been included due to immateriality. Acquisition-related costs were not material and have been recorded within general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting, and other advisors incurred to complete the merger. PreventionGenetics, LLC On December 31, 2021, the Company completed the acquisition (the “PreventionGenetics Acquisition”) of all of the outstanding equity interests of PreventionGenetics, LLC. The PreventionGenetics Acquisition provided the Company a Clinical Laboratory Improvement Amendments (“CLIA”) certified and College of American Pathologist (“CAP”) accredited sequencing lab based in Marshfield, Wisconsin. PreventionGenetics provides more than 5,000 predefined genetic tests for nearly all clinically relevant genes, additional custom panels, and comprehensive germline, whole exome (“PGxome®”), and whole genome (“PGnome®”) sequencing tests. The Company has included the financial results of PreventionGenetics in the consolidated financial statements from the date of the acquisition. The acquisition date fair value of the consideration transferred for PreventionGenetics was approximately $185.4 million, which consisted of the following: (In thousands) Cash $ 101,129 Common stock issued 84,252 Total purchase price $ 185,381 The fair value of the 1,070,410 common shares issued as part of consideration transferred was determined on the basis of the average of the high and low market price of the Company's shares on the acquisition date, which was $78.71. Of the total $101.1 million of consideration settled through the payment of cash, $85.8 million was paid as of December 31, 2021. The remaining $15.3 million represented withheld cash consideration used to cover working capital adjustments or seller claims that arose following the completion of the acquisition. The withheld cash consideration was settled during the year ended December 31, 2022, and there is no remaining liability on the consolidated balance sheet. The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including immaterial measurement period adjustments as follows: (In thousands) Cash and cash equivalents $ 1,574 Accounts receivable 6,328 Inventory 1,697 Prepaid expenses and other current assets 30 Property, plant and equipment 12,793 Developed technology 65,000 Customer relationships 4,000 Trade name 4,000 Total identifiable assets acquired 95,422 Accounts payable (1,628) Accrued liabilities (992) Total liabilities assumed (2,620) Net identifiable assets acquired 92,802 Goodwill 92,579 Net assets acquired $ 185,381 Developed technology represents purchased technology that had reached technological feasibility and for which PreventionGenetics had substantially completed development as of the date of acquisition. The developed technology is associated with PreventionGenetics’ ability to perform next-generation sequencing and use its developed software solutions and infrastructure to report on the sequencing process. The fair value of the developed technology has been determined using the income approach multi-period excess earnings method, which involves significant unobservable inputs (Level 3 inputs). These inputs include projected sales, margin, obsolescence factor, and discount rate. The developed technology intangible asset is amortized on a straight-line basis over its estimated useful life of 13 years. Customer relationships represent agreements and relationships with existing PreventionGenetics customers. The fair value of customer relationships has been determined using the excess earnings distributor model, which involves significant unobservable inputs (Level 3 inputs). These inputs include projected sales, margin, attrition rate, and discount rate. The customer relationship intangible asset is amortized on a straight-line basis over its estimated useful life of 9 years. Trade names represent the value associated with the PreventionGenetics trade name in the market. The fair value of trade names has been determined using the relief-from-royalty method, which involves significant unobservable inputs (Level 3 inputs). These inputs include projected sales, royalty rate, and discount rate. The trade name intangible asset is amortized on a straight-line basis over its estimated useful life of 4 years. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill, which is primarily attributed to the acquired workforce’s genetic sequencing, informatics, and counseling expertise, as well as expected sales force synergies. The total goodwill related to this acquisition is deductible for tax purposes. Pro forma impact and results of operations disclosures have not been included due to immateriality. Acquisition-related costs were not material and have been recorded in general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting and other advisors incurred to complete the merger. Ashion Analytics, LLC On April 14, 2021, the Company completed the acquisition (“Ashion Acquisition”) of all of the outstanding equity interests of Ashion Analytics, LLC from PMed Management, LLC (“PMed”), which is a subsidiary of The Translational Genomics Research Institute (“TGen”). The Ashion Acquisition provided the Company a CLIA-certified and CAP-accredited sequencing lab based in Phoenix, Arizona. Ashion developed GEM ExTra®, a comprehensive genomic cancer test, and provides access to whole exome, matched germline, and transcriptome sequencing capabilities. The Company has included the financial results of Ashion in the consolidated financial statements from the date of the acquisition. The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million, which consisted of the following: (In thousands) Cash $ 74,775 Common stock issued 16,224 Contingent consideration 19,000 Total purchase price $ 109,999 The fair value of the 125,444 common shares issued as part of consideration transferred was determined on the basis of the average of the high and low market price of the Company's shares on the acquisition date, which was $129.33. The contingent consideration arrangement requires the Company to pay $20.0 million of additional cash consideration to PMed upon the Company’s commercial launch, on or before the tenth anniversary of the Ashion Acquisition, of a test for molecular residual disease (“MRD”) detection and/or treatment (the “Commercial Launch Milestone”). The fair value of the Commercial Launch Milestone at the acquisition date was $19.0 million. The contingent consideration arrangement also requires the Company to pay $30.0 million of additional cash upon the Company’s achievement, on or before the fifth anniversary of the Ashion Acquisition, of cumulative revenues from MRD products of $500.0 million (the “MRD Product Revenue Milestone”). No value was ascribed to the MRD Product Revenue Milestone based on probability assessments as of the acquisition date. The fair value of the Commercial Launch Milestone and MRD Product Revenue Milestone was estimated using a probability-weighted scenario based discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The key assumptions are described in Note 7. The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values as follows: (In thousands) Cash and cash equivalents $ 2,474 Accounts receivable 2,349 Inventory 1,811 Prepaid expenses and other current assets 425 Property, plant and equipment 9,947 Operating lease right-of-use assets 548 Developed technology 39,000 Total identifiable assets acquired 56,554 Accounts payable (1,477) Accrued liabilities (1,190) Operating lease liabilities, current portion (343) Other current liabilities (98) Operating lease liabilities, less current portion (205) Total liabilities assumed (3,313) Net identifiable assets acquired 53,241 Goodwill 56,758 Net assets acquired $ 109,999 The Company recorded $39.0 million of identifiable intangible assets related to the developed technology associated with GEM ExTra. Developed technology represents purchased technology that had reached technological feasibility and for which Ashion had substantially completed development as of the date of acquisition. The fair value of the developed technology has been determined using the income approach multi-period excess earnings method, which involves significant unobservable inputs (Level 3 inputs). These inputs include projected sales, margin, and required rate of return and tax rate. Cash flows were discounted to their present value as of the closing date. The developed technology intangible asset is amortized on a straight-line basis over its estimated useful life of 13 years. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill, which is primarily attributed to the acquired workforce expertise, the capabilities in the advancement of creating and launching new products, including an MRD product, and expected sales force synergies related to the developed technology. The total goodwill related to this acquisition is deductible for tax purposes. Pro forma impact and results of operations disclosures have not been included due to immateriality. Acquisition-related costs were not material and have been recorded in general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting and other advisors incurred to complete the merger. Thrive Earlier Detection Corporation On January 5, 2021, the Company completed the acquisition (“Thrive Merger”) of all of the outstanding capital stock of Thrive Earlier Detection Corporation. Thrive, headquartered in Cambridge, Massachusetts, is a healthcare company dedicated to incorporating earlier cancer detection into routine medical care. The Company expects that combining Thrive's early-stage multi-cancer early detection test with the Company’s scientific platform, clinical organization, and commercial infrastructure will bring an accurate blood-based, multi-cancer early detection test to patients faster. The Company has included the financial results of Thrive in the consolidated financial statements from the date of the acquisition. The acquisition date fair value of the consideration transferred for Thrive was approximately $2.19 billion, which consisted of the following: (In thousands) Common stock issued $ 1,175,431 Cash 584,996 Contingent consideration 331,348 Fair value of replaced equity awards 52,245 Previously held equity investment fair value 43,034 Total purchase price $ 2,187,054 The Company issued 9,323,266 common shares that had a fair value of $1.19 billion based on the average of the high and low market price of the Company's shares on the acquisition date, which was $127.79. Of the total consideration for common stock issued, $1.18 billion was allocated to the purchase consideration and $16.0 million was recorded as compensation within general and administrative expenses in the consolidated statement of operations on the acquisition date due to accelerated vesting of legacy Thrive restricted stock awards (“RSA”) and RSU awards in connection with the acquisition. The Company paid $590.2 million in cash on the acquisition date. Of the total consideration for cash, $585.0 million was allocated to the purchase consideration and $5.2 million was recorded as compensation within general and administrative expenses on the acquisition date due to accelerated vesting of legacy Thrive RSU and RSAs that were cash-settled in connection with the acquisition. The contingent consideration arrangement requires the Company to pay up to $450.0 million of additional cash consideration to Thrive’s former shareholders upon the achievement of two discrete events, U.S. Food and Drug Administration (“FDA”) approval and CMS coverage, for $150.0 million and up to $300.0 million, respectively. The fair value of the contingent consideration arrangement at the acquisition date was $352.0 million. The fair value of the contingent consideration was estimated using a probability-weighted scenario based discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The key assumptions are described in Note 7. Of the total fair value of the contingent consideration, $331.3 million was allocated to the consideration transferred, $6.4 million was allocated to the Company’s previous ownership interest in Thrive, and $14.3 million was deemed compensatory as participation is dependent on replaced unvested equity awards vesting which requires future service. Compensation expense related to the milestones could be up to $18.2 million undiscounted and will be recognized in the future once probable and payable. The Company replaced unvested stock options, RSUs, and RSAs and vested stock options with an acquisition-date fair value of $197.0 million. Of the total consideration for replaced equity awards, $52.2 million was allocated to the consideration transferred and $144.8 million was deemed compensatory as it was attributable to post acquisition vesting. Of the total compensation related to replaced awards, $65.0 million was expensed on the acquisition date due to accelerated vesting of stock options in connection with the acquisition and $79.8 million relates to future services and will be expensed over the remaining service periods of the unvested stock options, RSUs, and RSAs on a straight-line basis. Including expense recognized for accelerated vesting of RSUs and RSAs described above, total expected stock-based compensation expense is $166.0 million, of which $86.2 million was recognized immediately to general and administrative expenses in the consolidated statement of operations due to accelerated vesting. The fair value of the stock options assumed by the Company was determined using the Black-Scholes option pricing model. The fair value of the RSA and RSUs assumed by the Company was determined based on the average of the high and low market price of the Company's shares on the acquisition date. The share conversion ratio of 0.06216 was applied to convert Thrive’s outstanding equity awards for Thrive’s common stock into equity awards for shares of the Company’s common stock. The fair value of options assumed were based on the assumptions in the following table: Option Plan Shares Assumed Risk-free interest rates 0.11% - 0.12% Expected term (in years) 1.26 - 1.57 Expected volatility 65.54% - 71.00% Dividend yield 0% Weighted average fair value per share of options assumed $109.74 - $124.89 The Company previously held a preferred stock investment of $12.5 million in Thrive and recognized a gain of approximately $30.5 million on the transaction within investment income (expense), net on the Company’s consolidated statement of operations, which represented the adjustment of the Company’s historical investment to the acquisition date fair value. The fair value of the Company’s previous ownership in Thrive was determined based on the pro-rata share payout applied to the Company’s interest combined with the fair value of the Company’s share of the contingent consideration arrangement, as discussed above. The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including immaterial measurement period adjustments as follows: (In thousands) Cash and cash equivalents $ 241,748 Prepaid expenses and other current assets 3,939 Property, plant and equipment 29,977 Operating lease right-of-use assets 39,027 Other long-term assets 67 In-process research and development (IPR&D) 1,250,000 Total identifiable assets acquired 1,564,758 Accounts payable (3,222) Accrued liabilities (8,080) Operating lease liabilities, current portion (2,980) Operating lease liabilities, less current portion (38,622) Deferred tax liability (272,905) Total liabilities assumed (325,809) Net identifiable assets acquired 1,238,949 Goodwill 948,105 Net assets acquired $ 2,187,054 IPR&D represents the fair value assigned to research and development assets that have not reached technological feasibility. The primary basis for determining technological feasibility of these projects is obtaining regulatory approval to market the underlying product and expected commercial release. The amounts capitalized are accounted for as indefinite-lived intangible assets, subject to impairment testing, until completion or abandonment of the research and development efforts associated with the projects. The Company recorded $1.25 billion of IPR&D related to a project associated with the development of an FDA approved blood-based, multi-cancer early detection test. The IPR&D asset was valued using the multiple-period excess earnings method approach, which involves significant unobservable inputs (Level 3 inputs). These inputs include inputs such as projected revenues, gross margin, required rate of return, tax rate, probability of commercial success, and obsolescence factor. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill, which is primarily attributed to the research and development workforce expertise, next generation sequencing capabilities, and expected synergies. The total goodwill related to this acquisition is not deductible for tax purposes. The net loss before tax of Thrive included in the Company’s consolidated statement of operations from the acquisition date of January 5, 2021 to December 31, 2021 was $255.0 million. The following unaudited pro forma financial information summarizes the combined results of operations for the Company and Thrive, as though the companies were combined as of the beginning of January 1, 2020. Year Ended December 31, (In thousands) 2021 2020 Total revenues $ 1,767,087 $ 1,491,391 Net loss before tax $ (761,337) $ (1,014,352) The unaudited pro forma financial information for all periods presented above has been calculated after adjusting the results of Thrive to reflect the business combination accounting effects resulting from this acquisition. The Company incurred $86.2 million of stock-based compensation expense related to accelerated vesting in connection with the acquisition, $13.5 million of stock-based compensation expense related to accelerated vesting for employees with qualifying termination events, and $10.3 million of transaction costs incurred to execute the acquisition during the first quarter of 2021. These expenses are included in general and administrative expenses on the consolidated statement of operations for the year ended December 31, 2021 and are reflected in pro forma earnings for the year ended December 31, 2020 in the table above. The Company recorded a realized gain of $30.5 million during the first quarter of 2021 in investment income (expense), net on the Company’s consolidated statement of operations relating to the Company’s pre-acquisition investment in Thrive. This gain has been reduced to $7.6 million due to the Company’s smaller ownership interest in Thrive on January 1, 2020, and is reflected in pro forma earnings for the year ended December 31, 2020 in the table above. The Company recorded a remeasurement of contingent consideration of $7.2 million related to Thrive in general and administrative expenses in the consolidated statement of operations for the year ended December 31, 2021. This expense is reflected in the year ended December 31, 2020 in the table above. The historical consolidated financial statements have been adjusted in the unaudited pro forma combined financial information to give effect to pro forma events that are directly attributable to the business combination and factually supportable. The unaudited pro forma financial information is for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place as of January 1, 2020. During the year ended December 31, 2021, the Company incurred $10.3 million of acquisition-related costs recorded in general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting and other advisors incurred to complete the merger. In connection with acquisition-related severances, the Company recorded $19.0 million of expense related to vesting of previously unvested equity awards and $3.9 million of additional benefit charges for the year ended December 31, 2021. Paradigm Diagnostics, Inc. and Viomics, Inc. On March 3, 2020, the Company acquired all of the outstanding capital stock of Paradigm Diagnostics, Inc. and Viomics, Inc., two related party companies of one another headquartered in Phoenix, Arizona, in transactions that are deemed to be a single business combination in accordance with ASC 805, Business Combinations, (“the Paradigm Acquisition”). Paradigm provides comprehensive genomic-based profiling tests that assist in the diagnosis and therapy recommendations for late-stage cancer. Viomics provides a platform for identification of biomarkers. The Company entered into this acquisition to enhance its product portfolio in cancer diagnostics and to enhance its capabilities for biomarker identification. The acquisition date fair value of the consideration to be transferred for Paradigm and Viomics was $40.4 million, which consisted of $32.2 million payable in shares of the Company’s common stock and $8.2 million which was settled through a cash payment. Of the $32.2 million to be settled through the issuance of common stock, $28.8 million was issued as of the acquisition date. The remaining $3.4 million was withheld and was included in other current liabilities in the consolidated balance sheet as of December 31, 2021. In December 2022 the Company executed a settlement agreement, which removed any seller claims or rights to the withheld consideration. The settlement was not material, and there is no remaining liability on the consolidated balance sheet as of December 31, 2022. Acquisition-related costs were not material and were recorded within general and administrative expenses in the consolidated statement of operations. These costs include fees associated with financial, legal, accounting, and other advisors incurred to complete the merger. Asset Acquisitions PFS Genomics Inc. On May 3, 2021, the Company acquired 90% of the outstanding capital stock of PFS Genomics Inc. (“PFS”). On June 23, 2021, the Company completed the acquisition of the remaining 10% interest in PFS. The Company paid cash of $33.6 million for 100% of the outstanding capital stock in PFS. PFS is a healthcare company focused on personalizing treatment for breast cancer patients to improve outcomes and reduce unnecessary treatment. The Company expects this acquisition to expand its ability to help guide early-stage breast cancer treatment through individualized radiotherapy treatment decisions. The transaction was treated as an asset acquisition under GAAP because substantially all of the fair value of the gross assets acquired were deemed to be associated with the acquired technology. The assets acquired and liabilities assumed were substantially comprised of the IPR&D asset as shown in the table below. The IPR&D asset acquired was recorded to research and development expense in the consolidated statement of operations immediately after acquisition as the asset was deemed to be incomplete and had no alternative future use at the time of acquisition. The Company accounted for the acquisition in accordance with the accounting standards codification guidance for business combinations, whereby the total purchase price was allocated to the acquired net tangible and intangible assets based on their estimated fair values as of the closing date. The following table summarizes the allocation of the purchase price to the fair values assigned to the assets acquired and liabilities assumed: (In thousands) Consideration Cash paid for acquisition of PFS Genomics outstanding shares $ 33,569 Assets acquired and liabilities assumed Cash 496 IPR&D asset 33,074 Other assets and liabilities (1) Net assets acquired $ 33,569 Acquisition related costs were not material in this asset acquisition. TARDIS License Agreement On January 11, 2021, the Company entered into a worldwide exclusive license to the proprietary TARDIS technology from TGen, an affiliate of City of Hope. Under the agreement, the Company acquired a royalty-free, worldwide exclusive license to proprietary TARDIS patents and know-how. The Company intends to develop and commercialize the TARDIS technology as a MRD test. The Company accounted for this transaction as an asset acquisition. In connection with the asset acquisition, the Company paid upfront fair value consideration of $52.3 million comprised of $25.0 million in cash and issuance of 191,336 shares of common stock valued at $27.3 million based on the average of the high and low market price of the Company’s shares on the acquisition date. In addition, the Company is obligated to make milestone payments to TGen of $10.0 million and $35.0 million upon achieving cumulative product revenue related to MRD detection and/or treatment totaling $100.0 million and $250.0 million, respectively. These payments are contingent upon achievement of these cumulative revenues on or before December 31, 2030. The upfront consideration was recorded to research and development expense in the consolidated statement of operations immediately after acquisition as the asset was deemed to be incomplete and had no alternative future use at the time of acquisition. The Company will record the sales milestones once achievement is deemed probable. No acquisition related costs were incurred in this asset acquisition during the year ended December 31, 2021. Base Genomics, Limited On October 26, 2020, the Company acquired all of the outstanding capital stock of Base Genomics, Limited (“Base Genomics”) in a cash transaction totaling $416.5 million. Base Genomics, headquartered in Oxford, England, exclusively licenses from Ludwig a non-bisulfite technology for the detection of methylated DNA and other epigenetic modifications. This technology (“TAPS”) simultaneously generates both genetic and epigenetic information at base resolution. TAPS overcomes the issues of the current gold standard for DNA methylation detection of bisulfite sequencing. The Company has included the financial results of Base Genomics in the consolidated statements from the date of the acquisition and not disclosed separately due to immateriality. Pro forma disclosures have not been included due to immateriality. While the acquisition was treated legally as a merger of the two entities, for accounting purposes, the transaction was treated as an asset acquisition under GAAP because substantially all of the fair value of the gross assets acquired were deemed to be associated with the TAPS technology. The assets and liabilities acquired in the merger were recorded at fair value as determined as of October 26, 2020, and were substantially comprised of the TAPS IPR&D asset of $412.6 million. The Company incurred approximately $4.6 million of direct transaction costs during the year ended December 31, 2020 associated with this acquisition. These acquisition-related transaction costs were capitalized to the acquired tangible and intangible assets based on their estimated fair values as of the closing date. The IPR&D asset acquired was recorded to research and development expense in the consolidated statement of operations immediately after acquisition as the asset was deemed to be incomplete and had no alternative future use at the time of acquisition. The Company accounted for the merger in accordance with the accounting standards codification guidance for business combinations, whereby the total purchase pr |
SEGMENT INFORMATION
SEGMENT INFORMATION | 12 Months Ended |
Dec. 31, 2022 | |
Segment Reporting [Abstract] | |
SEGMENT INFORMATION | SEGMENT INFORMATION Management determined that the Company functions as a single operating segment, and thus reports as a single reportable segment. This operating segment is focused on the development and global commercialization of clinical laboratory services allowing healthcare providers and patients to make individualized treatment decisions. Management assessed the discrete financial information routinely reviewed by the Company's Chief Operating Decision Maker, its President and Chief Executive Officer, to monitor the Company's operating performance and support decisions regarding allocation of resources to its operations. Performance is continuously monitored at the consolidated level to timely identify deviations from expected results. The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location. Year Ended December 31, (In thousands) 2022 2021 2020 United States $ 1,966,541 $ 1,657,174 $ 1,413,907 Outside of United States 117,738 109,913 77,484 Total revenues $ 2,084,279 $ 1,767,087 $ 1,491,391 Long-lived assets located in countries outside of the United States are not significant. |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | INCOME TAXES Under financial accounting standards, deferred tax assets or liabilities are computed based on the differences between the financial statement and income tax bases of assets and liabilities using the enacted tax rates. Deferred income tax expense or benefit represents the change in the deferred tax assets or liabilities from period to period. At December 31, 2022, the Company had federal net operating loss, state net operating loss, and foreign net operating loss carryforwards of approximately $475.2 million, $70.9 million, and $7.2 million, respectively, for financial reporting purposes, which may be used to offset future taxable income. The Tax Cuts and Jobs Act (H.R. 1) of 2017 limits the deduction for net operating losses to 80% of current year taxable income and provides for an indefinite carryover period for federal net operating losses. Both provisions are applicable for losses arising in tax years beginning after December 31, 2017. As of December 31, 2022 the Company has $300.2 million of federal net operating loss carryovers incurred after December 31, 2017 with an unlimited carryover period and $175.0 million of federal net operating loss carryovers expiring at various dates through 2037. State and foreign net operating loss carryovers expire at various dates through 2042. All net operating loss carryforwards are subject to review and possible adjustment by federal, state and foreign taxing jurisdictions. The Company also had federal and state research tax credit carryforwards of $59.2 million and $27.8 million, respectively, which may be used to offset future income tax liability. The federal credit carryforwards expire at various dates through 2042 and are subject to review and possible adjustment by the Internal Revenue Service. The state credit carryforwards expire at various dates through 2037 with the exception of $16.8 million of California research and development tax credits that have an indefinite carryforward period. All state tax credits are subject to review and possible adjustment by local tax jurisdictions. In the event of a change of ownership, the federal and state net operating loss and research and development tax credit carryforwards may be subject to annual limitations provided by the Internal Revenue Code and similar state provisions. Income (loss) before provision for taxes consisted of the following: Year Ended December 31, (In thousands) 2022 2021 2020 Income (loss) before income taxes: Domestic $ (617,240) $ (801,536) $ (423,025) Foreign (15,330) (40,970) (406,038) Total income (loss) before income taxes $ (632,570) $ (842,506) $ (829,063) The expense (benefit) for income taxes consists of: Year Ended December 31, (In thousands) 2022 2021 2020 Current expense (benefit): Federal $ — $ — $ (3) State 2,170 1,388 802 Foreign 1,131 4,898 933 Deferred tax expense (benefit): Federal (3,292) (222,693) (3,050) State (8,926) (30,528) (4,260) Foreign (147) 54 120 Total income tax expense (benefit) $ (9,064) $ (246,881) $ (5,458) The Company recorded an income tax benefit for the year ended December 31, 2022 of $9.1 million primarily related to the future limitations on and expiration of certain Federal and State deferred tax assets, offset by current foreign and state tax expense. The components of the net deferred tax asset with the approximate income tax effect of each type of carryforward, credit and temporary differences are as follows: December 31, (In thousands) 2022 2021 Deferred tax assets: Operating loss carryforwards $ 553,320 $ 516,344 Tax credit carryforwards 87,579 72,959 Compensation related differences 67,976 74,127 Lease liabilities 51,560 48,201 Capitalized research and development 108,117 23,035 Other temporary differences 19,353 20,087 Tax assets before valuation allowance 887,905 754,753 Less - Valuation allowance (419,356) (262,238) Total deferred tax assets 468,549 492,515 Deferred tax liabilities Amortization $ (435,991) $ (464,748) Property, plant and equipment (4,653) (4,756) Lease assets (40,674) (45,781) Other temporary differences (6,944) (6,012) Total deferred tax liabilities (488,262) (521,297) Net deferred tax liabilities $ (19,713) $ (28,782) A valuation allowance to reduce the deferred tax assets is reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has incurred significant losses since its inception and due to the uncertainty of the amount and timing of future taxable income and the realization of deferred tax liabilities, management has determined that a valuation allowance of $419.4 million and $262.2 million at December 31, 2022 and 2021, respectively, is necessary to reduce the tax assets to the amount that is more likely than not to be realized. Given the future limitations on and expiration of certain federal and state deferred tax assets, the recording of a valuation allowance resulted in a deferred tax liability of approximately $19.7 million remaining as of December 31, 2022, which is included in other long-term liabilities on the Company's consolidated balance sheet. The overall change in valuation allowance for December 31, 2022 and 2021 was an increase of $157.1 million and a decrease of $31.2 million, respectively. Activity associated with the Company's valuation allowance is as follows: December 31, (In thousands) 2022 2021 2020 Balance as of January 1, $ (262,238) $ (293,397) $ (195,401) Valuation allowances established (159,919) (206,574) (94,589) Changes to existing valuation allowances 2,780 (1,500) 2,151 Acquisition and purchase accounting 21 239,233 (5,558) Balance as of December 31, $ (419,356) $ (262,238) $ (293,397) During the year ended December 31, 2022, the Company recorded an increase to the valuation allowance of $159.9 million primarily related to losses from continuing operations. During the year ended December 31, 2021, the Company recorded an increase to the valuation allowance of $206.6 million primarily related to losses from continuing operations. Offsetting the increase, the Company recorded a decrease to the valuation allowance of $239.2 million related to the Thrive Merger offset against goodwill. During the year ended December 31, 2020, the Company recorded an increase to the valuation allowance of $94.6 million primarily related to losses from continuing operations. Additionally, the Company recorded an increase to the valuation allowance of $5.6 million related to the Genomic Health combination offset against goodwill. The effective tax rate differs from the statutory tax rate due to the following: December 31, 2022 2021 2020 U.S. Federal statutory rate 21.0 % 21.0 % 21.0 % State taxes 3.9 3.6 1.7 Federal and state tax rate changes (0.2) (0.3) — Foreign tax rate differential (0.1) (0.6) (1.0) Acquired IPR&D asset expense — (0.8) (9.4) Research and development tax credits 2.3 0.7 1.6 Stock-based compensation expense (2.0) 1.1 1.1 Non-deductible executive compensation (0.4) (0.2) (0.8) Transaction costs — (0.1) (0.1) Other adjustments 1.2 1.2 (2.2) Valuation allowance (24.4) 3.7 (11.3) Effective tax rate 1.3 % 29.3 % 0.6 % For the year ended December 31, 2022, the Company recognized an income tax benefit, representing an effective tax rate of 1.3%. The difference between the expected statutory federal tax rate of 21.0% and the effective tax rate of 1.3% for the year ended December 31, 2022, was primarily attributable to the valuation allowance established against the Company's current period losses. For the year ended December 31, 2021, the Company recognized an income tax benefit, representing an effective tax rate of 29.3%. The difference between the expected statutory federal tax rate of 21.0% and the effective tax rate of 29.3% for the year ended December 31, 2021, was primarily attributable to an income tax benefit of $239.2 million recorded as a result of a change in the deferred tax asset valuation allowance resulting from the Thrive Merger. For the year ended December 31, 2020, the Company recognized an income tax benefit, representing an effective tax rate of 0.6%. The difference between the expected statutory federal tax rate of 21.0% and the effective tax rate of 0.6% for the year ended December 31, 2020, was primarily attributable to the valuation allowance established against the Company's current period losses and the non-deductible IPR&D expense related to the Base Genomics acquisition. The Company had unrecognized tax benefits related to federal and state research and development tax credits of $28.3 million, $21.8 million, and $16.6 million as of December 31, 2022, 2021, and 2020, respectively. These amounts have been recorded as a reduction to the Company's deferred tax asset, if recognized they would not have an impact on the effective tax rate due to the existing valuation allowance. Certain of the Company's unrecognized tax benefits could change due to activities of various tax authorities, including possible settlement of audits, or through normal expiration of various statutes of limitations. The Company does not expect a material change in unrecognized tax benefits in the next twelve months. The following is a tabular reconciliation of the amounts of unrecognized tax benefits: December 31, (In thousands) 2022 2021 2020 January 1, $ 21,780 $ 16,629 $ 10,276 Increase due to current year tax positions 5,861 5,363 3,600 Increase due to prior year tax positions 629 — 2,753 Decrease due to prior year tax positions — (212) — Settlements — — — December 31, $ 28,270 $ 21,780 $ 16,629 As of December 31, 2022, due to the carryforward of unutilized net operating losses and research and development credits, the Company is subject to U.S. federal income tax examinations for the tax years 2000 through 2022, and to state income tax examinations for the tax years 2000 through 2022. There were no interest or penalties related to income taxes that have been accrued or recognized as of and for the years ended December 31, 2022, 2021 and 2020. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
Business | Business Exact Sciences Corporation (together with its subsidiaries, “Exact” or the “Company”) was incorporated in February 1995. Exact is a leading global cancer diagnostics company. It has developed some of the most impactful tests in cancer screening and diagnostics, including Cologuard ® and Oncotype DX ® |
Basis of Presentation and Principles of Consolidation | Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements include the accounts of Exact Sciences Corporation and those of its wholly-owned subsidiaries and variable interest entities. All intercompany transactions and balances have been eliminated upon consolidation. |
Use of Estimates | Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical accounting policies are those that affect the Company's financial statements materially and involve difficult, subjective or complex judgments by management, and actual results could differ from those estimates. These estimates include revenue recognition, valuation of intangible assets and goodwill, and accounting for income taxes among others. The spread of the coronavirus (“COVID-19”) has affected many segments of the global economy, including the cancer screening and diagnostics industry. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of December 31, 2021 and through the date of the filing of this Annual Report on Form 10-K. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, marketable and non-marketable investments, and the carrying value of the goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods. The pandemic and related precautionary measures began to materially disrupt the Company's operations in March 2020 and may continue to disrupt the business for an unknown period of time. As a result, the pandemic had an impact on the Company's revenues and operating results. The ultimate impact of COVID-19 depends on factors beyond the Company’s knowledge or control, including the duration and severity of the outbreak, as well as third-party actions taken to contain its spread and mitigate its public health effects. As a result, the Company is unable to estimate the extent to which COVID-19 will negatively impact its financial results or liquidity. |
Cash and Cash Equivalents | Cash and Cash EquivalentsThe Company considers cash on hand, demand deposits in a bank, money market funds, and all highly liquid investments with an original maturity of 90 days or less to be cash and cash equivalents. |
Marketable Securities | Marketable Securities Management determines the appropriate classification of debt securities at the time of purchase and re-evaluates such designation as of each balance sheet date. Debt securities carried at amortized cost are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities not classified as held-to-maturity are classified as available-for-sale. Available-for-sale securities are carried at fair value. The unrealized gains and losses, net of tax, on the Company's debt securities are reported in other comprehensive income. Marketable equity securities are measured at fair value and the unrealized gains and losses, net of tax, are recognized in other income (expense) in the consolidated statements of operations. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest rate method. Such amortization is included in investment income, net. Realized gains and losses and declines in value as a result of credit losses on available-for-sale securities are included in the consolidated statements of operations as investment income, net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in the consolidated statements of operations as investment income, net. The Company’s investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support its current operations (including those with a contractual term greater than one year from the date of purchase) are classified as current. |
Allowance for Doubtful Accounts | Allowance for Doubtful AccountsThe Company estimates an allowance for doubtful accounts against accounts receivable using historical collection trends, aging of accounts, current and future implications surrounding the ability to collect such as economic conditions, and regulatory changes. The allowance for doubtful accounts is evaluated on a regular basis and adjusted when trends, significant events, or other substantive evidence such as an adverse change in a payer's ability to pay indicate that expected collections will be less than previously estimated. |
Inventory | Inventory Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first out method (“FIFO”). The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale, no longer meet quality specifications, or has a cost basis in excess of its estimated realizable value and records a charge to cost of sales for such inventory as appropriate. Direct and indirect manufacturing costs incurred during process validation with probable future economic benefit are capitalized. Validation costs incurred for other research and development activities, which are not permitted to be sold, are expensed to research and development in the Company’s consolidated statements of operations. |
Property, Plant and Equipment | Property, Plant and EquipmentProperty, plant and equipment are stated at cost and depreciated using the straight-line method over the assets’ estimated useful lives. Land is stated at cost and does not depreciate. Additions and improvements are capitalized, including direct and indirect costs incurred to validate equipment and bring to working conditions. Revalidation costs, including maintenance and repairs are expensed when incurred. |
Software Development Costs | Software Development Costs Costs related to internal use software, including hosted arrangements, are incurred in three stages: the preliminary project stage, the application development stage, and the post-implementation stage. Costs incurred during the preliminary project and post-implementation stages are expensed as incurred. Costs incurred during the application development stage that meet the criteria for capitalization are capitalized and amortized, when the software is ready for its intended use, using the straight‑line method over the estimated useful life of the software, or the duration of the hosting agreement. |
Investments in Privately Held Companies | Investments in Privately Held Companies The Company determines whether its investments in privately held companies are debt or equity based on their characteristics. The Company also evaluates the investee to determine if the entity is a variable interest entity (“VIE”) and, if so, whether the Company is the primary beneficiary of the VIE, in order to determine whether consolidation of the VIE is required. If consolidation is not required and the Company does not have voting control of the entity, the investment is evaluated to determine if the equity method of accounting should be applied. The equity method applies to investments in common stock or in substance common stock where the Company exercises significant influence over the investee. Investments in privately held companies determined to be equity securities are accounted for as non-marketable securities. The Company adjusts the carrying value of its non-marketable equity securities for changes from observable transactions for identical or similar investments of the same issuer, less impairment. All gains and losses on non-marketable equity securities, realized and unrealized, are recognized in investment income, net in the consolidated statements of operations. Investments in privately held companies determined to be debt securities are accounted for as available-for-sale or held-to-maturity securities unless the fair value option is elected. |
Derivative Financial Instruments | Derivative Financial InstrumentsThe Company hedges a portion of its foreign currency exposures related to outstanding monetary assets and liabilities using foreign currency forward contracts. The foreign currency forward contracts are included in prepaid expenses and other current assets or in accrued liabilities in the consolidated balance sheets, depending on the contracts’ net position. These contracts are not designated as hedges, and as a result, changes in their fair value are recorded in other income (expense) in the consolidated statements of operations. |
Business Combinations and Asset Acquisitions | Business Combinations and Asset AcquisitionsBusiness Combinations are accounted for under the acquisition method in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations. The acquisition method requires identifiable assets acquired and liabilities assumed and any non-controlling interest in the business acquired be recognized and measured at fair value on the acquisition date, which is the date that the acquirer obtains control of the acquired business. The amount by which the fair value of consideration transferred as the purchase price exceeds the net fair value of assets acquired and liabilities assumed is recorded as goodwill. Acquisitions that do not meet the definition of a business combination under ASC 805 are accounted for as asset acquisitions. Asset acquisitions are accounted for by allocating the cost of the acquisition to the individual assets acquired and liabilities assumed on a relative fair value basis. Goodwill is not recognized in an asset acquisition with any consideration in excess of net assets acquired allocated to acquired assets on a relative fair value basis. Transaction costs are expensed in a business combination and are considered a component of the cost of the acquisition in an asset acquisition. |
Intangible Assets | Intangible Assets Purchased intangible assets are recorded at fair value. The Company uses a discounted cash flow model to value intangible assets. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital, terminal values and market participants. Patent costs are capitalized as incurred, only if the Company determines that there is some probable future economic benefit derived from the transaction. A capitalized patent is amortized over its estimated useful life, beginning when such patent is approved. Capitalized patent costs are expensed upon disapproval, upon a decision by the Company to no longer pursue the patent or when the related intellectual property is either sold or deemed to be no longer of value to the Company. The Company determined that all patent costs incurred during the years ended December 31, 2022, 2021 and 2020 should be expensed and not capitalized as the future economic benefit derived from the patent costs incurred cannot be determined. |
Acquired In-process Research and Development (IPR&D) | Acquired In-process Research and Development (“IPR&D”) Acquired IPR&D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and cost projections used to value acquired IPR&D are, as applicable, reduced based on the probability of success. IPR&D projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development (“R&D”) efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. There are often major risks and uncertainties associated with IPR&D projects as the Company is required to obtain regulatory approvals in order to market the resulting products. Such approvals require completing clinical trials that demonstrate the product's effectiveness. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. |
Contingent Consideration | Contingent Consideration Liabilities Certain of the Company’s business combinations involve potential payment of future consideration that is contingent upon the achievement of certain regulatory and product development milestones being achieved. The Company records contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred, estimated as the probability-weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected probabilities of success, projected payment dates, present value-factors, and projected revenues (for revenue-based considerations). Changes in probabilities of success, present-value factors, and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized as income or expense within general and administrative expenses on the Company’s consolidated statements of operations. Cash contingent consideration payments up to the acquisition date fair value of the contingent consideration liability are classified as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are classified as operating activities in the consolidated statements of cash flows. |
Collateralized Debt Instruments | Collateralized Debt Instruments Debt instruments that are collateralized by security interests in financial assets held by the Company are accounted for as a secured borrowing and therefore: (i) the asset balances pledged as collateral are included within the applicable balance sheet line item and the borrowings are included within long-term debt in the consolidated balance sheet; (ii) interest expense is included within the consolidated statements of operations; and (iii) in the case of collateralized accounts receivable, receipts from customers related to the underlying accounts receivable are reflected as operating cash flows, and (iv) borrowings and repayments under the collateralized loans are reflected as financing cash flows within the consolidated statements of cash flows. |
Goodwill | GoodwillThe Company evaluates goodwill for possible impairment at the reporting unit level on an annual basis during the fourth quarter, or more frequently if events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting the Company's business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. |
Impairment of Long-Lived Assets | Impairment of Long-Lived AssetsThe Company evaluates the fair value of long-lived assets, which include property, plant and equipment, leases, finite-lived intangible assets, and investments in privately held companies, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. |
Net Loss Per Share | Net Loss Per Share Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share is the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive as a result of the Company’s losses. |
Accounting for Stock-Based Compensation | Accounting for Stock-Based Compensation The Company requires all share-based payments to employees, including grants of employee stock options, restricted stock, restricted stock units, shares purchased under an employee stock purchase plan (if certain parameters are not met), and performance share units to be recognized in the financial statements based on their grant date fair values. Forfeitures of any share-based awards are recognized as they occur. The fair values and recognition of the Company's share-based payment awards are determined as follows: The fair value of each service-based option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes the following assumptions: Expected Term —Expected life of an option award is the average length of time over which the Company expects employees will exercise their options, which is based on historical experience with similar grants. Expected Volatility —Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards. Risk-Free Interest Rate —The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent expected term. The estimated fair value of these awards is recognized to expense using the straight-line method over the requisite service period. The fair value of service-based awards for each restricted stock unit award is determined on the date of grant using the closing stock price on that day. The estimated fair value of these awards is recognized to expense using the straight-line method over the vesting period. |
Research and Development Costs | Research and Development Costs Research and development costs are expensed as incurred. These expenses include the costs of the Company's proprietary research and development efforts, as well as costs of IPR&D projects acquired as part of an asset acquisition that have no alternative future use. Upfront and milestone payments due to third parties in connection with research and development collaborations prior to regulatory approval are expensed as incurred. Milestone payments due to third parties upon, or subsequent to, regulatory approval are capitalized and amortized into research and development costs over the shorter of the remaining license or product patent life, when there are no corresponding revenues related to the license or product. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received, rather than when the payment is made. The Company incurred research and development expenses of $393.4 million, $385.6 million, and $554.1 million during the years ended December 31, 2022, 2021, and 2020, respectively, including IPR&D of $85.3 million and $412.6 million that was acquired in asset acquisitions that had no alternative future use during the years ended December 31, 2021 and 2020, respectively. The value of the acquired IPR&D that was expensed was determined by identifying those acquired specific IPR&D projects that would be continued and which (a) were incomplete and (b) had no alternative future use. Acquired IPR&D assets that are acquired in an asset acquisition and which have no alternative future use are classified as an investing cash outflow in the consolidated statements of cash flows. |
Advertising Costs | Advertising Costs The Company expenses the costs of media advertising at the time the advertising takes place. The Company expensed approximately $170.3 million, $144.0 million, and $97.6 million of media advertising during the years ended December 31, 2022, 2021, and 2020, respectively, which is recorded in sales and marketing expenses on the Company's consolidated statements of operations. |
Fair Value Measurements | Fair Value Measurements The Financial Accounting Standards Board (“FASB”) has issued authoritative guidance that requires fair value to be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. Under that standard, fair value measurements are separately disclosed by level within the fair value hierarchy. The fair value hierarchy establishes and prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs. Observable inputs are inputs that reflect the assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. |
Leases | Leases The Company acts as lessee in its lease agreements, which include operating leases for corporate offices, laboratory space, warehouse space, vehicles, and certain laboratory and office equipment, and finance leases for certain equipment and vehicles. The Company determines whether an arrangement is, or contains, a lease at inception. At the beginning of fiscal year 2019, the company adopted ASC 842. The Company records the present value of lease payments as right-of-use (“ROU”) assets and lease liabilities on the consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company’s obligations. As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term and at an amount equal to the lease payments in a similar economic environment. The Company calculates its incremental borrowing rates for specific lease terms, used to discount future lease payments, as a function of the US. Treasury rate and an indicative Moody's rating for operating leases or finance leases. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. “Reasonably certain” is assessed internally based on economic, industry, company, strategic and contractual factors. The leases have remaining lease terms of 1 year to 15 years, some of which include options to extend the lease for up to 10 years, and some of which include options to terminate the lease within 1 year. Operating lease expense and amortization of finance lease ROU assets are recognized on a straight-line basis over the lease term as an operating expense. Finance lease interest expense is recorded as interest expense on the Company’s consolidated statements of operations. The Company accounts for leases acquired in business combinations by measuring the lease liability at the present value of the remaining lease payments as if the acquired lease were a new lease for the Company. This measurement includes recognition of a lease intangible for any below-market terms present in the leases acquired. The below-market lease intangible is included in the ROU asset on the consolidated balance sheets and are amortized over the remaining lease term. The Company has not acquired any leases with above-market terms. |
Revenue Recognition | Revenue Recognition Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard, Oncotype, PreventionGenetics, and COVID-19 tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The key aspects considered by the Company include the following: Contracts —The Company’s customer is primarily the patient, but the Company does not enter into a formal reimbursement contract with a patient. The Company establishes a contract with a patient in accordance with other customary business practices, which is the point in time an order is received from a provider and a patient specimen has been returned to the laboratory for testing. Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with Center for Medicare & Medicaid Services (“CMS”) and applicable reimbursement contracts established between the Company and payers. However, when a patient is considered self-pay, the Company requires payment from the patient prior to the commencement of the Company’s performance obligations. The Company’s consideration can be deemed variable or fixed depending on the structure of specific payer contracts, and the Company considers collection of such consideration to be probable to the extent that it is unconstrained. Under the Company’s Laboratory Service Agreements (“LSA”) and Laboratory Reference Agreements (“LRA”) the Company contracts with a direct bill payer who is the customer for an agreed upon amount of laboratory testing services for a specified amount of time at a fixed reimbursement rate, and certain of the Company’s agreements obligate the customer to pay for testing services prior to result. Performance obligations —A performance obligation is a promise in a contract to transfer a distinct good or service (or a bundle of goods or services) to the customer. The Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the release of a patient’s test result to the ordering healthcare provider. Or, in the context of some of the Company’s agreements, the satisfaction of the performance obligation occurs when a specimen sample is not returned to the laboratory for processing before the end of the allotted testing window. The Company elects the practical expedient to not disclose unsatisfied performance obligations, as the duration of time between providing testing supplies, the receipt of a sample, and the release of a test result to the ordering healthcare provider is far less than one year. Transaction price —The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration expected to be collected from a contract with a customer may include fixed amounts, variable amounts, or both. Fixed consideration is derived from the Company’s LSA, LRA, and direct bill payer contracts that exist between the Company and the direct bill payers. The contracted reimbursement rate is deemed to be fixed as the Company expects to fully collect all amounts billed under these relationships. Variable consideration is primarily derived from payer and patient billing and can result due to several factors such as the amount of contractual adjustments, any patient co-payments, deductibles or patient adherence incentives, the existence of secondary payers, and claim denials. The Company estimates the amount of variable consideration using the expected value method, which represents the sum of probability-weighted amounts in a range of possible consideration amounts. When estimating the amount of variable consideration, the Company considers several factors, such as historical collections experience, customer mix, patient insurance eligibility and payer reimbursement contracts. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more or less consideration than it originally estimated for a contract with a patient, it will account for the change as an increase or decrease in the estimate of the transaction price (i.e., an upward or downward revenue adjustment) in the period identified. When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon completion of the performance obligations associated with the Company's tests, with recognition, generally occurring at the date of cash receipt. Allocate transaction price —The transaction price is allocated entirely to the performance obligation contained within the contract with a customer. Point in time recognition —The Company’s single performance obligation is satisfied at a point in time. That point in time is defined as the date the Company releases a result to the ordering healthcare provider, or, in the context of some of the Company's agreements, that point in time could be the date the allotted testing window ends if a specimen sample is not returned to the laboratory for processing. The point in time in which revenue is recognized by the Company signifies fulfillment of the performance obligation to the patient or direct bill payer. Contract Balances —The timing of revenue recognition, billings and cash collections results in billed accounts receivable and deferred revenue on the consolidated balance sheets. Generally, billing occurs subsequent to the release of a patient’s test result to the ordering healthcare provider, resulting in an account receivable. However, the Company sometimes receives advance payment from a patient or a direct bill payer before a test result is completed, resulting in deferred revenue. The deferred revenue recorded is recognized as revenue at the point in time results are released to the patient’s healthcare provider. Or, in the context of some of the Company’s agreements, the satisfaction of the performance obligation occurs when a specimen sample is not returned to the laboratory for processing before the end of the allotted testing window. Practical Expedients —The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. The Company expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses in the Company’s consolidated statements of operations. The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications (e.g. adherence reminder letters). These costs are expensed as incurred and recorded within general and administrative expenses in the Company’s consolidated statements of operations. |
Foreign Currency Transactions | Foreign Currency Transactions The functional currency for most of the Company’s international subsidiaries is the U.S. dollar. When the functional currency differs from the local currency, monetary assets and liabilities are remeasured at the current period-end exchange rate, while non-monetary assets and liabilities are remeasured at the historical rate. The gains and losses as a result of exchange rate adjustments of these subsidiaries are recognized in the consolidated statements of operations. Net foreign currency transaction gains or losses were not material to the consolidated statements of operations for the periods presented. |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that subject the Company to credit risk consist of cash, cash equivalents and marketable securities. As of December 31, 2022, the Company had cash and cash equivalents deposited in financial institutions in which the balances exceed the federal government agency insured limit of $250,000 by approximately $125.7 million. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk. Through December 31, 2022, the Company’s revenues have been primarily derived from the sale of Cologuard, Oncotype, and COVID-19 tests. The following is a breakdown of revenue and accounts receivable from major payers: % Revenue for the years ended December 31, % Accounts Receivable at December 31, Major Payer 2022 2021 2020 2022 2021 2020 Centers for Medicare and Medicaid Services 14% 20% 21% 14% 11% 14% UnitedHealthcare 12% 11% 10% 9% 8% 7% State of Wisconsin 3% 8% 12% 5% 9% 22% |
Tax Positions | Tax Positions A valuation allowance to reduce the deferred tax assets is reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has incurred significant losses since its inception and due to the uncertainty of the amount and timing of future taxable income, the Company has determined that a valuation allowance at December 31, 2022 and 2021 is necessary to reduce the tax assets to the amount that is more likely than not to be realized. Due to the existence of the valuation allowance, future changes in the Company's unrecognized tax benefits will not impact the Company's effective tax rate. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In August 2020, The FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt – Debt with Conversion and Other Options (subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) . This update simplifies the accounting for convertible debt instruments by removing the beneficial conversion and cash conversion separation models for convertible instruments. Under the update, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives or that do not result in substantial premiums accounted for as paid-in capital. The update also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will no longer be available. This standard may be adopted through either a modified retrospective method of transition or a full retrospective method of transition. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted the standard on January 1, 2021 through application of the full retrospective method of transition. This method of adoption was applied to enhance comparability between the periods presented in the Company’s financial statements. The Company applied the standard to convertible notes outstanding as of the date of the first offering of the Company’s outstanding convertible notes as discussed in Note 10. The Company’s convertible debt instruments are now accounted for as a single liability measured at its amortized cost. The notes are no longer bifurcated between debt and equity, rather accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. Gain or loss on extinguishment of convertible notes is calculated as the difference between the (i) fair value of the consideration transferred and (ii) the sum of the carrying value of the debt at the time of repurchase. For the year ended December 31, 2020, interest expense in the consolidated statement of operations decreased by $28.1 million as a result of a decrease in amortization of debt discounts, premiums, and issuance costs of $70.9 million, which was offset by an increase in loss on extinguishment of $42.8 million in connection with the extinguishment of $100.0 million face value of the 2025 Notes. Income tax benefit decreased by $3.1 million and net loss per share, basic and diluted, decreased by $0.17 per share. In October 2021, The FASB issued ASU No. 2021-08, Business Combinations (Topic 805) . This update requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606. This differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. The amendments in this update should be applied prospectively, and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company early adopted the amendments in this update during the first quarter of 2022. There was no material impact to the Company's consolidated financial statements. In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832) . This update requires certain annual disclosures about transactions with a government that are accounted for by applying a grant or contribution model by analogy. The amendments in this update are effective for fiscal years beginning after December 15, 2021. Early application of the amendments is permitted. The Company early adopted these disclosure requirements and applied them to its disclosure of the WEDC tax credits earned during fiscal year 2021 and the funding received as part of the CARES Act in 2020. In June 2022, the FASB issued ASU No. 2022-03, Fair Value Measurement (Topic 820) – Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions |
Guarantees and Indemnifications | Guarantees and Indemnifications The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a directors and officers insurance policy that limits its exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of December 31, 2022 and 2021. |
Reclassifications | Reclassifications Certain prior year amounts have been reclassified to conform to the current year presentation in the consolidated financial statements and accompanying notes to the consolidated financial statements. |
Accounting for Government Assistance, Policy | Accounting for Government Assistance There is no GAAP that specifically addresses the accounting by business entities for government assistance and tax credits. Absent authoritative accounting standards, interpretative guidance issued and commonly applied by financial statement preparers allows for the selection of accounting policies amongst acceptable alternatives. Based on the facts and circumstances of the government assistance and tax credits received by the Company as discussed below, the Company determined it most appropriate to account for the these transactions by analogy to International Accounting Standards 20 (“IAS 20”), Accounting for Government Grants and Disclosure of Government Assistance. IAS 20 permits for the recognition in earnings either separately under a general heading such as other income, or as a reduction of the related expenses. In April 2020, the Company received $23.7 million from the United States Department of Health and Human Services (“HHS”) as a distribution from the Public Health and Social Services Emergency Fund provided for in the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The fund payments are grants, not loans, and HHS will not require repayment provided the funds are utilized to offset expenses incurred to address COVID-19 or to replace lost revenues. The Company accepted the terms and conditions of the grant in May 2020 and recognized the entire $23.7 million during the year ended December 31, 2020, due to lost revenue attributable to COVID-19. The Company has elected to recognize government grant income separately to present a clearer distinction in its consolidated financial statements between its operating income and the amount of income resulting from the CARES Act grant received. The Company believes this presentation method promotes greater comparability amongst all periods presented. Accordingly, the $23.7 million grant recognized during the year ended December 31, 2020 was reflected in other operating income in the consolidated statement of operations and as an operating activity in the consolidated statement of cash flows. |
Cost of Goods and Service | Cost of Sales Cost of sales reflects the aggregate costs incurred in delivering our products and services and includes material and service costs, personnel costs, including stock-based compensation expense, equipment and infrastructure expenses associated with laboratory testing services, order and delivery systems, shipping charges, and allocated overhead such as rent, information technology costs, equipment depreciation and utilities. Costs associated with performing the Company’s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
Schedule of potentially issuable common shares not included in the computation of diluted net loss per share because they would have an anti-dilutive effect | The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period: December 31, (In thousands) 2022 2021 2020 Shares issuable in connection with acquisitions — 45 157 Shares issuable upon exercise of stock options 1,518 2,284 2,231 Shares issuable upon the release of restricted stock awards 5,255 4,321 3,968 Shares issuable upon the release of performance share units 968 878 619 Shares issuable upon conversion of convertible notes 20,309 20,309 20,309 28,050 27,837 27,284 |
REVENUE (Tables)
REVENUE (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of disaggregation by revenue source | The following table presents the Company's revenues disaggregated by revenue source: Year Ended December 31, (In thousands) 2022 2021 2020 Screening Medicare Parts B & C $ 545,458 $ 438,646 $ 365,471 Commercial 743,238 569,944 409,671 Other 136,007 53,718 39,925 Total Screening 1,424,703 1,062,308 815,067 Precision Oncology Medicare Parts B & C $ 197,327 $ 197,394 $ 165,799 Commercial 177,518 180,177 153,410 International 117,738 109,913 77,484 Other 108,905 74,192 43,800 Total Precision Oncology 601,488 561,676 440,493 COVID-19 Testing $ 58,088 $ 143,103 $ 235,831 Total $ 2,084,279 $ 1,767,087 $ 1,491,391 |
MARKETABLE SECURITIES (Tables)
MARKETABLE SECURITIES (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Cash and Cash Equivalents [Abstract] | |
Schedule of cash and cash equivalents | The following table sets forth the Company’s cash, cash equivalents, and marketable securities at December 31, 2022 and 2021: December 31, (In thousands) 2022 2021 Cash and cash equivalents Cash and money market $ 178,168 $ 247,335 Cash equivalents 64,325 68,136 Total cash and cash equivalents 242,493 315,471 Marketable securities Available-for-sale debt securities $ 384,415 $ 711,669 Equity securities 5,149 3,336 Total marketable securities 389,564 715,005 Total cash, cash equivalents, and marketable securities $ 632,057 $ 1,030,476 |
Schedule of available-for-sale securities | Available-for-sale debt securities, including the classification within the consolidated balance sheet at December 31, 2022, consisted of the following: (In thousands) Amortized Cost Gains in Accumulated Other Comprehensive Income (Loss) (1) Losses in Accumulated Other Comprehensive Income (Loss) (1) Estimated Fair Value Cash equivalents Commercial paper $ 63,021 $ — $ — $ 63,021 U.S. government agency securities 1,304 — — 1,304 Total cash equivalents 64,325 — — 64,325 Marketable securities U.S. government agency securities $ 228,012 $ — $ (2,789) $ 225,223 Corporate bonds 116,318 20 (1,667) 114,671 Asset backed securities 45,374 2 (855) 44,521 Total marketable securities 389,704 22 (5,311) 384,415 Total available-for-sale debt securities $ 454,029 $ 22 $ (5,311) $ 448,740 _________________________________ (1) Gains and losses in accumulated other comprehensive loss (“AOCI”) are reported before tax impact. Available-for-sale debt securities, including the classification within the consolidated balance sheet at December 31, 2021, consisted of the following: (In thousands) Amortized Cost Gains in Accumulated Other Comprehensive Income (Loss) (1) Losses in Accumulated Other Comprehensive Income (Loss) (1) Estimated Fair Value Cash equivalents Commercial paper $ 64,593 $ — $ — $ 64,593 U.S. government agency securities 3,543 — — 3,543 Total cash equivalents 68,136 — — 68,136 Marketable securities Corporate bonds $ 313,634 $ 13 $ (493) $ 313,154 U.S. government agency securities 250,793 — (873) 249,920 Asset backed securities 94,565 2 (107) 94,460 Certificates of deposit 47,147 2 (10) 47,139 Commercial paper 6,996 — — 6,996 Total marketable securities 713,135 17 (1,483) 711,669 Total available-for-sale debt securities $ 781,271 $ 17 $ (1,483) $ 779,805 _________________________________ (1) Gains and losses in AOCI are reported before tax impact. |
Schedule of contractual maturities of available-for-sale investments | The following table summarizes contractual underlying maturities of the Company’s available-for-sale debt securities at December 31, 2022: Due one year or less Due after one year through five years (In thousands) Cost Fair Value Cost Fair Value Cash equivalents Commercial paper $ 63,021 $ 63,021 $ — $ — U.S. government agency securities 1,304 1,304 — — Total cash equivalents 64,325 64,325 — — Marketable securities U.S. government agency securities $ 218,364 $ 215,620 $ 9,648 $ 9,603 Corporate bonds 90,368 89,102 25,950 25,569 Asset backed securities — — 45,374 44,521 Total marketable securities 308,732 304,722 80,972 79,693 Total available-for-sale securities $ 373,057 $ 369,047 $ 80,972 $ 79,693 |
Schedule of gross unrealized losses and fair values of investments in an unrealized loss position | The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of December 31, 2022, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position: Less than 12 months 12 months or greater Total (In thousands) Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Marketable securities U.S. government agency securities $ 37,458 $ (337) $ 187,766 $ (2,452) $ 225,224 $ (2,789) Corporate bonds 35,055 (575) 73,702 (1,092) 108,757 (1,667) Asset backed securities 27,984 (735) 15,536 (120) 43,520 (855) Total available-for-sale securities $ 100,497 $ (1,647) $ 277,004 $ (3,664) $ 377,501 $ (5,311) The following table summarizes the gross unrealized losses and fair values of available-for-sale debt securities in an unrealized loss position as of December 31, 2021, aggregated by investment category and length of time those individual securities have been in a continuous unrealized loss position: Less than 12 months 12 months or greater Total (In thousands) Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Fair Value Gross Unrealized Loss Marketable securities Corporate bonds $ 299,448 $ (493) $ — $ — $ 299,448 $ (493) U.S. government agency securities 249,921 (873) — — 249,921 (873) Asset backed securities 89,990 (107) — — 89,990 (107) Certificates of deposit 24,137 (10) — — 24,137 (10) Total available-for-sale securities $ 663,496 $ (1,483) $ — $ — $ 663,496 $ (1,483) |
INVENTORY (Tables)
INVENTORY (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Inventory Disclosure [Abstract] | |
Schedule of inventory | Inventory consisted of the following: December 31, (In thousands) 2022 2021 Raw materials $ 61,207 $ 51,321 Semi-finished and finished goods 57,052 53,673 Total inventory $ 118,259 $ 104,994 |
PROPERTY, PLANT, AND EQUIPMENT
PROPERTY, PLANT, AND EQUIPMENT (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Property, Plant and Equipment [Abstract] | |
Schedule of property, plant and equipment, net | The carrying value and estimated useful lives of property, plant and equipment are as follows: December 31, (In thousands) Estimated Useful Life 2022 2021 Property, plant and equipment Land n/a $ 4,716 $ 4,716 Leasehold and building improvements (1) 200,588 147,083 Land improvements 15 years 6,417 5,206 Buildings 30 - 40 years 288,941 210,560 Computer equipment and computer software 3 years 142,896 109,119 Laboratory equipment 3 - 10 years 246,344 189,748 Furniture and fixtures 3 - 10 years 34,047 28,293 Assets under construction n/a 68,398 100,339 Property, plant and equipment, at cost 992,347 795,064 Accumulated depreciation (307,591) (214,816) Property, plant and equipment, net $ 684,756 $ 580,248 _________________________________ (1) Lesser of remaining lease term, building life, or estimated useful life. |
INTANGIBLE ASSETS AND GOODWILL
INTANGIBLE ASSETS AND GOODWILL (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of net-book value and estimated remaining life and finite lived intangible assets | The following table summarizes the net-book-value and estimated remaining life of the Company's intangible assets as of December 31, 2022: (In thousands) Weighted Average Remaining Life (Years) Cost Accumulated Amortization Net Balance at December 31, 2022 Finite-lived intangible assets Trade name 12.5 $ 104,000 $ (20,653) $ 83,347 Customer relationships 8.0 4,000 (444) 3,556 Patents and licenses 4.2 11,542 (8,152) 3,390 Acquired developed technology (1) 7.8 861,474 (245,527) 615,948 Total finite-lived intangible assets 981,016 (274,776) 706,240 In-process research and development n/a 1,250,000 — 1,250,000 Total intangible assets $ 2,231,016 $ (274,776) $ 1,956,240 _________________________________ (1) The gross carrying amount includes an immaterial foreign currency translation adjustment related to the intangible assets acquired as a result of the acquisition of OmicEra Diagnostics GmbH (“OmicEra”), whose functional currency is also its local currency. Intangible asset balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income. The following table summarizes the net-book-value and estimated remaining life of the Company’s intangible assets as of December 31, 2021: (In thousands) Weighted Average Remaining Life (Years) Cost Accumulated Amortization Net Balance at December 31, 2021 Finite-lived intangible assets Trade name 13.4 $ 104,700 $ (13,554) $ 91,146 Customer relationships 9.6 6,700 (1,577) 5,123 Patents and licenses 3.6 10,942 (6,763) 4,179 Supply agreement 5.4 2,295 (101) 2,194 Acquired developed technology 8.6 918,171 (176,402) 741,769 Total finite-lived intangible assets 1,042,808 (198,397) 844,411 In-process research and development n/a 1,250,000 — 1,250,000 Total intangible assets $ 2,292,808 $ (198,397) $ 2,094,411 |
Schedule of estimated future amortization expense, intangible assets | As of December 31, 2022, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows: (In thousands) 2023 $ 91,713 2024 91,379 2025 90,331 2026 89,271 2027 89,271 Thereafter 254,275 Total $ 706,240 |
Schedule of carrying amount of goodwill | The change in the carrying amount of goodwill for the years ended December 31, 2022 and 2021 is as follows: (In thousands) Balance, January 1, 2021 $ 1,237,672 Thrive Earlier Detection Corporation (“Thrive”) acquisition 948,105 Ashion Analytics, LLC (“Ashion”) acquisition 56,758 PreventionGenetics acquisition 92,637 Balance, December 31, 2021 2,335,172 OmicEra Acquisition 10,809 PreventionGenetics acquisition adjustment (58) Effects of changes in foreign currency exchange rates (1) 117 Balance, December 31, 2022 $ 2,346,040 _________________________________ (1) Represents the impact of foreign currency translation related to the goodwill acquired as a result of the acquisition of OmicEra. Goodwill balances are translated into U.S. dollars using exchange rates in effect at period end, and adjustments related to foreign currency translation are included in other comprehensive income. |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Schedule of fair value measurements along with the level within the fair value hierarchy in which the fair value measurements fall | The following table presents the Company’s fair value measurements as of December 31, 2022 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall. (In thousands) Fair value at December 31, 2022 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash, cash equivalents, and restricted cash Cash and money market $ 178,168 $ 178,168 $ — $ — Commercial paper 63,021 — 63,021 — U.S. government agency securities 1,304 — 1,304 — Restricted cash 297 297 — — Marketable securities U.S. government agency securities $ 225,223 $ — $ 225,223 $ — Corporate bonds 114,671 — 114,671 — Asset backed securities 44,521 — 44,521 — Equity securities (1) 5,149 5,149 — — Non-marketable securities $ 10,065 $ — $ — $ 10,065 Liabilities Contingent consideration $ (306,927) $ — $ — $ (306,927) Total $ 335,492 $ 183,614 $ 448,740 $ (296,862) _________________________________ (1) Inclusive of the American Depository Shares of MDxHealth received as part of the sale of the Company’s GPS test, which are restricted to a holding period of six months after the date of the sale of August 2, 2022. The shares have a fair value of $4.6 million as of December 31, 2022. The following table presents the Company’s fair value measurements as of December 31, 2021 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall. (In thousands) Fair Value at December 31, 2021 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Cash and cash equivalents Cash and money market $ 247,335 $ 247,335 $ — $ — Commercial paper 64,593 — 64,593 — U.S. government agency securities 3,543 — 3,543 — Restricted cash 297 297 — — Marketable securities Corporate bonds $ 313,154 $ — $ 313,154 $ — U.S. government agency securities 249,920 — 249,920 — Asset backed securities 94,460 — 94,460 — Certificates of deposit 47,139 — 47,139 — Commercial paper 6,996 — 6,996 — Equity securities 3,336 3,336 — — Non-marketable securities $ 3,090 $ — $ — $ 3,090 Liabilities Contingent consideration $ (359,021) $ — $ — $ (359,021) Total $ 674,842 $ 250,968 $ 779,805 $ (355,931) |
Schedule of fair value of contingent consideration | The following table provides a reconciliation of the beginning and ending balances of contingent consideration: (In thousands) Contingent consideration Balance, January 1, 2021 (1) $ 2,477 Purchase price contingent consideration (2) 350,348 Changes in fair value 6,359 Payments (163) Balance, December 31, 2021 359,021 Purchase price contingent consideration (3) 4,600 Changes in fair value (56,617) Payments (77) Balance, December 31, 2022 $ 306,927 _________________________________ (1) The change in fair value of the contingent consideration liability during the year ended December 31, 2020 was not material to the consolidated financial statements. (2) The increase in the contingent consideration liability is due to the contingent consideration associated with the acquisitions of Ashion and Thrive. Refer to Note 18 for further information. |
ACCRUED LIABILITIES (Tables)
ACCRUED LIABILITIES (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Payables and Accruals [Abstract] | |
Schedule of accrued expenses | Accrued liabilities at December 31, 2022 and 2021 consisted of the following: December 31, (In thousands) 2022 2021 Compensation $ 201,252 $ 183,517 Pfizer, Inc. (“Pfizer”) Promotion Agreement related costs — 91,436 Professional fees 43,715 50,077 Other 22,329 32,116 Assets under construction 10,462 22,611 Research and trial related expenses 17,455 15,534 Licenses 4,003 3,265 Total $ 299,216 $ 398,556 |
CONVERTIBLE NOTES (Tables)
CONVERTIBLE NOTES (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
CONVERTIBLE DEBT | |
Schedule of debt, net of discounts and deferred financing costs | Convertible note obligations included in the consolidated balance sheet consisted of the following as of December 31, 2022: Fair Value (1) (In thousands) Principal Amount Unamortized Debt Discount and Issuance Costs Net Carrying Amount Amount Leveling 2028 Convertible notes - 0.375% $ 1,150,000 $ (15,775) $ 1,134,225 $ 908,500 2 2027 Convertible notes - 0.375% 747,500 (9,445) 738,055 612,950 2 2025 Convertible notes - 1.000% 315,005 (1,179) 313,826 326,808 2 Convertible note obligations included in the consolidated balance sheet consisted of the following as of December 31, 2021: Fair Value (1) (In thousands) Principal Amount Unamortized Debt Discount and Issuance Costs Net Carrying Amount Amount Leveling 2028 Convertible notes - 0.375% $ 1,150,000 $ (18,826) $ 1,131,174 $ 1,139,650 2 2027 Convertible notes - 0.375% 747,500 (11,691) 735,809 771,794 2 2025 Convertible notes - 1.000% 315,005 (1,756) 313,249 415,473 2 ____________________________ |
Schedule of Allocation of Transaction Costs Related to Convertible Debt | The following table summarizes the original issuance costs at the time of issuance for each set of Notes: (In thousands) January 2025 Notes $ 10,284 June 2025 Notes 7,362 2027 Notes 14,285 2028 Notes 24,453 |
Schedule of Interest Expense | Interest expense includes the following: Year Ended December 31, (In thousands) 2022 2021 2020 Debt issuance costs amortization $ 5,727 $ 5,727 $ 5,303 Debt discount amortization 147 147 131 Loss on settlement of convertible notes — — 50,819 Coupon interest expense 10,266 10,266 9,631 Total interest expense on convertible notes $ 16,140 $ 16,140 $ 65,884 The following table summarizes the effective interest rates of the Notes: Year Ended December 31, 2022 2021 2020 2025 Convertible Notes 1.18 % 1.18 % 1.20 % 2027 Convertible Notes 0.68 % 0.68 % 0.68 % 2028 Convertible Notes 0.64 % 0.64 % 0.54 % |
STOCKHOLDERS' EQUITY (Tables)
STOCKHOLDERS' EQUITY (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Equity [Abstract] | |
Schedule of business acquisitions, by acquisition | Stock issuances in relation to acquisitions during the years ended December 31, 2022, 2021 and 2020 were as follows: (In millions) Period of Acquisition Shares Issued Fair Value of Shares Issued OmicEra May 2022 0.3 $ 14.8 PreventionGenetics December 2021 1.1 84.2 Ashion April 2021 0.1 16.2 Thrive January 2021 9.3 1,190.0 Targeted Digital Sequencing (“TARDIS”) license January 2021 0.2 27.3 Paradigm Diagnostics, Inc. (“Paradigm”) and Viomics, Inc. (“Viomics”) March 2020 0.4 28.8 The acquisition date fair value of the consideration transferred for OmicEra was approximately $19.4 million, which consisted of the following: (In thousands) Common stock issued $ 14,792 Contingent consideration 4,600 Cash paid related to working capital adjustment 16 Total purchase price $ 19,408 The acquisition date fair value of the consideration transferred for PreventionGenetics was approximately $185.4 million, which consisted of the following: (In thousands) Cash $ 101,129 Common stock issued 84,252 Total purchase price $ 185,381 The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million, which consisted of the following: (In thousands) Cash $ 74,775 Common stock issued 16,224 Contingent consideration 19,000 Total purchase price $ 109,999 The acquisition date fair value of the consideration transferred for Thrive was approximately $2.19 billion, which consisted of the following: (In thousands) Common stock issued $ 1,175,431 Cash 584,996 Contingent consideration 331,348 Fair value of replaced equity awards 52,245 Previously held equity investment fair value 43,034 Total purchase price $ 2,187,054 |
Schedule of amounts recognized in accumulated other comprehensive income (loss) (AOCI) | The amount recognized in AOCI for the years ended December 31, 2022, 2021 and 2020 were as follows: (In thousands) Cumulative Translation Adjustment Unrealized Gain (Loss) on Securities Accumulated Other Comprehensive Income (Loss) Balance at January 1, 2020 $ (25) $ (75) $ (100) Other comprehensive income before reclassifications — 771 771 Amounts reclassified from accumulated other comprehensive loss 25 — 25 Net current period change in accumulated other comprehensive loss 25 771 796 Income tax expense related to items of other comprehensive loss — (170) (170) Balance at December 31, 2020 $ — $ 526 $ 526 Other comprehensive income (loss) before reclassifications 23 (1,648) (1,625) Amounts reclassified from accumulated other comprehensive loss — (514) (514) Net current period change in accumulated other comprehensive loss 23 (2,162) (2,139) Income tax benefit related to items of other comprehensive loss — 170 170 Balance at December 31, 2021 $ 23 $ (1,466) $ (1,443) Other comprehensive income (loss) before reclassifications 30 (4,049) (4,019) Amounts reclassified from accumulated other comprehensive loss — 226 226 Net current period change in accumulated other comprehensive loss 30 (3,823) (3,793) Balance at December 31, 2022 $ 53 $ (5,289) $ (5,236) _________________________________ (1) There was no tax impact from the amounts recognized in AOCI for the year ended December 31, 2022. |
Schedule of amounts reclassified from accumulated other comprehensive income (loss) | Amounts reclassified from AOCI for the years ended December 31, 2022, 2021 and 2020 were as follows: Year Ended December 31, Details about AOCI Components (In thousands) Affected Line Item in the 2022 2021 2020 Change in value of available-for-sale investments Sales and maturities of available-for-sale investments Investment income $ 226 $ (514) $ — Foreign currency adjustment General and administrative — — 25 Total reclassifications $ 226 $ (514) $ 25 |
STOCK-BASED COMPENSATION (Table
STOCK-BASED COMPENSATION (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of non-cash stock-based compensation expense by department | A summary of non-cash stock-based compensation expense by expense category included in the Company's consolidated statements of operations for the years ended December 31, 2022, 2021, and 2020 is as follows: Year Ended December 31, (In thousands) 2022 2021 2020 Cost of sales $ 19,218 $ 16,835 $ 12,852 Research and development 33,825 49,723 19,976 Sales and marketing 62,568 55,716 44,079 General and administrative 91,212 216,952 75,999 Total stock-based compensation $ 206,823 $ 339,226 $ 152,906 |
Schedule of valuation assumptions | The Company determines the fair value of each service-based option award on the date of grant using the Black-Scholes option-pricing model, which utilizes several key assumptions which are disclosed in the following table: Year Ended December 31 2022 2021 2020 Risk-free interest rates (1) (1) 1.26% - 1.47% Expected term (in years) (1) (1) 6.15 Expected volatility (1) (1) 65.67% - 65.71% Dividend yield (1) (1) 0% _________________________________ (1) The Company did not grant stock options under its 2010 Omnibus Long-Term Incentive Plan or 2019 Omnibus Long-Term Incentive Plan during the period. The fair value of ESPP shares is based on the assumptions in the following table: Year Ended December 31, 2022 2021 2020 Risk-free interest rates 1.49% - 4.71% 0.04% - 0.16% 0.11% - 0.20% Expected term (in years) 0.5 - 2 0.5 - 2 0.5 - 2 Expected volatility 50.94% - 63.13% 43% - 68.51% 61.59% - 89.00% Dividend yield 0% 0% 0% |
Summary of stock option activity under the Stock Plans | A summary of stock option activity under the Stock Plans is as follows: Options Shares Weighted Average Exercise Price (1) Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (2) (Aggregate intrinsic value in thousands) Outstanding, January 1, 2022 2,284,276 $ 34.65 5.5 Granted — — Exercised (706,593) 9.27 Forfeited (59,807) 78.63 Outstanding, December 31, 2022 1,517,876 $ 44.82 4.7 $ 28,204 Vested and expected to vest, December 31, 2022 1,517,876 $ 44.82 4.7 $ 28,204 Exercisable, December 31, 2022 1,345,998 $ 38.69 4.4 $ 27,932 _________________________________ (1) The weighted average grant date fair value of options granted during the year ended December 31, 2020 was $58.57. (2) The total intrinsic value of options exercised during the years ended December 31, 2022, 2021, and 2020 was $36.4 million, $155.8 million, and $40.6 million, respectively, determined as of the date of exercise. |
Summary of restricted stock and restricted stock unit activity under the Stock Plans | A summary of restricted stock and restricted stock unit activity is as follows: Restricted Shares Weighted Average Grant Date Fair Value (1) Outstanding, January 1, 2022 4,320,910 $ 108.84 Granted 3,954,761 68.18 Released (2) (1,896,223) 91.22 Forfeited (1,124,739) 86.89 Outstanding, December 31, 2022 5,254,709 $ 89.29 _________________________________ (1) The weighted average grant date fair value of the restricted stock units granted during the years ended December 31, 2021 and 2020 was $129.16 and $92.55, respectively. (2) The fair value of restricted stock units vested and converted to shares of the Company's common stock was $117.6 million, $219.4 million, and $152.4 million for the years ended December 31, 2022, 2021, and 2020, respectively. |
Share-based Payment Arrangement, Performance Shares, Activity | A summary of performance share unit activity is as follows: Performance Share Units (1) Weighted Average Grant Date Fair Value (2) Outstanding, January 1, 2022 878,114 $ 107.18 Granted 805,782 89.43 Released (3) (292,134) 93.22 Forfeited (423,916) 92.02 Outstanding, December 31, 2022 967,846 $ 102.58 _________________________________ (1) The performance share units listed above assumes attainment of maximum payout rates as set forth in the performance criteria. Applying actual or expected payout rates, the number of outstanding performance share units as of December 31, 2022 was 146,134. (2) The weighted average grant date fair value of the performance share units granted during the years ended December 31, 2021 and 2020 was $138.09 and $90.17, respectively. |
Schedule of shares of common stock issued | A summary of ESPP activity is as follows: Year Ended December 31, (in thousands, except share and per share amounts) 2022 2021 2020 Shares issued under the 2010 Purchase Plan 668,605 331,769 301,064 Cash received under the 2010 Purchase Plan $ 25,491 $ 23,070 $ 18,355 Weighted average fair value per share of stock purchase rights granted during the period $ 17.52 $ 34.93 $ 32.57 |
Schedule of Common Stock Issued | The 668,605 shares issued during the year ended December 31, 2022 were as follows: Offering period ended Number of Shares Weighted Average price per Share April 30, 2022 326,138 $ 47.41 November 1, 2022 342,467 $ 29.33 |
Summary of shares of authorized common stock reserved for issuance | The Company has reserved shares of its authorized common stock for issuance pursuant to its employee stock purchase and equity plans, including all outstanding stock option grants noted above at December 31, 2022, as follows: Shares reserved for issuance 2019 Stock Plan 17,323,264 2010 Purchase Plan 2,758,641 20,081,905 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Components of lease expense | The components of lease expense were as follows: Year Ended December 31, (In thousands) 2022 2021 2020 Finance lease cost Amortization of right-of-use assets $ 4,612 $ 5,731 $ 1,935 Interest on lease liabilities 808 1,018 383 Operating lease cost 36,291 31,730 22,551 Short-term lease cost 476 628 356 Variable lease cost 7,985 5,212 2,703 Total lease Cost $ 50,172 $ 44,319 $ 27,928 Year Ended December 31, (In thousands) 2022 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 33,448 $ 27,461 $ 17,531 Operating cash flows from finance leases 699 938 381 Finance cash flows from finance leases 4,345 5,290 1,756 Non-cash investing and financing activities: Right-of-use assets obtained in exchange for new operating lease liabilities (1) 24,572 74,369 13,261 Right-of-use assets obtained in exchange for new finance lease liabilities 11,276 5,460 20,349 Weighted-average remaining lease term - operating leases (in years) 7.43 8.33 8.75 Weighted-average remaining lease term - finance leases (in years) 3.27 2.95 3.68 Weighted-average discount rate - operating leases 6.37 % 6.11 % 6.80 % Weighted-average discount rate - finance leases 6.60 % 5.36 % 5.67 % _________________________________ (1) This includes an immaterial amount of right-of-use assets acquired as part of the business combinations described in Note 18 for the year ended December 31, 2022, and $39.6 million for the year ended December 31, 2021. |
Operating lease maturity | Maturities of operating lease liabilities on an annual basis as of December 31, 2022 were as follows: (In thousands) 2023 $ 38,321 2024 39,122 2025 34,952 2026 33,322 2027 32,528 Thereafter 89,098 Total minimum lease payments 267,343 Imputed interest (56,578) Total $ 210,765 |
Finance lease maturity | Maturities of finance lease liabilities on an annual basis as of December 31, 2022 were as follows (amounts in thousands): (In thousands) 2023 $ 3,692 2024 3,632 2025 3,111 2026 1,278 2027 16 Thereafter — Total minimum lease payments 11,729 Imputed interest (1,150) Total $ 10,579 |
BUSINESS COMBINATIONS AND ASS_2
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Business Combination and Asset Acquisition [Abstract] | |
Schedule of business acquisitions, by acquisition | Stock issuances in relation to acquisitions during the years ended December 31, 2022, 2021 and 2020 were as follows: (In millions) Period of Acquisition Shares Issued Fair Value of Shares Issued OmicEra May 2022 0.3 $ 14.8 PreventionGenetics December 2021 1.1 84.2 Ashion April 2021 0.1 16.2 Thrive January 2021 9.3 1,190.0 Targeted Digital Sequencing (“TARDIS”) license January 2021 0.2 27.3 Paradigm Diagnostics, Inc. (“Paradigm”) and Viomics, Inc. (“Viomics”) March 2020 0.4 28.8 The acquisition date fair value of the consideration transferred for OmicEra was approximately $19.4 million, which consisted of the following: (In thousands) Common stock issued $ 14,792 Contingent consideration 4,600 Cash paid related to working capital adjustment 16 Total purchase price $ 19,408 The acquisition date fair value of the consideration transferred for PreventionGenetics was approximately $185.4 million, which consisted of the following: (In thousands) Cash $ 101,129 Common stock issued 84,252 Total purchase price $ 185,381 The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million, which consisted of the following: (In thousands) Cash $ 74,775 Common stock issued 16,224 Contingent consideration 19,000 Total purchase price $ 109,999 The acquisition date fair value of the consideration transferred for Thrive was approximately $2.19 billion, which consisted of the following: (In thousands) Common stock issued $ 1,175,431 Cash 584,996 Contingent consideration 331,348 Fair value of replaced equity awards 52,245 Previously held equity investment fair value 43,034 Total purchase price $ 2,187,054 |
Schedule of allocated to the underlying assets acquired and liabilities assumed | The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including immaterial measurement period adjustments as follows: (In thousands) Net operating assets $ 2,586 Developed technology 10,000 Total identifiable assets acquired 12,586 Net operating liabilities (3,987) Net identifiable assets acquired 8,599 Goodwill 10,809 Net assets acquired $ 19,408 (In thousands) Cash and cash equivalents $ 1,574 Accounts receivable 6,328 Inventory 1,697 Prepaid expenses and other current assets 30 Property, plant and equipment 12,793 Developed technology 65,000 Customer relationships 4,000 Trade name 4,000 Total identifiable assets acquired 95,422 Accounts payable (1,628) Accrued liabilities (992) Total liabilities assumed (2,620) Net identifiable assets acquired 92,802 Goodwill 92,579 Net assets acquired $ 185,381 (In thousands) Cash and cash equivalents $ 2,474 Accounts receivable 2,349 Inventory 1,811 Prepaid expenses and other current assets 425 Property, plant and equipment 9,947 Operating lease right-of-use assets 548 Developed technology 39,000 Total identifiable assets acquired 56,554 Accounts payable (1,477) Accrued liabilities (1,190) Operating lease liabilities, current portion (343) Other current liabilities (98) Operating lease liabilities, less current portion (205) Total liabilities assumed (3,313) Net identifiable assets acquired 53,241 Goodwill 56,758 Net assets acquired $ 109,999 The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including immaterial measurement period adjustments as follows: (In thousands) Cash and cash equivalents $ 241,748 Prepaid expenses and other current assets 3,939 Property, plant and equipment 29,977 Operating lease right-of-use assets 39,027 Other long-term assets 67 In-process research and development (IPR&D) 1,250,000 Total identifiable assets acquired 1,564,758 Accounts payable (3,222) Accrued liabilities (8,080) Operating lease liabilities, current portion (2,980) Operating lease liabilities, less current portion (38,622) Deferred tax liability (272,905) Total liabilities assumed (325,809) Net identifiable assets acquired 1,238,949 Goodwill 948,105 Net assets acquired $ 2,187,054 The following table summarizes the allocation of the purchase price to the fair values assigned to the assets acquired and liabilities assumed: (In thousands) Consideration Cash paid for acquisition of PFS Genomics outstanding shares $ 33,569 Assets acquired and liabilities assumed Cash 496 IPR&D asset 33,074 Other assets and liabilities (1) Net assets acquired $ 33,569 Acquisition related costs were not material in this asset acquisition. |
Schedule of share-based payment award, stock options, valuation assumptions | The fair value of options assumed were based on the assumptions in the following table: Option Plan Shares Assumed Risk-free interest rates 0.11% - 0.12% Expected term (in years) 1.26 - 1.57 Expected volatility 65.54% - 71.00% Dividend yield 0% Weighted average fair value per share of options assumed $109.74 - $124.89 |
Business combination, pro forma information | The following unaudited pro forma financial information summarizes the combined results of operations for the Company and Thrive, as though the companies were combined as of the beginning of January 1, 2020. Year Ended December 31, (In thousands) 2021 2020 Total revenues $ 1,767,087 $ 1,491,391 Net loss before tax $ (761,337) $ (1,014,352) |
Schedule of Noncash or Part Noncash Divestitures | The closing date fair value of the consideration received for the asset was approximately $29.6 million, which consisted of the following: (In thousands) Cash $ 25,000 MDxHealth American Depository Shares 4,631 Contingent consideration — Total consideration $ 29,631 |
SEGMENT INFORMATION (Tables)
SEGMENT INFORMATION (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Segment Reporting [Abstract] | |
Revenue from external customers by geographic areas | The following table summarizes total revenue from customers by geographic region. Product revenues are attributed to countries based on ship-to location. Year Ended December 31, (In thousands) 2022 2021 2020 United States $ 1,966,541 $ 1,657,174 $ 1,413,907 Outside of United States 117,738 109,913 77,484 Total revenues $ 2,084,279 $ 1,767,087 $ 1,491,391 |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
Schedule of income before income tax, domestic and foreign | Income (loss) before provision for taxes consisted of the following: Year Ended December 31, (In thousands) 2022 2021 2020 Income (loss) before income taxes: Domestic $ (617,240) $ (801,536) $ (423,025) Foreign (15,330) (40,970) (406,038) Total income (loss) before income taxes $ (632,570) $ (842,506) $ (829,063) |
Schedule of expense (benefit) for income taxes | The expense (benefit) for income taxes consists of: Year Ended December 31, (In thousands) 2022 2021 2020 Current expense (benefit): Federal $ — $ — $ (3) State 2,170 1,388 802 Foreign 1,131 4,898 933 Deferred tax expense (benefit): Federal (3,292) (222,693) (3,050) State (8,926) (30,528) (4,260) Foreign (147) 54 120 Total income tax expense (benefit) $ (9,064) $ (246,881) $ (5,458) |
Schedule of components of the net deferred tax asset | The components of the net deferred tax asset with the approximate income tax effect of each type of carryforward, credit and temporary differences are as follows: December 31, (In thousands) 2022 2021 Deferred tax assets: Operating loss carryforwards $ 553,320 $ 516,344 Tax credit carryforwards 87,579 72,959 Compensation related differences 67,976 74,127 Lease liabilities 51,560 48,201 Capitalized research and development 108,117 23,035 Other temporary differences 19,353 20,087 Tax assets before valuation allowance 887,905 754,753 Less - Valuation allowance (419,356) (262,238) Total deferred tax assets 468,549 492,515 Deferred tax liabilities Amortization $ (435,991) $ (464,748) Property, plant and equipment (4,653) (4,756) Lease assets (40,674) (45,781) Other temporary differences (6,944) (6,012) Total deferred tax liabilities (488,262) (521,297) Net deferred tax liabilities $ (19,713) $ (28,782) |
Summary of valuation allowance | Activity associated with the Company's valuation allowance is as follows: December 31, (In thousands) 2022 2021 2020 Balance as of January 1, $ (262,238) $ (293,397) $ (195,401) Valuation allowances established (159,919) (206,574) (94,589) Changes to existing valuation allowances 2,780 (1,500) 2,151 Acquisition and purchase accounting 21 239,233 (5,558) Balance as of December 31, $ (419,356) $ (262,238) $ (293,397) |
Schedule of differences between the effective income tax rate and the statutory tax rate | The effective tax rate differs from the statutory tax rate due to the following: December 31, 2022 2021 2020 U.S. Federal statutory rate 21.0 % 21.0 % 21.0 % State taxes 3.9 3.6 1.7 Federal and state tax rate changes (0.2) (0.3) — Foreign tax rate differential (0.1) (0.6) (1.0) Acquired IPR&D asset expense — (0.8) (9.4) Research and development tax credits 2.3 0.7 1.6 Stock-based compensation expense (2.0) 1.1 1.1 Non-deductible executive compensation (0.4) (0.2) (0.8) Transaction costs — (0.1) (0.1) Other adjustments 1.2 1.2 (2.2) Valuation allowance (24.4) 3.7 (11.3) Effective tax rate 1.3 % 29.3 % 0.6 % |
Schedule of unrecognized tax benefits | The following is a tabular reconciliation of the amounts of unrecognized tax benefits: December 31, (In thousands) 2022 2021 2020 January 1, $ 21,780 $ 16,629 $ 10,276 Increase due to current year tax positions 5,861 5,363 3,600 Increase due to prior year tax positions 629 — 2,753 Decrease due to prior year tax positions — (212) — Settlements — — — December 31, $ 28,270 $ 21,780 $ 16,629 |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Use of Estimates (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended |
Apr. 30, 2020 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | ||
CARES Act, grant payment received | $ 23.7 | $ 23.7 |
SUMMARY OF SIGNIFICANT ACCOUN_5
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Loss Per Share (Details) - shares shares in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Common shares not included in the computation of diluted net loss per share | |||
Antidilutive shares (in shares) | 28,050 | 27,837 | 27,284 |
Shares issuable in connection with acquisitions | |||
Common shares not included in the computation of diluted net loss per share | |||
Antidilutive shares (in shares) | 0 | 45 | 157 |
Shares issuable upon exercise of stock options | |||
Common shares not included in the computation of diluted net loss per share | |||
Antidilutive shares (in shares) | 1,518 | 2,284 | 2,231 |
Shares issuable upon the release of restricted stock awards | |||
Common shares not included in the computation of diluted net loss per share | |||
Antidilutive shares (in shares) | 5,255 | 4,321 | 3,968 |
Shares issuable upon the release of performance share units | |||
Common shares not included in the computation of diluted net loss per share | |||
Antidilutive shares (in shares) | 968 | 878 | 619 |
Shares issuable upon conversion of convertible notes | |||
Common shares not included in the computation of diluted net loss per share | |||
Antidilutive shares (in shares) | 20,309 | 20,309 | 20,309 |
SUMMARY OF SIGNIFICANT ACCOUN_6
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Research and Development Costs (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | |||
Research and development | $ 393,418 | $ 385,646 | $ 554,052 |
Asset acquisition IPR&D expense | $ 0 | $ 85,337 | $ 412,568 |
SUMMARY OF SIGNIFICANT ACCOUN_7
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | |||
Advertising expense | $ 170.3 | $ 144 | $ 97.6 |
SUMMARY OF SIGNIFICANT ACCOUN_8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases (Details) | 12 Months Ended |
Dec. 31, 2022 | |
Lessee, Lease, Description [Line Items] | |
Operating lease, term extension | 10 years |
Operating lease, termination period | 1 year |
Minimum | |
Lessee, Lease, Description [Line Items] | |
Operating lease, remaining lease term | 1 year |
Maximum | |
Lessee, Lease, Description [Line Items] | |
Operating lease, remaining lease term | 15 years |
SUMMARY OF SIGNIFICANT ACCOUN_9
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Credit Risk (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Concentration of Credit Risk | |||
Cash and cash equivalents, federal government agency insured limit | $ 125.7 | ||
Revenue | Customer Concentration Risk | Centers for Medicare and Medicaid Services | |||
Concentration of Credit Risk | |||
Concentration risk (as a percent) | 14% | 20% | 21% |
Revenue | Customer Concentration Risk | UnitedHealthcare | |||
Concentration of Credit Risk | |||
Concentration risk (as a percent) | 12% | 11% | 10% |
Revenue | Customer Concentration Risk | State of Wisconsin | |||
Concentration of Credit Risk | |||
Concentration risk (as a percent) | 3% | 8% | 12% |
Accounts Receivable | Customer Concentration Risk | Centers for Medicare and Medicaid Services | |||
Concentration of Credit Risk | |||
Concentration risk (as a percent) | 14% | 11% | 14% |
Accounts Receivable | Customer Concentration Risk | UnitedHealthcare | |||
Concentration of Credit Risk | |||
Concentration risk (as a percent) | 9% | 8% | 7% |
Accounts Receivable | Customer Concentration Risk | State of Wisconsin | |||
Concentration of Credit Risk | |||
Concentration risk (as a percent) | 5% | 9% | 22% |
SUMMARY OF SIGNIFICANT ACCOU_10
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Tax Positions (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | |||
Deferred tax asset valuation allowance | $ 419,356 | $ 262,238 | |
Increase (decrease) in valuation allowance | 157,100 | (31,200) | |
Income tax benefit | $ 9,064 | $ 246,881 | $ 5,458 |
SUMMARY OF SIGNIFICANT ACCOU_11
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recent Accounting Pronouncements (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 12 Months Ended | |||
Feb. 29, 2020 | Mar. 31, 2019 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||
Deferred tax asset valuation allowance | $ 419,356 | $ 262,238 | |||
Decrease in amortization debt discount | (7,127) | (6,683) | $ (1,546) | ||
Loss on extinguishment of debt | $ 50,800 | 0 | 0 | 50,819 | |
Tax expense (benefit) | $ (9,064) | $ (246,881) | $ (5,458) | ||
Increase (decrease) in net loss per share (in usd per share) | $ (3.54) | $ (3.48) | $ (5.45) | ||
Increase (decrease) in net loss per share (in usd per share) | $ (3.54) | $ (3.48) | $ (5.45) | ||
2025 Convertible notes | |||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||
Loss on extinguishment of debt | $ 187,700 | ||||
2025 Convertible notes | |||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||
Loss on extinguishment of debt | $ 42,800 | ||||
Extinguishment of debt, amount | 100,000 | ||||
Cumulative Effect, Period of Adoption, Adjustment | |||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||
Interest income (expense) | 28,100 | ||||
Decrease in amortization debt discount | 70,900 | ||||
Tax expense (benefit) | $ (3,100) | ||||
Increase (decrease) in net loss per share (in usd per share) | $ (0.17) | ||||
Increase (decrease) in net loss per share (in usd per share) | $ (0.17) |
REVENUE - Schedule of Disaggreg
REVENUE - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Disaggregation of Revenue [Line Items] | |||
Revenue recognized | $ 2,084,279 | $ 1,767,087 | $ 1,491,391 |
Screening | |||
Disaggregation of Revenue [Line Items] | |||
Revenue recognized | 1,424,703 | 1,062,308 | 815,067 |
Screening | Medicare Parts B & C | |||
Disaggregation of Revenue [Line Items] | |||
Revenue recognized | 545,458 | 438,646 | 365,471 |
Screening | Commercial | |||
Disaggregation of Revenue [Line Items] | |||
Revenue recognized | 743,238 | 569,944 | 409,671 |
Screening | Other | |||
Disaggregation of Revenue [Line Items] | |||
Revenue recognized | 136,007 | 53,718 | 39,925 |
Precision Oncology | |||
Disaggregation of Revenue [Line Items] | |||
Revenue recognized | 601,488 | 561,676 | 440,493 |
Precision Oncology | Medicare Parts B & C | |||
Disaggregation of Revenue [Line Items] | |||
Revenue recognized | 197,327 | 197,394 | 165,799 |
Precision Oncology | Commercial | |||
Disaggregation of Revenue [Line Items] | |||
Revenue recognized | 177,518 | 180,177 | 153,410 |
Precision Oncology | Other | |||
Disaggregation of Revenue [Line Items] | |||
Revenue recognized | 108,905 | 74,192 | 43,800 |
Precision Oncology | International | |||
Disaggregation of Revenue [Line Items] | |||
Revenue recognized | 117,738 | 109,913 | 77,484 |
COVID-19 Testing | |||
Disaggregation of Revenue [Line Items] | |||
Revenue recognized | $ 58,088 | $ 143,103 | $ 235,831 |
REVENUE - Narrative (Details)
REVENUE - Narrative (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Disaggregation of Revenue [Line Items] | |||
Deferred revenue | $ 3.1 | $ 1 | |
Deferred revenue, revenue recognized during period | 24.6 | ||
COVID-19 | |||
Disaggregation of Revenue [Line Items] | |||
Deferred revenue, revenue recognized during period | 24.2 | ||
Variable consideration | |||
Disaggregation of Revenue [Line Items] | |||
Revenue recognized from changes in transaction price | $ 20.3 | $ 11.8 | $ 9.6 |
MARKETABLE SECURITIES - Schedul
MARKETABLE SECURITIES - Schedule of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Marketable Securities [Line Items] | ||
Total cash and cash equivalents | $ 242,493 | $ 315,471 |
Available-for-sale debt securities | 448,740 | 779,805 |
Equity securities | 5,149 | 3,336 |
Total marketable securities | 389,564 | 715,005 |
Total cash, cash equivalents, and marketable securities | 632,057 | 1,030,476 |
Cash equivalents | ||
Marketable Securities [Line Items] | ||
Total cash and cash equivalents | 64,325 | 68,136 |
Available-for-sale debt securities | 64,325 | 68,136 |
Marketable securities | ||
Marketable Securities [Line Items] | ||
Available-for-sale debt securities | 384,415 | 711,669 |
Cash and money market | ||
Marketable Securities [Line Items] | ||
Total cash and cash equivalents | $ 178,168 | $ 247,335 |
MARKETABLE SECURITIES - Sched_2
MARKETABLE SECURITIES - Schedule of Available For Sale Securities (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Available-for-sale securities | ||
Amortized Cost | $ 454,029 | $ 781,271 |
Gains in Accumulated Other Comprehensive Income (Loss) | 22 | 17 |
Losses in Accumulated Other Comprehensive Income (Loss) | (5,311) | (1,483) |
Estimated Fair Value | 448,740 | 779,805 |
Cash equivalents | ||
Available-for-sale securities | ||
Amortized Cost | 64,325 | 68,136 |
Gains in Accumulated Other Comprehensive Income (Loss) | 0 | 0 |
Losses in Accumulated Other Comprehensive Income (Loss) | 0 | 0 |
Estimated Fair Value | 64,325 | 68,136 |
Marketable securities | ||
Available-for-sale securities | ||
Amortized Cost | 389,704 | 713,135 |
Gains in Accumulated Other Comprehensive Income (Loss) | 22 | 17 |
Losses in Accumulated Other Comprehensive Income (Loss) | (5,311) | (1,483) |
Estimated Fair Value | 384,415 | 711,669 |
U.S. government agency securities | Cash equivalents | ||
Available-for-sale securities | ||
Amortized Cost | 1,304 | 3,543 |
Gains in Accumulated Other Comprehensive Income (Loss) | 0 | 0 |
Losses in Accumulated Other Comprehensive Income (Loss) | 0 | 0 |
Estimated Fair Value | 1,304 | 3,543 |
U.S. government agency securities | Marketable securities | ||
Available-for-sale securities | ||
Amortized Cost | 228,012 | 250,793 |
Gains in Accumulated Other Comprehensive Income (Loss) | 0 | 0 |
Losses in Accumulated Other Comprehensive Income (Loss) | (2,789) | (873) |
Estimated Fair Value | 225,223 | 249,920 |
Commercial paper | Cash equivalents | ||
Available-for-sale securities | ||
Amortized Cost | 63,021 | 64,593 |
Gains in Accumulated Other Comprehensive Income (Loss) | 0 | 0 |
Losses in Accumulated Other Comprehensive Income (Loss) | 0 | 0 |
Estimated Fair Value | 63,021 | 64,593 |
Corporate bonds | Marketable securities | ||
Available-for-sale securities | ||
Amortized Cost | 116,318 | 313,634 |
Gains in Accumulated Other Comprehensive Income (Loss) | 20 | 13 |
Losses in Accumulated Other Comprehensive Income (Loss) | (1,667) | (493) |
Estimated Fair Value | 114,671 | 313,154 |
Asset backed securities | Marketable securities | ||
Available-for-sale securities | ||
Amortized Cost | 45,374 | 94,565 |
Gains in Accumulated Other Comprehensive Income (Loss) | 2 | 2 |
Losses in Accumulated Other Comprehensive Income (Loss) | (855) | (107) |
Estimated Fair Value | $ 44,521 | 94,460 |
Commercial paper | Marketable securities | ||
Available-for-sale securities | ||
Amortized Cost | 6,996 | |
Gains in Accumulated Other Comprehensive Income (Loss) | 0 | |
Losses in Accumulated Other Comprehensive Income (Loss) | 0 | |
Estimated Fair Value | 6,996 | |
Certificates of deposit | Marketable securities | ||
Available-for-sale securities | ||
Amortized Cost | 47,147 | |
Gains in Accumulated Other Comprehensive Income (Loss) | 2 | |
Losses in Accumulated Other Comprehensive Income (Loss) | (10) | |
Estimated Fair Value | $ 47,139 |
MARKETABLE SECURITIES - Sched_3
MARKETABLE SECURITIES - Schedule of Underlying Maturities of AFS Securities (Details) $ in Thousands | Dec. 31, 2022 USD ($) |
Available-for-sale securities | |
Due in one year or less, Cost | $ 373,057 |
Due in one year or less, Fair Value | 369,047 |
Due after one year through four years, Cost | 80,972 |
Due after one year through four years, Fair Value | 79,693 |
Cash equivalents | |
Available-for-sale securities | |
Due in one year or less, Cost | 64,325 |
Due in one year or less, Fair Value | 64,325 |
Due after one year through four years, Cost | 0 |
Due after one year through four years, Fair Value | 0 |
Cash equivalents | Commercial paper | |
Available-for-sale securities | |
Due in one year or less, Cost | 63,021 |
Due in one year or less, Fair Value | 63,021 |
Due after one year through four years, Cost | 0 |
Due after one year through four years, Fair Value | 0 |
Cash equivalents | U.S. government agency securities | |
Available-for-sale securities | |
Due in one year or less, Cost | 1,304 |
Due in one year or less, Fair Value | 1,304 |
Due after one year through four years, Cost | 0 |
Due after one year through four years, Fair Value | 0 |
Marketable securities | |
Available-for-sale securities | |
Due in one year or less, Cost | 308,732 |
Due in one year or less, Fair Value | 304,722 |
Due after one year through four years, Cost | 80,972 |
Due after one year through four years, Fair Value | 79,693 |
Marketable securities | U.S. government agency securities | |
Available-for-sale securities | |
Due in one year or less, Cost | 218,364 |
Due in one year or less, Fair Value | 215,620 |
Due after one year through four years, Cost | 9,648 |
Due after one year through four years, Fair Value | 9,603 |
Marketable securities | Corporate bonds | |
Available-for-sale securities | |
Due in one year or less, Cost | 90,368 |
Due in one year or less, Fair Value | 89,102 |
Due after one year through four years, Cost | 25,950 |
Due after one year through four years, Fair Value | 25,569 |
Marketable securities | Asset backed securities | |
Available-for-sale securities | |
Due in one year or less, Cost | 0 |
Due in one year or less, Fair Value | 0 |
Due after one year through four years, Cost | 45,374 |
Due after one year through four years, Fair Value | $ 44,521 |
MARKETABLE SECURITIES - Sched_4
MARKETABLE SECURITIES - Schedule of Gross Unrealized Losses And Fair Value of Available For Sale Securities (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Marketable Securities [Line Items] | ||
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months | $ 100,497 | $ 663,496 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months | (1,647) | (1,483) |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater | 277,004 | 0 |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater, accumulated loss | (3,664) | 0 |
Total fair value of available-for-sale securities in a continuous unrealized loss position | 377,501 | 663,496 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position | (5,311) | (1,483) |
Marketable securities | Corporate bonds | ||
Marketable Securities [Line Items] | ||
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months | 35,055 | 299,448 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months | (575) | (493) |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater | 73,702 | 0 |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater, accumulated loss | (1,092) | 0 |
Total fair value of available-for-sale securities in a continuous unrealized loss position | 108,757 | 299,448 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position | (1,667) | (493) |
Marketable securities | U.S. government agency securities | ||
Marketable Securities [Line Items] | ||
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months | 37,458 | 249,921 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months | (337) | (873) |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater | 187,766 | 0 |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater, accumulated loss | (2,452) | 0 |
Total fair value of available-for-sale securities in a continuous unrealized loss position | 225,224 | 249,921 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position | (2,789) | (873) |
Marketable securities | Asset backed securities | ||
Marketable Securities [Line Items] | ||
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months | 27,984 | 89,990 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months | (735) | (107) |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater | 15,536 | 0 |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater, accumulated loss | (120) | 0 |
Total fair value of available-for-sale securities in a continuous unrealized loss position | 43,520 | 89,990 |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position | $ (855) | (107) |
Marketable securities | Certificates of deposit | ||
Marketable Securities [Line Items] | ||
Total fair value of available-for-sale securities in a continuous unrealized loss position for less than twelve months | 24,137 | |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position for less than twelve months | (10) | |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater | 0 | |
Debt securities, available-for-sale, continuous unrealized loss position, 12 months or greater, accumulated loss | 0 | |
Total fair value of available-for-sale securities in a continuous unrealized loss position | 24,137 | |
Total gross unrealized losses of available-for-sale securities in a continuous unrealized loss position | $ (10) |
INVENTORY (Details)
INVENTORY (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 61,207 | $ 51,321 |
Semi-finished and finished goods | 57,052 | 53,673 |
Inventory | $ 118,259 | $ 104,994 |
PROPERTY, PLANT AND EQUIPMENT -
PROPERTY, PLANT AND EQUIPMENT - Schedule of Estimated Useful Lives (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Property, plant and equipment | ||
Property, plant and equipment, at cost | $ 992,347 | $ 795,064 |
Accumulated depreciation | (307,591) | (214,816) |
Property, plant and equipment, net | 684,756 | 580,248 |
Land | ||
Property, plant and equipment | ||
Property, plant and equipment, at cost | 4,716 | 4,716 |
Leasehold and building improvements | ||
Property, plant and equipment | ||
Property, plant and equipment, at cost | $ 200,588 | 147,083 |
Land improvements | ||
Property, plant and equipment | ||
Estimated Useful Life | 15 years | |
Property, plant and equipment, at cost | $ 6,417 | 5,206 |
Buildings | ||
Property, plant and equipment | ||
Property, plant and equipment, at cost | $ 288,941 | 210,560 |
Buildings | Minimum | ||
Property, plant and equipment | ||
Estimated Useful Life | 30 years | |
Buildings | Maximum | ||
Property, plant and equipment | ||
Estimated Useful Life | 40 years | |
Computer equipment and computer software | ||
Property, plant and equipment | ||
Estimated Useful Life | 3 years | |
Property, plant and equipment, at cost | $ 142,896 | 109,119 |
Laboratory equipment | ||
Property, plant and equipment | ||
Property, plant and equipment, at cost | $ 246,344 | 189,748 |
Laboratory equipment | Minimum | ||
Property, plant and equipment | ||
Estimated Useful Life | 3 years | |
Laboratory equipment | Maximum | ||
Property, plant and equipment | ||
Estimated Useful Life | 10 years | |
Furniture and fixtures | ||
Property, plant and equipment | ||
Property, plant and equipment, at cost | $ 34,047 | 28,293 |
Furniture and fixtures | Minimum | ||
Property, plant and equipment | ||
Estimated Useful Life | 3 years | |
Furniture and fixtures | Maximum | ||
Property, plant and equipment | ||
Estimated Useful Life | 10 years | |
Assets under construction | ||
Property, plant and equipment | ||
Property, plant and equipment, at cost | $ 68,398 | $ 100,339 |
PROPERTY, PLANT AND EQUIPMENT_2
PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Property, plant and equipment | |||
Depreciation | $ 100,100 | $ 85,300 | $ 70,000 |
Property, plant and equipment, gross | 992,347 | 795,064 | |
Assets under construction | |||
Property, plant and equipment | |||
Property, plant and equipment, gross | 68,398 | 100,339 | |
Buildings under construction | |||
Property, plant and equipment | |||
Assets under construction | 10,900 | ||
Leasehold improvements | |||
Property, plant and equipment | |||
Assets under construction | 2,200 | ||
Laboratory equipment | |||
Property, plant and equipment | |||
Property, plant and equipment, gross | 246,344 | $ 189,748 | |
Assets under construction | 45,200 | ||
Software projects | |||
Property, plant and equipment | |||
Assets under construction | $ 10,000 |
INTANGIBLE ASSETS AND GOODWIL_2
INTANGIBLE ASSETS AND GOODWILL - Schedule of Finite Lived Intangible Assets Net Balances and Weighted Average Useful Lives (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Finite-Lived Intangible Assets [Line Items] | ||
Cost | $ 981,016 | $ 1,042,808 |
Accumulated Amortization | (274,776) | (198,397) |
Finite-lived intangible assets, net | 706,240 | 844,411 |
In-process research and development | 1,250,000 | 1,250,000 |
Finite-lived and indefinite-lived intangible assets, gross | 2,231,016 | 2,292,808 |
Finite-lived and indefinite-lived intangible assets, net | $ 1,956,240 | $ 2,094,411 |
Trade name | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted Average Remaining Life (Years) | 12 years 6 months | 13 years 4 months 24 days |
Cost | $ 104,000 | $ 104,700 |
Accumulated Amortization | (20,653) | (13,554) |
Finite-lived intangible assets, net | $ 83,347 | $ 91,146 |
Customer relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted Average Remaining Life (Years) | 8 years | 9 years 7 months 6 days |
Cost | $ 4,000 | $ 6,700 |
Accumulated Amortization | (444) | (1,577) |
Finite-lived intangible assets, net | $ 3,556 | $ 5,123 |
Patents and licenses | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted Average Remaining Life (Years) | 4 years 2 months 12 days | 3 years 7 months 6 days |
Cost | $ 11,542 | $ 10,942 |
Accumulated Amortization | (8,152) | (6,763) |
Finite-lived intangible assets, net | $ 3,390 | $ 4,179 |
Supply agreement | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted Average Remaining Life (Years) | 5 years 4 months 24 days | |
Cost | $ 2,295 | |
Accumulated Amortization | (101) | |
Finite-lived intangible assets, net | $ 2,194 | |
Developed technology | ||
Finite-Lived Intangible Assets [Line Items] | ||
Weighted Average Remaining Life (Years) | 7 years 9 months 18 days | 8 years 7 months 6 days |
Cost | $ 861,474 | $ 918,171 |
Accumulated Amortization | (245,527) | (176,402) |
Finite-lived intangible assets, net | $ 615,948 | $ 741,769 |
INTANGIBLE ASSETS AND GOODWIL_3
INTANGIBLE ASSETS AND GOODWILL - Schedule of Future Amortization Expense (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
2023 | $ 91,713 | |
2024 | 91,379 | |
2025 | 90,331 | |
2026 | 89,271 | |
2027 | 89,271 | |
Thereafter | 254,275 | |
Finite-lived intangible assets, net | $ 706,240 | $ 844,411 |
INTANGIBLE ASSETS AND GOODWIL_4
INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||
Sep. 30, 2022 | Jun. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Aug. 02, 2022 | |
Finite-Lived Intangible Assets [Line Items] | ||||||||
Cost | $ 981,016,000 | $ 1,042,808,000 | ||||||
Finite-lived intangible assets, accumulated amortization | 274,776,000 | 198,397,000 | ||||||
Finite-lived Intangible assets, net | 706,240,000 | 844,411,000 | ||||||
Goodwill, impairment loss | 0 | 0 | $ 0 | |||||
Oncotype DX Genomic Prostate Score Test | Disposal Group, Disposed of by Sale, Not Discontinued Operations | ||||||||
Finite-Lived Intangible Assets [Line Items] | ||||||||
Cost | $ 59,000,000 | |||||||
Finite-lived intangible assets, accumulated amortization | 16,100,000 | |||||||
Finite-lived Intangible assets, net | $ 42,900,000 | |||||||
Supply agreement | ||||||||
Finite-Lived Intangible Assets [Line Items] | ||||||||
Cost | 2,295,000 | |||||||
Finite-lived intangible assets, accumulated amortization | 101,000 | |||||||
Finite-lived Intangible assets, net | 2,194,000 | |||||||
Impairment of long-lived assets | $ 2,000,000 | |||||||
Developed technology | ||||||||
Finite-Lived Intangible Assets [Line Items] | ||||||||
Cost | 861,474,000 | 918,171,000 | ||||||
Finite-lived intangible assets, accumulated amortization | 245,527,000 | 176,402,000 | ||||||
Finite-lived Intangible assets, net | $ 615,948,000 | $ 741,769,000 | ||||||
Impairment of long-lived assets | $ 6,600,000 | |||||||
In-process research and development | ||||||||
Finite-Lived Intangible Assets [Line Items] | ||||||||
Impairment of long-lived assets | $ 20,200,000 | |||||||
In-process research and development | Armune Biosciences Agreement | ||||||||
Finite-Lived Intangible Assets [Line Items] | ||||||||
Impairment of long-lived assets | $ 9,700,000 | |||||||
In-process research and development | Biocartis Agreement | ||||||||
Finite-Lived Intangible Assets [Line Items] | ||||||||
Impairment of long-lived assets | $ 200,000,000 |
INTANGIBLE ASSETS AND GOODWIL_5
INTANGIBLE ASSETS AND GOODWILL - Schedule of Changes in Goodwill (Details) - USD ($) $ in Thousands | 12 Months Ended | ||||
Dec. 31, 2022 | Dec. 31, 2021 | May 02, 2022 | Apr. 14, 2021 | Jan. 05, 2021 | |
Carrying amount of goodwill | |||||
Beginning of the period | $ 2,335,172 | $ 1,237,672 | |||
Goodwill, Foreign Currency Translation Gain (Loss) | 117 | ||||
Ending of the period | 2,346,040 | 2,335,172 | |||
Goodwill | 2,346,040 | 2,335,172 | |||
Thrive | |||||
Carrying amount of goodwill | |||||
Acquisition | (948,105) | ||||
Goodwill | $ 948,105 | ||||
Ashion Analytics | |||||
Carrying amount of goodwill | |||||
Acquisition | (56,758) | ||||
Goodwill | $ 56,758 | ||||
PreventionGenetics | |||||
Carrying amount of goodwill | |||||
Beginning of the period | 92,579 | ||||
Acquisition | (92,637) | ||||
Genomic Health acquisition adjustment | 58 | ||||
Ending of the period | 92,579 | ||||
Goodwill | $ 92,579 | ||||
OmicEra | |||||
Carrying amount of goodwill | |||||
Acquisition | $ (10,809) | ||||
Goodwill | $ 10,809 |
FAIR VALUE MEASUREMENTS - Sched
FAIR VALUE MEASUREMENTS - Schedule of Fair Value (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Fair value measurements | ||
Total cash and cash equivalents | $ 242,493 | $ 315,471 |
Equity securities | 5,149 | 3,336 |
Fair Value, Recurring | ||
Fair value measurements | ||
Equity securities | 5,149 | 3,336 |
Non-marketable securities | 10,065 | 3,090 |
Contingent consideration | (306,927) | (359,021) |
Total | 335,492 | 674,842 |
Fair Value, Recurring | MDxHealth | ||
Fair value measurements | ||
Equity securities | 4,600 | |
Fair Value, Recurring | Corporate bonds | ||
Fair value measurements | ||
Estimated Fair Value | 114,671 | 313,154 |
Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Estimated Fair Value | 225,223 | 249,920 |
Fair Value, Recurring | Asset backed securities | ||
Fair value measurements | ||
Estimated Fair Value | 44,521 | 94,460 |
Fair Value, Recurring | Certificates of deposit | ||
Fair value measurements | ||
Estimated Fair Value | 47,139 | |
Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Estimated Fair Value | 6,996 | |
Fair Value, Recurring | Cash and money market | ||
Fair value measurements | ||
Total cash and cash equivalents | 178,168 | 247,335 |
Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Total cash and cash equivalents | 63,021 | 64,593 |
Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Total cash and cash equivalents | 1,304 | 3,543 |
Fair Value, Recurring | Restricted cash | ||
Fair value measurements | ||
Total cash and cash equivalents | 297 | 297 |
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | ||
Fair value measurements | ||
Equity securities | 5,149 | 3,336 |
Non-marketable securities | 0 | 0 |
Contingent consideration | 0 | 0 |
Total | 183,614 | 250,968 |
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Corporate bonds | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Asset backed securities | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Certificates of deposit | ||
Fair value measurements | ||
Estimated Fair Value | 0 | |
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Estimated Fair Value | 0 | |
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Cash and money market | ||
Fair value measurements | ||
Total cash and cash equivalents | 178,168 | 247,335 |
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Total cash and cash equivalents | 0 | 0 |
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Total cash and cash equivalents | 0 | 0 |
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Recurring | Restricted cash | ||
Fair value measurements | ||
Total cash and cash equivalents | 297 | 297 |
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | ||
Fair value measurements | ||
Equity securities | 0 | 0 |
Non-marketable securities | 0 | 0 |
Contingent consideration | 0 | 0 |
Total | 448,740 | 779,805 |
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Corporate bonds | ||
Fair value measurements | ||
Estimated Fair Value | 114,671 | 313,154 |
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Estimated Fair Value | 225,223 | 249,920 |
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Asset backed securities | ||
Fair value measurements | ||
Estimated Fair Value | 44,521 | 94,460 |
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Certificates of deposit | ||
Fair value measurements | ||
Estimated Fair Value | 47,139 | |
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Estimated Fair Value | 6,996 | |
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Cash and money market | ||
Fair value measurements | ||
Total cash and cash equivalents | 0 | 0 |
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Total cash and cash equivalents | 63,021 | 64,593 |
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Total cash and cash equivalents | 1,304 | 3,543 |
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring | Restricted cash | ||
Fair value measurements | ||
Total cash and cash equivalents | 0 | 0 |
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | ||
Fair value measurements | ||
Equity securities | 0 | 0 |
Non-marketable securities | 10,065 | 3,090 |
Contingent consideration | (306,927) | (359,021) |
Total | (296,862) | (355,931) |
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Corporate bonds | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Asset backed securities | ||
Fair value measurements | ||
Estimated Fair Value | 0 | 0 |
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Certificates of deposit | ||
Fair value measurements | ||
Estimated Fair Value | 0 | |
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Estimated Fair Value | 0 | |
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Cash and money market | ||
Fair value measurements | ||
Total cash and cash equivalents | 0 | 0 |
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Commercial paper | ||
Fair value measurements | ||
Total cash and cash equivalents | 0 | 0 |
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | U.S. government agency securities | ||
Fair value measurements | ||
Total cash and cash equivalents | 0 | 0 |
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring | Restricted cash | ||
Fair value measurements | ||
Total cash and cash equivalents | $ 0 | $ 0 |
FAIR VALUE MEASUREMENTS - Narra
FAIR VALUE MEASUREMENTS - Narrative (Details) | 3 Months Ended | 12 Months Ended | |||
Dec. 31, 2022 USD ($) | Sep. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||
Contingent consideration, liability | $ 306,927,000 | $ 306,927,000 | $ 359,021,000 | $ 2,477,000 | |
Venture Capital Investment Fund | |||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||
Investment owned, fair value | 3,900,000 | 3,900,000 | $ 1,500,000 | ||
Committed capital | 17,500,000 | ||||
Committed capital callable | $ 13,700,000 | $ 13,700,000 | |||
Weighted Average | Product Development and Other Milestone-based Payments | Measurement Input, Probability of Success | |||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||
Contingent consideration liability, measurement input | 0.91 | 0.91 | |||
Weighted Average | Product Development and Other Milestone-based Payments | Measurement Input, Present-value Factor | |||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||
Contingent consideration liability, measurement input | 0.062 | 0.062 | 0.023 | ||
Foreign Exchange Forward | |||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||
Derivative, notional amount | $ 22,300,000 | $ 22,300,000 | $ 46,700,000 | ||
Derivative, fair value | 0 | 0 | 0 | ||
Fair Value, Nonrecurring | |||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||
Investment owned, fair value | 39,800,000 | 39,800,000 | 25,300,000 | ||
Fair Value, Nonrecurring | Significant Unobservable Inputs (Level 3) | |||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||
Impairment loss, annual amount | 8,600,000 | $ 10,000,000 | |||
Thrive and Ashion | Fair Value | |||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||||
Contingent consideration, liability | $ 306,800,000 | $ 306,800,000 | $ 357,800,000 |
FAIR VALUE MEASUREMENTS - Fair
FAIR VALUE MEASUREMENTS - Fair Value of Contingent Consideration (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Fair Value Disclosures [Abstract] | |||
Beginning balance | $ 359,021 | $ 2,477 | |
Changes in fair value | 56,617 | 6,359 | |
Payments | (77) | (163) | |
Business acquisition contingent consideration liability | 4,600 | 350,348 | $ 0 |
Ending balance | $ 306,927 | $ 359,021 | $ 2,477 |
ACCRUED LIABILITIES (Details)
ACCRUED LIABILITIES (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
Payables and Accruals [Abstract] | ||
Compensation | $ 201,252 | $ 183,517 |
Pfizer, Inc. (“Pfizer”) Promotion Agreement related costs | 0 | 91,436 |
Professional fees | 43,715 | 50,077 |
Other | 22,329 | 32,116 |
Assets under construction | 10,462 | 22,611 |
Research and trial related expenses | 17,455 | 15,534 |
Licenses | 4,003 | 3,265 |
Accrued liabilities | $ 299,216 | $ 398,556 |
LONG-TERM DEBT - Narrative (Det
LONG-TERM DEBT - Narrative (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||
Nov. 30, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | Jun. 29, 2022 | Dec. 31, 2018 | |
Long-term debt | |||||
Financing Receivable, Amount Elected to Collateralize | $ 50,000,000 | ||||
Construction Loans | |||||
Long-term debt | |||||
Face amount | $ 25,600,000 | ||||
Construction Loans | 1-month LIBOR | |||||
Long-term debt | |||||
Variable rate | 2.25% | ||||
Interest-only payment, period | 24 months | ||||
Line of Credit | City Letter of Credit | Revolver | |||||
Long-term debt | |||||
Proceeds from lines of credit | 2,900,000 | ||||
Line of Credit | Revolving Credit Facility | Revolver | |||||
Long-term debt | |||||
Borrowing capacity | $ 150,000,000 | ||||
Debt instrument, covenant, collateral minimum market value | 150,000,000 | ||||
Debt instrument, covenant, maximum outstanding cash advances threshold | $ 20,000,000 | ||||
Remaining borrowing capacity | 147,100,000 | ||||
Line of Credit | Revolving Credit Facility | Daily Bloomberg Short-Term Bank Yield Index Rate | Revolver | |||||
Long-term debt | |||||
Variable rate | 0.60% | ||||
Securitized Receivables | |||||
Long-term debt | |||||
Borrowing capacity | $ 150,000,000 | ||||
Long-term Debt, Excluding Current Maturities | 50,000,000 | ||||
Line of Credit Facility, Current Borrowing Capacity | $ 107,200,000 | ||||
Line of Credit Facility, Interest Rate at Period End | 5.91% | ||||
Securitized Receivables | Minimum | |||||
Long-term debt | |||||
Long-term Debt, Excluding Current Maturities | $ 50,000,000 |
CONVERTIBLE NOTES - Schedule of
CONVERTIBLE NOTES - Schedule of Convertible Notes (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 | Feb. 29, 2020 | Mar. 31, 2019 | Jun. 30, 2018 |
2028 Convertible notes | |||||
Long-term debt | |||||
Coupon interest rate | 0.375% | 0.375% | 0.375% | ||
Principal Amount | $ 1,150,000 | $ 1,150,000 | |||
Unamortized Debt Discount and Issuance Costs | (15,775) | (18,826) | |||
Net Carrying Amount | 1,134,225 | 1,131,174 | |||
2028 Convertible notes | Significant Other Observable Inputs (Level 2) | Fair Value | |||||
Long-term debt | |||||
Amount | $ 908,500 | $ 1,139,650 | |||
2027 Convertible notes | |||||
Long-term debt | |||||
Coupon interest rate | 0.375% | 0.375% | 0.375% | ||
Principal Amount | $ 747,500 | $ 747,500 | |||
Unamortized Debt Discount and Issuance Costs | (9,445) | (11,691) | |||
Net Carrying Amount | 738,055 | 735,809 | |||
2027 Convertible notes | Significant Other Observable Inputs (Level 2) | Fair Value | |||||
Long-term debt | |||||
Amount | $ 612,950 | $ 771,794 | |||
2025 Convertible notes | |||||
Long-term debt | |||||
Coupon interest rate | 1% | 1% | 1% | ||
Principal Amount | $ 315,005 | $ 315,005 | |||
Unamortized Debt Discount and Issuance Costs | (1,179) | (1,756) | |||
Net Carrying Amount | 313,826 | 313,249 | |||
2025 Convertible notes | Significant Other Observable Inputs (Level 2) | Fair Value | |||||
Long-term debt | |||||
Amount | $ 326,808 | $ 415,473 |
CONVERTIBLE NOTES - Issuances a
CONVERTIBLE NOTES - Issuances and Settlements (Details) - USD ($) shares in Millions | 1 Months Ended | 12 Months Ended | |||||
Feb. 29, 2020 | Mar. 31, 2019 | Jun. 30, 2018 | Jan. 31, 2018 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Debt Instrument [Line Items] | |||||||
Net proceeds from issuance | $ 0 | $ 0 | $ 1,125,547,000 | ||||
Loss on extinguishment of debt | $ 50,800,000 | $ 0 | $ 0 | 50,819,000 | |||
2025 Convertible notes | |||||||
Debt Instrument [Line Items] | |||||||
Stock issued in conversion of convertible notes (in shares) | 2.2 | ||||||
Value of stock after conversion of convertible notes | $ 182,400,000 | ||||||
Repayments of convertible debt in cash and by issuance of shares | 676,500,000 | ||||||
Repayments of debt | 493,400,000 | ||||||
Accrued interest on notes | 700,000 | ||||||
Loss on extinguishment of debt | 187,700,000 | ||||||
2025 Convertible notes | |||||||
Debt Instrument [Line Items] | |||||||
Face amount | $ 218,500,000 | $ 690,000,000 | |||||
Interest rate (as a percent) | 1% | 1% | 1% | ||||
Net proceeds from issuance | $ 225,300,000 | $ 671,100,000 | |||||
Repayments of convertible debt | 150,100,000 | ||||||
Accrued interest on notes | 100,000 | ||||||
Loss on extinguishment of debt | $ 42,800,000 | ||||||
Amount settled | 100,000,000 | ||||||
2027 Convertible notes | |||||||
Debt Instrument [Line Items] | |||||||
Face amount | $ 747,500,000 | ||||||
Interest rate (as a percent) | 0.375% | 0.375% | 0.375% | ||||
Net proceeds from issuance | $ 729,500,000 | ||||||
2027 Convertible notes | 2025 Convertible notes | |||||||
Debt Instrument [Line Items] | |||||||
Repayments of convertible debt | $ 494,100,000 | ||||||
2028 Convertible notes | |||||||
Debt Instrument [Line Items] | |||||||
Face amount | $ 1,150,000,000 | ||||||
Interest rate (as a percent) | 0.375% | 0.375% | 0.375% | ||||
Net proceeds from issuance | $ 1,130,000,000 |
CONVERTIBLE NOTES - Summary of
CONVERTIBLE NOTES - Summary of Conversion Features (Details) shares in Millions | 12 Months Ended |
Dec. 31, 2022 shares $ / shares | |
Debt Instrument [Line Items] | |
Repurchase price, as percentage of principal amount, if company undergoes change of control | 100 |
Shares issued, price per share (in usd per share) | $ 49.51 |
2025 Convertible notes | |
Debt Instrument [Line Items] | |
Conversion rate, number of shares to be issued per $1,000 of principal amount | 13.26 |
Conversion price per share of common stock (in usd per share) | $ 75.43 |
Convertible debt, if converted (in shares) | shares | 4.2 |
2027 Convertible notes | |
Debt Instrument [Line Items] | |
Conversion rate, number of shares to be issued per $1,000 of principal amount | 8.96 |
Conversion price per share of common stock (in usd per share) | $ 111.66 |
Convertible debt, if converted (in shares) | shares | 6.7 |
2028 Convertible notes | |
Debt Instrument [Line Items] | |
Conversion rate, number of shares to be issued per $1,000 of principal amount | 8.21 |
Conversion price per share of common stock (in usd per share) | $ 121.84 |
Convertible debt, if converted (in shares) | shares | 9.4 |
CONVERTIBLE NOTES - Ranking of
CONVERTIBLE NOTES - Ranking of Convertible Notes (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2022 USD ($) | |
January 2025 Notes | |
Debt Instrument [Line Items] | |
Total transaction costs | $ 10,284 |
June 2025 Notes | |
Debt Instrument [Line Items] | |
Total transaction costs | 7,362 |
2027 Convertible notes | |
Debt Instrument [Line Items] | |
Total transaction costs | 14,285 |
2028 Convertible notes | |
Debt Instrument [Line Items] | |
Total transaction costs | $ 24,453 |
CONVERTIBLE NOTES - Schedule _2
CONVERTIBLE NOTES - Schedule of Interest Expense (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended | ||
Feb. 29, 2020 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Debt Instrument [Line Items] | ||||
Debt issuance costs amortization | $ 5,727 | $ 5,727 | $ 5,303 | |
Debt discount amortization | 147 | 147 | 131 | |
Loss on settlement of convertible notes | $ 50,800 | 0 | 0 | 50,819 |
Coupon interest expense | 10,266 | 10,266 | 9,631 | |
Total interest expense on convertible notes | $ 16,140 | $ 16,140 | 65,884 | |
2025 Convertible notes | ||||
Debt Instrument [Line Items] | ||||
Loss on settlement of convertible notes | $ 42,800 | |||
Effective interest rate | 1.18% | 1.18% | 1.20% | |
Convertible debt, remaining discount amortization period | 2 years 14 days | |||
2027 Convertible notes | ||||
Debt Instrument [Line Items] | ||||
Effective interest rate | 0.68% | 0.68% | 0.68% | |
Convertible debt, remaining discount amortization period | 4 years 2 months 15 days | |||
2028 Convertible notes | ||||
Debt Instrument [Line Items] | ||||
Effective interest rate | 0.64% | 0.64% | 0.54% | |
Convertible debt, remaining discount amortization period | 5 years 2 months 1 day |
LICENSE AND COLLABORATION AGR_2
LICENSE AND COLLABORATION AGREEMENTS - Mayo (Details) $ in Thousands | 1 Months Ended | 12 Months Ended | ||
Oct. 31, 2017 USD ($) installment | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
Research and development | $ 393,418 | $ 385,646 | $ 554,052 | |
Licensing Agreements | Mayo | ||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
License fees payable in five annual installments | $ 6,300 | |||
Number of annual installments in which license fees are payable | installment | 5 | |||
Time period after the last licensed patent expires that the license agreement will remain in effect | 5 years | |||
Licensing Agreements | Mayo | Sales Milestone Range One | ||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
Amount agreed to be paid upon reaching the specified amount of net sales | $ 200 | |||
Net sales of a licensed product | 5,000 | |||
Licensing Agreements | Mayo | Sales Milestone Range Two | ||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
Amount agreed to be paid upon reaching the specified amount of net sales | 800 | |||
Net sales of a licensed product | 20,000 | |||
Licensing Agreements | Mayo | Sales Milestone Range Three | ||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
Amount agreed to be paid upon reaching the specified amount of net sales | 2,000 | |||
Net sales of a licensed product | $ 50,000 | |||
Licensing Agreements | Mayo | ||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
Research and development | $ 5,300 | $ 5,000 | $ 3,900 |
LICENSE AND COLLABORATION AGR_3
LICENSE AND COLLABORATION AGREEMENTS - Johns Hopkins University (Details) - Thrive - Licensing Agreements $ in Millions | Jan. 05, 2021 USD ($) |
Sales Milestone Range One | |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |
Payments contingent on milestones | $ 10 |
Net sales of a licensed product | 500 |
Sales Milestone Range Three | |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |
Payments contingent on milestones | 20 |
Net sales of a licensed product | 1,500 |
Sales Milestone Range Two | |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |
Payments contingent on milestones | 15 |
Net sales of a licensed product | $ 1,000 |
PFIZER PROMOTION AGREEMENT (Det
PFIZER PROMOTION AGREEMENT (Details) - Manufactured Product, Other - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Nov. 30, 2021 | |
Pfizer Inc | ||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
Contract termination fee | $ 35.9 | |||
Pfizer Inc | ||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
Service fee based on incremental gross profits over specified baselines and royalties | $ 7.5 | $ 81.3 | $ 51.2 | |
Charges for promotion, sales and marketing | $ 85.8 | $ 121 | $ 85.3 |
STOCKHOLDERS' EQUITY - Stock Is
STOCKHOLDERS' EQUITY - Stock Issued by Acquisition (Details) - USD ($) $ in Millions | 1 Months Ended | |||||||||
Apr. 14, 2021 | Jan. 11, 2021 | Jan. 05, 2021 | May 31, 2022 | Dec. 31, 2021 | Apr. 30, 2021 | Jan. 31, 2021 | Mar. 31, 2020 | May 01, 2022 | Mar. 01, 2021 | |
OmicEra Diagnostics Acquisition | ||||||||||
Changes in Accumulated Other Comprehensive Income (Loss) | ||||||||||
Equity issued to acquire business (in shares) | 265,186 | |||||||||
PreventionGenetics | ||||||||||
Changes in Accumulated Other Comprehensive Income (Loss) | ||||||||||
Equity issued to acquire business (in shares) | 1,070,410 | |||||||||
Fair value of stock issued in acquisition | $ 84.2 | |||||||||
Ashion Analytics | ||||||||||
Changes in Accumulated Other Comprehensive Income (Loss) | ||||||||||
Equity issued to acquire business (in shares) | 125,444 | 100,000 | ||||||||
Fair value of stock issued in acquisition | $ 16.2 | |||||||||
Thrive | ||||||||||
Changes in Accumulated Other Comprehensive Income (Loss) | ||||||||||
Equity issued to acquire business (in shares) | 9,323,266 | 9,300,000 | ||||||||
Fair value of stock issued in acquisition | $ 1,190 | $ 1,190 | ||||||||
TARDIS Technology | ||||||||||
Changes in Accumulated Other Comprehensive Income (Loss) | ||||||||||
Equity issued to acquire business (in shares) | 200,000 | |||||||||
Fair value of stock issued in acquisition | $ 27.3 | |||||||||
Paradigm & Viomics | ||||||||||
Changes in Accumulated Other Comprehensive Income (Loss) | ||||||||||
Equity issued to acquire business (in shares) | 400,000 | |||||||||
Fair value of stock issued in acquisition | $ 28.8 | $ 28.8 | ||||||||
OmicEra | ||||||||||
Changes in Accumulated Other Comprehensive Income (Loss) | ||||||||||
Equity issued to acquire business (in shares) | 300,000 | |||||||||
Fair value of stock issued in acquisition | $ 14.8 |
STOCKHOLDERS' EQUITY - Narrativ
STOCKHOLDERS' EQUITY - Narrative (Details) $ / shares in Units, shares in Millions, $ in Millions | 1 Months Ended |
Oct. 31, 2020 USD ($) $ / shares shares | |
Equity [Abstract] | |
Sale of stock, number of shares issued in transaction (in shares) | shares | 8.6 |
Sale of stock, price per share (in usd per share) | $ / shares | $ 101 |
Sale of stock, consideration received on transaction | $ 861.7 |
Underwriting discount and other stock issuance costs | $ 7.5 |
STOCKHOLDERS' EQUITY - Schedule
STOCKHOLDERS' EQUITY - Schedule of OCI (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | $ 3,387,636 | $ 2,235,553 | $ 1,957,639 |
Other comprehensive income (loss) before reclassifications | (4,019) | (1,625) | 771 |
Amounts reclassified from accumulated other comprehensive loss | 226 | (514) | 25 |
Net current period change in accumulated other comprehensive loss | (3,793) | (2,139) | 796 |
Income tax benefit related to items of other comprehensive loss | 170 | (170) | |
Ending balance | 3,043,162 | 3,387,636 | 2,235,553 |
Accumulated Other Comprehensive Income (Loss) | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | (1,443) | 526 | (100) |
Ending balance | (5,236) | (1,443) | 526 |
Cumulative Translation Adjustment | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | 23 | 0 | (25) |
Other comprehensive income (loss) before reclassifications | 30 | 23 | 0 |
Amounts reclassified from accumulated other comprehensive loss | 0 | 0 | 25 |
Net current period change in accumulated other comprehensive loss | 30 | 23 | 25 |
Income tax benefit related to items of other comprehensive loss | 0 | 0 | |
Ending balance | 53 | 23 | 0 |
Unrealized Gain (Loss) on Securities | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | (1,466) | 526 | (75) |
Other comprehensive income (loss) before reclassifications | (4,049) | (1,648) | 771 |
Amounts reclassified from accumulated other comprehensive loss | 226 | (514) | 0 |
Net current period change in accumulated other comprehensive loss | (3,823) | (2,162) | 771 |
Income tax benefit related to items of other comprehensive loss | 170 | (170) | |
Ending balance | $ (5,289) | $ (1,466) | $ 526 |
STOCKHOLDERS' EQUITY - Schedu_2
STOCKHOLDERS' EQUITY - Schedule of amounts reclassified from AOCI (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Changes in Accumulated Other Comprehensive Income (Loss) | |||
General and administrative | $ (737,304) | $ (801,262) | $ (481,393) |
Total reclassifications | 226 | (514) | 25 |
Reclassification Out Of Accumulated Other Comprehensive Income | Unrealized Gain (Loss) on Securities | |||
Changes in Accumulated Other Comprehensive Income (Loss) | |||
Investment income, net | 226 | (514) | 0 |
Reclassification Out Of Accumulated Other Comprehensive Income | Cumulative Translation Adjustment | |||
Changes in Accumulated Other Comprehensive Income (Loss) | |||
General and administrative | $ 0 | $ 0 | $ 25 |
STOCK-BASED COMPENSATION - Stoc
STOCK-BASED COMPENSATION - Stock-Based Compensation Plans (Details) | 12 Months Ended | 138 Months Ended | |||
Jun. 09, 2022 shares | Jul. 28, 2016 shares | Jul. 24, 2014 shares | Dec. 31, 2022 USD ($) item shares | Dec. 31, 2021 shares | |
Stock-based compensation | |||||
Period by which all options to purchase common stock will accelerate upon an acquisition of the company | 1 year | ||||
Shares outstanding (in shares) | 1,517,876 | 2,284,276 | |||
Shares available for future grant (in shares) | 20,081,905 | ||||
Omnibus Long Term Incentive Plan 2019 | |||||
Stock-based compensation | |||||
Further grants or awards after termination of plan (in shares) | 0 | ||||
Shares available for future grant (in shares) | 17,323,264 | ||||
Increase in number of shares reserved for issuance (in shares) | 14,000,000 | ||||
Omnibus Long Term Incentive Plan 2019 | Minimum | |||||
Stock-based compensation | |||||
Vesting period | 3 years | ||||
Omnibus Long Term Incentive Plan 2019 | Maximum | |||||
Stock-based compensation | |||||
Vesting period | 4 years | ||||
Omnibus Long Term Incentive Plan 2019 | Stock Options | |||||
Stock-based compensation | |||||
Expiration period from the date of grant | 10 years | ||||
Shares outstanding (in shares) | 579,261 | ||||
Omnibus Long Term Incentive Plan 2019 | Restricted Stock | |||||
Stock-based compensation | |||||
Shares outstanding (in shares) | 6,071,725 | ||||
Omnibus Long Term Incentive Plan 2010 | |||||
Stock-based compensation | |||||
Further grants or awards after termination of plan (in shares) | 0 | ||||
Shares available for future grant (in shares) | 0 | ||||
Omnibus Long Term Incentive Plan 2010 | Minimum | |||||
Stock-based compensation | |||||
Vesting period | 3 years | ||||
Omnibus Long Term Incentive Plan 2010 | Maximum | |||||
Stock-based compensation | |||||
Vesting period | 4 years | ||||
Omnibus Long Term Incentive Plan 2010 | Stock Options | |||||
Stock-based compensation | |||||
Expiration period from the date of grant | 10 years | ||||
Shares outstanding (in shares) | 938,615 | ||||
Omnibus Long Term Incentive Plan 2010 | Restricted Stock | |||||
Stock-based compensation | |||||
Shares outstanding (in shares) | 150,830 | ||||
Employee Stock Purchase Plan 2010 | |||||
Stock-based compensation | |||||
Shares available for future grant (in shares) | 2,758,641 | ||||
Increase in number of shares reserved for issuance (in shares) | 3,000,000 | 2,000,000 | 500,000 | ||
Option exercise price, expressed as a percentage of fair market value | 85% | ||||
Maximum value of shares that an employee is permitted to purchase | $ | $ 25,000 | ||||
Number of shares (in shares) | 668,605 | 3,041,359 | |||
Employee Stock Purchase Plan 2010 | Minimum | |||||
Stock-based compensation | |||||
Number of hours per week of customary employment required to participate in the plan | item | 20 | ||||
Number of months of customary employment required to participate in the plan | 5 months | ||||
Percentage of employee's compensation to be deducted from the employee's pay | 1% | ||||
Employee Stock Purchase Plan 2010 | Maximum | |||||
Stock-based compensation | |||||
Percentage of employee's compensation to be deducted from the employee's pay | 15% |
STOCK-BASED COMPENSATION - St_2
STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Stock-based compensation expense | |||
Stock-based compensation expense | $ 206,823 | $ 339,226 | $ 152,906 |
Cost of sales | |||
Stock-based compensation expense | |||
Stock-based compensation expense | 19,218 | 16,835 | 12,852 |
Research and development | |||
Stock-based compensation expense | |||
Stock-based compensation expense | 33,825 | 49,723 | 19,976 |
General and administrative | |||
Stock-based compensation expense | |||
Stock-based compensation expense | 91,212 | 216,952 | 75,999 |
Sales and marketing | |||
Stock-based compensation expense | |||
Stock-based compensation expense | $ 62,568 | $ 55,716 | $ 44,079 |
STOCK-BASED COMPENSATION - St_3
STOCK-BASED COMPENSATION - Stock-Based Compensation Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||
Jan. 05, 2021 | Mar. 31, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Stock-based compensation | |||||
Unrecognized compensation cost | $ 345,500 | ||||
Weighted average period for recognition of unrecognized compensation cost | 2 years 3 months 29 days | ||||
Stock-based compensation | $ 206,823 | $ 253,063 | $ 152,906 | ||
Thrive | |||||
Stock-based compensation | |||||
Stock-based compensation | 19,000 | ||||
Non-cash stock-based compensation expense | $ 65,000 | ||||
Thrive | General and administrative | |||||
Stock-based compensation | |||||
Non-cash stock-based compensation expense | $ 86,200 | $ 86,200 | |||
Stock Options | Thrive | |||||
Stock-based compensation | |||||
Accelerated vesting (in shares) | 139,096 | ||||
Stock Options | Genomic Health Inc | |||||
Stock-based compensation | |||||
Accelerated vesting (in shares) | 83,593 | ||||
Restricted Shares and RSUs | Thrive | |||||
Stock-based compensation | |||||
Accelerated vesting (in shares) | 58,171 | ||||
Restricted Shares and RSUs | Genomic Health Inc | |||||
Stock-based compensation | |||||
Accelerated vesting (in shares) | 93,770 | ||||
Non-cash stock-based compensation expense | $ 9,700 |
STOCK-BASED COMPENSATION - Sche
STOCK-BASED COMPENSATION - Schedule of Fair Value of Options and ESPP (Details) - shares | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Valuation assumptions | |||
Granted (in shares) | 0 | ||
Stock Options | |||
Valuation assumptions | |||
Risk-free interest rates, minimum | 1.26% | ||
Risk-free interest rates, maximum | 1.47% | ||
Expected term (in years) | 6 years 1 month 24 days | ||
Expected volatility, minimum (as a percent) | 65.67% | ||
Expected volatility, maximum (as a percent) | 65.71% | ||
Dividend yield | 0% | ||
Employee Stock | |||
Valuation assumptions | |||
Risk-free interest rates, minimum | 1.49% | 0.04% | 0.11% |
Risk-free interest rates, maximum | 4.71% | 0.16% | 0.20% |
Expected volatility, minimum (as a percent) | 50.94% | 43% | 61.59% |
Expected volatility, maximum (as a percent) | 63.13% | 68.51% | 89% |
Dividend yield | 0% | 0% | 0% |
Minimum | Employee Stock | |||
Valuation assumptions | |||
Expected term (in years) | 6 months | 6 months | 6 months |
Maximum | Employee Stock | |||
Valuation assumptions | |||
Expected term (in years) | 2 years | 2 years | 2 years |
STOCK-BASED COMPENSATION - St_4
STOCK-BASED COMPENSATION - Stock Option, Restricted Stock, and Performance Shares (Details) | 12 Months Ended | ||
Dec. 31, 2022 USD ($) employees $ / shares shares | Dec. 31, 2021 USD ($) $ / shares shares | Dec. 31, 2020 USD ($) $ / shares | |
Shares | |||
Outstanding at the beginning of the period (in shares) | shares | 2,284,276 | ||
Granted (in shares) | shares | 0 | ||
Exercised (in shares) | shares | (706,593) | ||
Forfeited (in shares) | shares | (59,807) | ||
Outstanding at the end of the period (in shares) | shares | 1,517,876 | 2,284,276 | |
Vested and expected to vest (in shares) | shares | 1,517,876 | ||
Exercisable at the end of the period (in shares) | shares | 1,345,998 | ||
Weighted Average Exercise Price | |||
Outstanding at the beginning of the period (in dollars per share) | $ / shares | $ 34.65 | ||
Granted (in dollars per share) | $ / shares | 0 | ||
Exercised (in dollars per share) | $ / shares | 9.27 | ||
Forfeited (in dollars per share) | $ / shares | 78.63 | ||
Outstanding at the end of the period (in dollars per share) | $ / shares | 44.82 | $ 34.65 | |
Vested and expected to vest (in dollars per share) | $ / shares | 44.82 | ||
Exercisable at the end of the period (in dollars per share) | $ / shares | $ 38.69 | ||
Weighted Average Remaining Contractual Term | |||
Outstanding at the end of the period | 4 years 8 months 12 days | 5 years 6 months | |
Vested and expected to vest at end of period | 4 years 8 months 12 days | ||
Exercisable at the end of the period | 4 years 4 months 24 days | ||
Aggregate Intrinsic Value | |||
Outstanding at the end of the period | $ | $ 28,204,000 | ||
Vested and expected to vest at the end of the period | $ | 28,204,000 | ||
Exercisable at the end of the period | $ | 27,932,000 | ||
Additional disclosures | |||
Total intrinsic value of options exercised | $ | 36,400,000 | $ 155,800,000 | $ 40,600,000 |
Proceeds from stock option exercises | $ | $ 6,500,000 | $ 14,400,000 | $ 27,100,000 |
Weighted Average Grant Date Fair Value | |||
Number of employees impacted by change in operational milestones | employees | 36 | ||
Restricted Shares and RSUs | |||
Restricted Shares and Performance Shares | |||
Outstanding at the beginning of the period (in shares) | shares | 4,320,910 | ||
Granted (in shares) | shares | 3,954,761 | ||
Released (in shares) | shares | (1,896,223) | ||
Forfeited (in shares) | shares | (1,124,739) | ||
Outstanding at the end of the period (in shares) | shares | 5,254,709 | 4,320,910 | |
Weighted Average Grant Date Fair Value | |||
Outstanding at the beginning of the period (in dollars per share) | $ / shares | $ 108.84 | ||
Granted (in dollars per share) | $ / shares | 68.18 | $ 129.16 | $ 92.55 |
Released (in dollars per share) | $ / shares | 91.22 | ||
Forfeited (in dollars per share) | $ / shares | 86.89 | ||
Outstanding at the end of the period (in dollars per share) | $ / shares | $ 89.29 | $ 108.84 | |
Fair value of equity instruments other than options | $ | $ 117,600,000 | $ 219,400,000 | $ 152,400,000 |
Performance Shares | |||
Restricted Shares and Performance Shares | |||
Outstanding at the beginning of the period (in shares) | shares | 878,114 | ||
Granted (in shares) | shares | 805,782 | ||
Released (in shares) | shares | (292,134) | ||
Forfeited (in shares) | shares | (423,916) | ||
Outstanding at the end of the period (in shares) | shares | 967,846 | 878,114 | |
Weighted Average Grant Date Fair Value | |||
Outstanding at the beginning of the period (in dollars per share) | $ / shares | $ 107.18 | ||
Granted (in dollars per share) | $ / shares | 89.43 | $ 138.09 | $ 90.17 |
Released (in dollars per share) | $ / shares | 93.22 | ||
Forfeited (in dollars per share) | $ / shares | 92.02 | ||
Outstanding at the end of the period (in dollars per share) | $ / shares | $ 102.58 | $ 107.18 | |
Fair value of equity instruments other than options | $ | $ 27,200,000 | $ 0 | $ 0 |
Number of outstanding performance share units (in shares) | shares | 146,134 | ||
Stock Options | |||
Additional disclosures | |||
Weighted average fair value per share of options granted during the period (in dollars per share) | $ / shares | $ 58.57 |
STOCK-BASED COMPENSATION - Issu
STOCK-BASED COMPENSATION - Issuance of Stock Under ESPP (Details) - Employee Stock Purchase Plan 2010 - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | 138 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | |
Stock-based compensation | ||||
Stock issued under the Company's stock purchase plan (in shares) | 668,605 | 3,041,359 | ||
Employee Stock | ||||
Stock-based compensation | ||||
Stock issued under the Company's stock purchase plan (in shares) | 668,605 | 331,769 | 301,064 | |
Cash received under the 2010 Purchase Plan | $ 25,491 | $ 23,070 | $ 18,355 | |
Weighted average fair value per share of options granted during the period (in dollars per share) | $ 17.52 | $ 34.93 | $ 32.57 |
STOCK-BASED COMPENSATION - Sc_2
STOCK-BASED COMPENSATION - Schedule of Share Issued During Period (Details) - Employee Stock Purchase Plan 2010 - $ / shares | 12 Months Ended | 138 Months Ended | ||
Nov. 01, 2022 | Apr. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | |
Stock-based compensation | ||||
Stock issued under the Company's stock purchase plan (in shares) | 668,605 | 3,041,359 | ||
Offering Period End Date One | ||||
Stock-based compensation | ||||
Stock issued under the Company's stock purchase plan (in shares) | 326,138 | |||
Weighted average price per share (in dollars per share) | $ 47.41 | |||
Offering Period End Date Two | ||||
Stock-based compensation | ||||
Stock issued under the Company's stock purchase plan (in shares) | 342,467 | |||
Weighted average price per share (in dollars per share) | $ 29.33 |
STOCK-BASED COMPENSATION - Shar
STOCK-BASED COMPENSATION - Shares Reserved for Issuance (Details) | Dec. 31, 2022 shares |
Shares reserved for issuance | |
Shares reserved for issuance (in shares) | 20,081,905 |
Employee Stock Purchase Plan 2019 | |
Shares reserved for issuance | |
Shares reserved for issuance (in shares) | 17,323,264 |
Employee Stock Purchase Plan 2010 | |
Shares reserved for issuance | |
Shares reserved for issuance (in shares) | 2,758,641 |
COMMITMENTS AND CONTINGENCIES -
COMMITMENTS AND CONTINGENCIES - Lease Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Finance lease cost | |||
Amortization of right-of-use assets | $ 4,612 | $ 5,731 | $ 1,935 |
Interest on lease liabilities | 808 | 1,018 | 383 |
Operating lease cost | 36,291 | 31,730 | 22,551 |
Short-term lease cost | 476 | 628 | 356 |
Variable lease cost | 7,985 | 5,212 | 2,703 |
Total lease Cost | $ 50,172 | $ 44,319 | $ 27,928 |
COMMITMENTS AND CONTINGENCIES_2
COMMITMENTS AND CONTINGENCIES - Supplemental Disclosure of Cash Flow Information (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Cash paid for amounts included in the measurement of lease liabilities: | |||
Operating cash flows from operating leases | $ 33,448 | $ 27,461 | $ 17,531 |
Operating cash flows from finance leases | 699 | 938 | 381 |
Finance cash flows from finance leases | 4,345 | 5,290 | 1,756 |
Non-cash investing and financing activities: | |||
Right-of-use assets obtained in exchange for new operating lease liabilities | 24,572 | 74,369 | 13,261 |
Right-of-use assets obtained in exchange for new finance lease liabilities | $ 11,276 | $ 5,460 | $ 20,349 |
Weighted-average remaining lease term - operating leases (in years) | 7 years 5 months 4 days | 8 years 3 months 29 days | 8 years 9 months |
Weighted-average remaining lease term - finance leases (in years) | 3 years 3 months 7 days | 2 years 11 months 12 days | 3 years 8 months 4 days |
Weighted-average discount rate - operating leases | 6.37% | 6.11% | 6.80% |
Weighted-average discount rate - finance leases | 6.60% | 5.36% | 5.67% |
ASU 2016-02 | |||
Non-cash investing and financing activities: | |||
Right-of-use assets obtained in exchange for new operating lease liabilities | $ 39,600 |
COMMITMENTS AND CONTINGENCIES_3
COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Jun. 01, 2022 | May 31, 2022 | Dec. 31, 2021 |
Commitments and Contingencies Disclosure [Abstract] | ||||
Recognition of ROU assets | $ 167,003 | $ 8,100 | $ 174,225 | |
Recognition of lease liabilities | 210,765 | $ 8,600 | 201,900 | |
Operating lease liability, current | 28,366 | 19,710 | ||
Operating lease liability, noncurrent | 182,399 | 182,166 | ||
Finance lease, right-of-use asset | $ 10,200 | $ 10,300 | $ 18,200 | |
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] | Other long-term assets, net | Other long-term assets, net | Other long-term assets, net | |
Finance lease obligations | $ 10,579 | $ 10,800 | $ 18,700 | |
Finance lease liability, current | $ 3,200 | $ 6,200 | ||
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] | Other current liabilities | Other current liabilities | ||
Finance lease liability, noncurrent | $ 7,400 | $ 12,500 | ||
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] | Other long-term liabilities | Other long-term liabilities | ||
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] | Other current liabilities, Other long-term liabilities |
COMMITMENTS AND CONTINGENCIES_4
COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Operating Lease Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | Jun. 01, 2022 | Dec. 31, 2021 |
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] | |||
2023 | $ 38,321 | ||
2024 | 39,122 | ||
2025 | 34,952 | ||
2026 | 33,322 | ||
2027 | 32,528 | ||
Thereafter | 89,098 | ||
Total minimum lease payments | 267,343 | ||
Imputed interest | (56,578) | ||
Total | $ 210,765 | $ 8,600 | $ 201,900 |
COMMITMENTS AND CONTINGENCIES_5
COMMITMENTS AND CONTINGENCIES - Schedule of Maturities on Finance Lease Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2022 | May 31, 2022 | Dec. 31, 2021 |
Finance Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] | |||
2023 | $ 3,692 | ||
2024 | 3,632 | ||
2025 | 3,111 | ||
2026 | 1,278 | ||
2027 | 16 | ||
Thereafter | 0 | ||
Total minimum lease payments | 11,729 | ||
Imputed interest | (1,150) | ||
Total | $ 10,579 | $ 10,800 | $ 18,700 |
Legal Matters - COMMITMENTS AND
Legal Matters - COMMITMENTS AND CONTINGENCIES (Details) - DOS Rule Investigation - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2022 | Jun. 30, 2021 | |
Loss Contingencies [Line Items] | ||
Estimated litigation liability | $ 48.2 | |
Loss Contingency, Damages Sought, Value | $ 53.8 | |
Loss contingency accrual | $ 10 |
EMPLOYEE BENEFIT PLAN (Details)
EMPLOYEE BENEFIT PLAN (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Retirement Benefits [Abstract] | |||
Matching contribution by employer | 100% | 100% | 100% |
Percentage of participant's salary matched by employer | 6% | 6% | 6% |
Compensation expense in connection with the 401 (k) Plan | $ 36.5 | $ 30 | $ 22.8 |
WISCONSIN ECONOMIC DEVELOPMEN_2
WISCONSIN ECONOMIC DEVELOPMENT TAX CREDIT (Details) $ in Millions | 1 Months Ended | 12 Months Ended | ||
Dec. 31, 2021 USD ($) position | Feb. 28, 2015 USD ($) position | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Wisconsin Economic Development Tax Credit Agreement | ||||
Agreements | ||||
Refundable tax credits earned | $ 9 | $ 9 | ||
Capital investment expenditures over specified period, requirement to earn the refundable tax credits | $ 26.3 | |||
Full-time positions that must be created over a specified time period to earn the refundable tax credits | position | 758 | |||
Period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed | 7 years | |||
Refundable tax credit received | 9 | |||
Amended Wisconsin Economic Development Tax Credit Agreement | ||||
Agreements | ||||
Refundable tax credits earned | $ 18.5 | 9 | ||
Capital investment expenditures over specified period, requirement to earn the refundable tax credits | $ 350 | $ 350 | ||
Full-time positions that must be created over a specified time period to earn the refundable tax credits | position | 1,300 | |||
Period over which the capital investment expenditures must be incurred and the creation of full-time positions must be completed | 5 years | |||
Credit earning rate | 10% | |||
Maximum credits to earn | $ 7 | |||
Amended Wisconsin Economic Development Tax Credit Agreement | Capital Expenditures | ||||
Agreements | ||||
Amortization of tax credits | 0 | 7 | ||
Amended Wisconsin Economic Development Tax Credit Agreement | Operating Expense | ||||
Agreements | ||||
Amortization of tax credits | 1 | $ 1 | ||
Amended Wisconsin Economic Development Tax Credit Agreement | Prepaid expenses and other current assets | ||||
Agreements | ||||
Refundable tax credit receivable | 5.5 | |||
Amended Wisconsin Economic Development Tax Credit Agreement | Other long-term assets | ||||
Agreements | ||||
Refundable tax credit receivable | $ 3.5 |
BUSINESS COMBINATIONS AND ASS_3
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narrative (Details) | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||||||||||||
Aug. 02, 2022 USD ($) $ / shares shares | May 02, 2022 USD ($) $ / shares | Dec. 31, 2021 USD ($) test $ / shares | Jun. 23, 2021 USD ($) | Apr. 14, 2021 USD ($) $ / shares shares | Jan. 11, 2021 USD ($) shares | Jan. 05, 2021 USD ($) $ / shares shares | Oct. 26, 2020 USD ($) | May 31, 2022 shares | Dec. 31, 2021 USD ($) $ / shares shares | Apr. 30, 2021 USD ($) shares | Jan. 31, 2021 USD ($) shares | Mar. 31, 2020 USD ($) shares | Mar. 31, 2021 USD ($) | Dec. 31, 2022 USD ($) $ / shares | Dec. 31, 2021 USD ($) $ / shares | Dec. 31, 2021 USD ($) $ / shares | Dec. 31, 2020 USD ($) | May 01, 2022 USD ($) | May 03, 2021 | Mar. 01, 2021 USD ($) | |
Acquisition | |||||||||||||||||||||
Shares issued, price per share (in usd per share) | $ / shares | $ 49.51 | ||||||||||||||||||||
Contingent consideration, liability | $ 359,021,000 | $ 359,021,000 | $ 306,927,000 | $ 359,021,000 | $ 359,021,000 | $ 2,477,000 | |||||||||||||||
Stock-based compensation expense | 206,823,000 | 339,226,000 | 152,906,000 | ||||||||||||||||||
Remeasurement of contingent consideration | (56,617,000) | 6,360,000 | (323,000) | ||||||||||||||||||
Stock-based compensation | 206,823,000 | 253,063,000 | 152,906,000 | ||||||||||||||||||
Stock issued during period, value, acquisitions | 14,792,000 | 1,355,170,000 | 28,847,000 | ||||||||||||||||||
Consideration transferred, net of cash acquired | 14,686,000 | 499,730,000 | 6,658,000 | ||||||||||||||||||
Transaction costs | 4,600,000 | ||||||||||||||||||||
Noncash or part noncash divestiture, amount of consideration received, fair value | $ / shares | $ 6.70 | ||||||||||||||||||||
Finite-lived Intangible assets, net | 844,411,000 | 844,411,000 | $ 706,240,000 | 844,411,000 | 844,411,000 | ||||||||||||||||
Period of lab testing services | 24 months | ||||||||||||||||||||
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] | Other operating income (loss) | ||||||||||||||||||||
Payments for (Proceeds from) Productive Assets | $ 416,500,000 | ||||||||||||||||||||
Asset Acquisition, Assets Acquired and Liabilities Assumed, In Process Research and Development | $ 412,600,000 | ||||||||||||||||||||
TARDIS Technology | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Asset acquisition, consideration transferred | $ 52,300,000 | ||||||||||||||||||||
Payments to acquire productive assets | $ 25,000,000 | ||||||||||||||||||||
Payments to acquire productive assets (in shares) | shares | 191,336 | ||||||||||||||||||||
Stock issued to acquire productive assets, value | $ 27,300,000 | ||||||||||||||||||||
TARDIS Technology | Sales Milestone Range One | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Payments contingent on milestones | 10,000,000 | ||||||||||||||||||||
Net sales of a licensed product | $ 100,000,000 | ||||||||||||||||||||
TARDIS Technology | Sales Milestone Range Two | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Payments contingent on milestones | $ 35,000,000 | ||||||||||||||||||||
Net sales of a licensed product | $ 250,000,000 | ||||||||||||||||||||
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Oncotype DX Genomic Prostate Score Test | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Total consideration | $ 29,631,000 | ||||||||||||||||||||
Noncash or part noncash divestiture, amount of consideration received, shares | shares | 691,171 | ||||||||||||||||||||
Disposal group, contingent consideration arrangements, range of outcomes, value, high | $ 70,000,000 | ||||||||||||||||||||
Finite-lived Intangible assets, net | $ 42,900,000 | ||||||||||||||||||||
Disposal group, not discontinued operation, gain (loss) on disposal | $ 13,200,000 | ||||||||||||||||||||
Thrive | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Investment owned, fair value | $ 12,500,000 | ||||||||||||||||||||
Business combination, equity interest in acquiree, remeasurement gain | $ 7,600,000 | ||||||||||||||||||||
Remeasurement of contingent consideration | 7,200,000 | ||||||||||||||||||||
Developed technology | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Finite-lived Intangible assets, net | 741,769,000 | 741,769,000 | 615,948,000 | 741,769,000 | 741,769,000 | ||||||||||||||||
Customer relationships | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Finite-lived Intangible assets, net | 5,123,000 | 5,123,000 | 3,556,000 | 5,123,000 | 5,123,000 | ||||||||||||||||
Trade name | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Finite-lived Intangible assets, net | 91,146,000 | $ 91,146,000 | 83,347,000 | $ 91,146,000 | 91,146,000 | ||||||||||||||||
General and administrative | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Stock-based compensation expense | 91,212,000 | $ 216,952,000 | $ 75,999,000 | ||||||||||||||||||
Investment Income | Thrive | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Business combination, equity interest in acquiree, remeasurement gain | 30,500,000 | ||||||||||||||||||||
OmicEra | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Total purchase price | $ 19,408,000 | ||||||||||||||||||||
Equity issued to acquire business (in shares) | shares | 300,000 | ||||||||||||||||||||
Shares issued, price per share (in usd per share) | $ / shares | $ 55.78 | ||||||||||||||||||||
Contingent payment obligations | $ 6,000,000 | ||||||||||||||||||||
Contingent consideration, liability | 4,600,000 | ||||||||||||||||||||
Developed technology | $ 10,000,000 | ||||||||||||||||||||
Weighted-average remaining useful life of finite-lived intangible asset (in years) | 16 years | ||||||||||||||||||||
Fair value of stock issued in acquisition | $ 14,800,000 | ||||||||||||||||||||
Common stock issued | $ 14,792,000 | ||||||||||||||||||||
OmicEra Diagnostics Acquisition | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Equity issued to acquire business (in shares) | shares | 265,186 | ||||||||||||||||||||
PreventionGenetics | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Total purchase price | $ 185,381,000 | ||||||||||||||||||||
Equity issued to acquire business (in shares) | shares | 1,070,410 | ||||||||||||||||||||
Shares issued, price per share (in usd per share) | $ / shares | $ 78.71 | $ 78.71 | $ 78.71 | $ 78.71 | |||||||||||||||||
Number of tests provided | test | 5,000 | ||||||||||||||||||||
Cash | $ 101,129,000 | ||||||||||||||||||||
Business combination, cash withheld | $ 15,300,000 | ||||||||||||||||||||
Fair value of stock issued in acquisition | 84,200,000 | $ 84,200,000 | $ 84,200,000 | $ 84,200,000 | |||||||||||||||||
Common stock issued | $ 84,252,000 | ||||||||||||||||||||
PreventionGenetics | Developed technology | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Weighted-average remaining useful life of finite-lived intangible asset (in years) | 13 years | ||||||||||||||||||||
Intangible assets | $ 65,000,000 | 65,000,000 | 65,000,000 | 65,000,000 | |||||||||||||||||
PreventionGenetics | Customer relationships | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Weighted-average remaining useful life of finite-lived intangible asset (in years) | 9 years | ||||||||||||||||||||
Intangible assets | $ 4,000,000 | 4,000,000 | 4,000,000 | 4,000,000 | |||||||||||||||||
PreventionGenetics | Trade name | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Weighted-average remaining useful life of finite-lived intangible asset (in years) | 4 years | ||||||||||||||||||||
Intangible assets | $ 4,000,000 | 4,000,000 | 4,000,000 | 4,000,000 | |||||||||||||||||
PreventionGenetics | Payment 1 | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Cash | 85,800,000 | ||||||||||||||||||||
Ashion Analytics | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Total purchase price | $ 109,999,000 | ||||||||||||||||||||
Equity issued to acquire business (in shares) | shares | 125,444 | 100,000 | |||||||||||||||||||
Shares issued, price per share (in usd per share) | $ / shares | $ 129.33 | ||||||||||||||||||||
Weighted-average remaining useful life of finite-lived intangible asset (in years) | 13 years | ||||||||||||||||||||
Cash | $ 74,775,000 | ||||||||||||||||||||
Intangible assets | 39,000,000 | ||||||||||||||||||||
Fair value of stock issued in acquisition | $ 16,200,000 | ||||||||||||||||||||
Common stock issued | 16,224,000 | ||||||||||||||||||||
Ashion Analytics | Commercial Launch Milestone | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Contingent consideration, liability | 19,000,000 | ||||||||||||||||||||
Additional cash consideration to be paid | 20,000,000 | ||||||||||||||||||||
Ashion Analytics | MRD Product Revenue Milestone | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Contingent consideration, liability | 30,000,000 | ||||||||||||||||||||
Revenue milestone | $ 500,000,000 | ||||||||||||||||||||
Thrive | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Total purchase price | $ 2,187,054,000 | ||||||||||||||||||||
Equity issued to acquire business (in shares) | shares | 9,323,266 | 9,300,000 | |||||||||||||||||||
Shares issued, price per share (in usd per share) | $ / shares | $ 127.79 | ||||||||||||||||||||
Contingent consideration, liability | $ 450,000,000 | ||||||||||||||||||||
Cash | 584,996,000 | ||||||||||||||||||||
Fair value of stock issued in acquisition | 1,190,000,000 | $ 1,190,000,000 | |||||||||||||||||||
Common stock issued | 1,175,431,000 | ||||||||||||||||||||
Payments to acquire businesses and accelerated vesting of awards | 590,200,000 | ||||||||||||||||||||
Stock-based compensation expense | 166,000,000 | ||||||||||||||||||||
Compensation consideration assumed | 197,000,000 | ||||||||||||||||||||
Compensation consideration assumed and allocated to consideration transferred | 52,200,000 | ||||||||||||||||||||
Compensation consideration assumed and deemed compensatory | 144,800,000 | ||||||||||||||||||||
Non-cash stock-based compensation expense | 65,000,000 | ||||||||||||||||||||
Share based compensation, costs not yet recognized | $ 79,800,000 | ||||||||||||||||||||
Share conversion ratio | 0.06216 | ||||||||||||||||||||
In-process research and development (IPR&D) | $ 1,250,000,000 | ||||||||||||||||||||
Business combination, pro forma loss | 255,000,000 | ||||||||||||||||||||
Acquisition related costs | 10,300,000 | 10,300,000 | |||||||||||||||||||
Stock-based compensation | 19,000,000 | ||||||||||||||||||||
Additional benefit charges | 3,900,000 | ||||||||||||||||||||
Thrive | Employees with Qualifying Termination Events | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Non-cash stock-based compensation expense | 13,500,000 | ||||||||||||||||||||
Thrive | Fair Value | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Contingent consideration, liability | 352,000,000 | ||||||||||||||||||||
Thrive | FDA Approval | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Contingent consideration, liability | 150,000,000 | ||||||||||||||||||||
Thrive | CSM Coverage | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Contingent consideration, liability | 300,000,000 | ||||||||||||||||||||
Thrive | Allocated to Consideration Transferred | Fair Value | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Contingent consideration, liability | 331,300,000 | ||||||||||||||||||||
Thrive | Allocated to Previous Ownership Interest | Fair Value | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Contingent consideration, liability | 6,400,000 | ||||||||||||||||||||
Thrive | Allocated to Compensation | Fair Value | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Contingent consideration, liability | 14,300,000 | ||||||||||||||||||||
Thrive | Compensation Expense | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Contingent payment obligations | 18,200,000 | ||||||||||||||||||||
Thrive | General and administrative | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Incremental share based compensation expense | 16,000,000 | ||||||||||||||||||||
Stock-based compensation expense | $ 5,200,000 | ||||||||||||||||||||
Non-cash stock-based compensation expense | $ 86,200,000 | 86,200,000 | |||||||||||||||||||
Paradigm & Viomics | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Total purchase price | $ 40,400,000 | ||||||||||||||||||||
Equity issued to acquire business (in shares) | shares | 400,000 | ||||||||||||||||||||
Fair value of stock issued in acquisition | $ 28,800,000 | $ 28,800,000 | |||||||||||||||||||
Stock issued during period, value, acquisitions | 32,200,000 | ||||||||||||||||||||
Consideration transferred, net of cash acquired | $ 8,200,000 | ||||||||||||||||||||
Amount of shares held for future issuance | $ 3,400,000 | $ 3,400,000 | $ 3,400,000 | $ 3,400,000 | |||||||||||||||||
PFS Genomics | |||||||||||||||||||||
Acquisition | |||||||||||||||||||||
Total purchase price | $ 33,569,000 | ||||||||||||||||||||
Intangible assets | $ 33,074,000 | ||||||||||||||||||||
Percent of equity acquired | 10% | 90% | |||||||||||||||||||
Equity interest in acquiree after subsequent acquisition | 100% |
BUSINESS COMBINATIONS AND ASS_4
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Details of Consideration Transferred (Details) - USD ($) | May 02, 2022 | Dec. 31, 2021 | Apr. 14, 2021 | Jan. 05, 2021 |
OmicEra | ||||
Acquisition | ||||
Common stock issued | $ 14,792,000 | |||
Contingent consideration | 4,600,000 | |||
Cash paid related to working capital adjustment | 16,000 | |||
Total purchase price | $ 19,408,000 | |||
PreventionGenetics | ||||
Acquisition | ||||
Common stock issued | $ 84,252,000 | |||
Cash | 101,129,000 | |||
Total purchase price | $ 185,381,000 | |||
Ashion Analytics | ||||
Acquisition | ||||
Common stock issued | $ 16,224,000 | |||
Contingent consideration | 19,000,000 | |||
Cash | 74,775,000 | |||
Total purchase price | $ 109,999,000 | |||
Thrive | ||||
Acquisition | ||||
Common stock issued | $ 1,175,431,000 | |||
Contingent consideration | 331,348,000 | |||
Cash | 584,996,000 | |||
Total purchase price | 2,187,054,000 | |||
Fair value of replaced equity awards | 52,245,000 | |||
Previously held equity investment fair value | $ 43,034,000 |
BUSINESS COMBINATIONS AND ASS_5
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Purchase Price Allocated to the Underlying Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands | May 02, 2022 | Dec. 31, 2021 | Jun. 23, 2021 | Apr. 14, 2021 | Jan. 05, 2021 | Dec. 31, 2022 | Dec. 31, 2020 |
Acquisition | |||||||
Goodwill | $ 2,335,172 | $ 2,346,040 | $ 1,237,672 | ||||
OmicEra | |||||||
Acquisition | |||||||
Net operating assets | $ 2,586 | ||||||
Developed technology | 10,000 | ||||||
Total identifiable assets acquired | 12,586 | ||||||
Net identifiable assets acquired | 8,599 | ||||||
Goodwill | 10,809 | ||||||
Net assets acquired | 19,408 | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | (3,987) | ||||||
Total purchase price | $ 19,408 | ||||||
PreventionGenetics | |||||||
Acquisition | |||||||
Total identifiable assets acquired | 95,422 | ||||||
Net identifiable assets acquired | 92,802 | ||||||
Goodwill | 92,579 | ||||||
Net assets acquired | 185,381 | ||||||
Cash and cash equivalents | 1,574 | ||||||
Accounts receivable | 6,328 | ||||||
Inventory | 1,697 | ||||||
Prepaid expenses and other current assets | 30 | ||||||
Property, plant and equipment | 12,793 | ||||||
Accounts payable | (1,628) | ||||||
Accrued liabilities | (992) | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | (2,620) | ||||||
Total purchase price | 185,381 | ||||||
PreventionGenetics | Developed technology | |||||||
Acquisition | |||||||
Intangible assets | 65,000 | ||||||
PreventionGenetics | Customer relationships | |||||||
Acquisition | |||||||
Intangible assets | 4,000 | ||||||
PreventionGenetics | Trade name | |||||||
Acquisition | |||||||
Intangible assets | $ 4,000 | ||||||
Ashion Analytics | |||||||
Acquisition | |||||||
Total identifiable assets acquired | $ 56,554 | ||||||
Net identifiable assets acquired | 53,241 | ||||||
Goodwill | 56,758 | ||||||
Net assets acquired | 109,999 | ||||||
Cash and cash equivalents | 2,474 | ||||||
Accounts receivable | 2,349 | ||||||
Inventory | 1,811 | ||||||
Prepaid expenses and other current assets | 425 | ||||||
Property, plant and equipment | 9,947 | ||||||
Intangible assets | 39,000 | ||||||
Accounts payable | (1,477) | ||||||
Accrued liabilities | (1,190) | ||||||
Operating lease right-of-use assets | 548 | ||||||
Operating lease liabilities, current portion | (343) | ||||||
Other current liabilities | (98) | ||||||
Operating lease liabilities, less current portion | (205) | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | (3,313) | ||||||
Total purchase price | $ 109,999 | ||||||
Thrive | |||||||
Acquisition | |||||||
Total identifiable assets acquired | $ 1,564,758 | ||||||
Net identifiable assets acquired | 1,238,949 | ||||||
Goodwill | 948,105 | ||||||
Net assets acquired | 2,187,054 | ||||||
Cash and cash equivalents | 241,748 | ||||||
Prepaid expenses and other current assets | 3,939 | ||||||
Property, plant and equipment | 29,977 | ||||||
Accounts payable | (3,222) | ||||||
Accrued liabilities | (8,080) | ||||||
Operating lease right-of-use assets | 39,027 | ||||||
Operating lease liabilities, current portion | (2,980) | ||||||
Operating lease liabilities, less current portion | (38,622) | ||||||
Other long-term assets | 67 | ||||||
In-process research and development (IPR&D) | 1,250,000 | ||||||
Deferred tax liability | (272,905) | ||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | (325,809) | ||||||
Total purchase price | $ 2,187,054 | ||||||
PFS Genomics | |||||||
Acquisition | |||||||
Net identifiable assets acquired | $ 33,569 | ||||||
Cash and cash equivalents | 496 | ||||||
Intangible assets | 33,074 | ||||||
Total purchase price | 33,569 | ||||||
Other assets and liabilities | $ (1) |
BUSINESS COMBINATIONS AND ASS_6
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details) - Options - Thrive | Jan. 05, 2021 $ / shares |
Acquisition | |
Risk-free interest rates, minimum | 0.11% |
Risk-free interest rates, maximum | 0.12% |
Expected volatility, minimum (as a percent) | 65.54% |
Expected volatility, maximum (as a percent) | 71% |
Dividend yield | 0% |
Minimum | |
Acquisition | |
Expected term (in years) | 1 year 3 months 3 days |
Weighted average fair value per share of options granted during the period (in dollars per share) | $ 109.74 |
Maximum | |
Acquisition | |
Expected term (in years) | 1 year 6 months 25 days |
Weighted average fair value per share of options granted during the period (in dollars per share) | $ 124.89 |
BUSINESS COMBINATIONS AND ASS_7
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Business Combination, Pro-Forma Information (Details) - Thrive - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Acquisition | ||
Total revenues | $ 1,767,087 | $ 1,491,391 |
Net loss before tax | $ (761,337) | $ (1,014,352) |
BUSINESS COMBINATIONS AND ASS_8
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Divestiture (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations - Oncotype DX Genomic Prostate Score Test $ in Thousands | Aug. 02, 2022 USD ($) |
Noncash or Part Noncash Divestitures [Line Items] | |
Cash | $ 25,000 |
MDxHealth American Depository Shares | 4,631 |
Contingent consideration | 0 |
Total consideration | $ 29,631 |
SEGMENT INFORMATION (Details)
SEGMENT INFORMATION (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Segment Reporting Information [Line Items] | |||
Revenue | $ 2,084,279 | $ 1,767,087 | $ 1,491,391 |
United States | |||
Segment Reporting Information [Line Items] | |||
Revenue | 1,966,541 | 1,657,174 | 1,413,907 |
Outside of United States | |||
Segment Reporting Information [Line Items] | |||
Revenue | $ 117,738 | $ 109,913 | $ 77,484 |
INCOME TAXES - Narrative (Detai
INCOME TAXES - Narrative (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Operating Loss Carryforwards [Line Items] | |||
Income tax benefit | $ 9,064,000 | $ 246,881,000 | $ 5,458,000 |
Deferred tax asset valuation allowance | 419,356,000 | 262,238,000 | |
Deferred tax liability | 19,713,000 | 28,782,000 | |
Increase (decrease) in valuation allowance | $ 157,100,000 | $ (31,200,000) | |
Effective tax rate | 1.30% | 29.30% | 0.60% |
Unrecognized tax benefit that would impact effective tax rate | $ 28,300,000 | $ 21,800,000 | $ 16,600,000 |
Accrued interest or penalties | 0 | 0 | 0 |
Recognized interest or penalties | 0 | 0 | 0 |
Deferred tax asset | |||
Operating Loss Carryforwards [Line Items] | |||
Valuation allowances established | 159,919,000 | 206,574,000 | 94,589,000 |
Acquisition and purchase accounting | 21,000 | 239,233,000 | (5,558,000) |
Deferred tax asset | Thrive | |||
Operating Loss Carryforwards [Line Items] | |||
Acquisition and purchase accounting | 239,200,000 | ||
Deferred tax asset | Genomic Health Inc | |||
Operating Loss Carryforwards [Line Items] | |||
Acquisition and purchase accounting | $ 239,200,000 | $ (5,600,000) | |
Federal | |||
Operating Loss Carryforwards [Line Items] | |||
Operating loss carryforwards | 475,200,000 | ||
Operating loss carryforwards with no expiration date | 300,200,000 | ||
Operating loss carryforwards with expiration date | 175,000,000 | ||
Federal | Research | |||
Operating Loss Carryforwards [Line Items] | |||
Tax credit carryforwards | 59,200,000 | ||
State | |||
Operating Loss Carryforwards [Line Items] | |||
Operating loss carryforwards | 70,900,000 | ||
State | Research | |||
Operating Loss Carryforwards [Line Items] | |||
Tax credit carryforwards | 27,800,000 | ||
State | Research | California | |||
Operating Loss Carryforwards [Line Items] | |||
Tax credit carryforwards | 16,800,000 | ||
Foreign | |||
Operating Loss Carryforwards [Line Items] | |||
Operating loss carryforwards | $ 7,200,000 |
INCOME TAXES - Income (Loss) Be
INCOME TAXES - Income (Loss) Before Income Taxes, Domestic and Foreign (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |||
Domestic | $ (617,240) | $ (801,536) | $ (423,025) |
Foreign | (15,330) | (40,970) | (406,038) |
Net loss before tax | $ (632,570) | $ (842,506) | $ (829,063) |
INCOME TAXES - Additional Infor
INCOME TAXES - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Expense (benefit) for income taxes | |||
Total income tax expense (benefit) | $ (9,064) | $ (246,881) | $ (5,458) |
Deferred tax assets: | |||
Operating loss carryforwards | 553,320 | 516,344 | |
Tax credit carryforwards | 87,579 | 72,959 | |
Compensation related differences | 67,976 | 74,127 | |
Lease liabilities | 51,560 | 48,201 | |
Capitalized research and development | 108,117 | 23,035 | |
Other temporary differences | 19,353 | 20,087 | |
Tax assets before valuation allowance | 887,905 | 754,753 | |
Less - Valuation allowance | (419,356) | (262,238) | |
Total deferred tax assets | 468,549 | 492,515 | |
Deferred tax liabilities | |||
Amortization | (435,991) | (464,748) | |
Property, plant and equipment | (4,653) | (4,756) | |
Lease assets | (40,674) | (45,781) | |
Other temporary differences | (6,944) | (6,012) | |
Total deferred tax liabilities | (488,262) | (521,297) | |
Net deferred tax liabilities | $ (19,713) | $ (28,782) | |
Differences between the effective income tax rate and the statutory tax rate | |||
U.S. Federal statutory rate | 21% | 21% | 21% |
State taxes | 3.90% | 3.60% | 1.70% |
Federal and state tax rate changes | (0.20%) | (0.30%) | 0% |
Foreign tax rate differential | (0.10%) | (0.60%) | (1.00%) |
Acquired IPR&D asset expense | 0% | (0.80%) | (9.40%) |
Research and development tax credits | 2.30% | 0.70% | 1.60% |
Stock-based compensation expense | (2.00%) | 1.10% | 1.10% |
Non-deductible executive compensation | (0.40%) | (0.20%) | (0.80%) |
Transaction costs | 0% | (0.10%) | (0.10%) |
Other adjustments | 1.20% | 1.20% | (2.20%) |
Valuation allowance | (24.40%) | 3.70% | (11.30%) |
Effective tax rate | 1.30% | 29.30% | 0.60% |
Reconciliation of the amounts of unrecognized tax benefits | |||
Beginning of the period | $ 21,780 | $ 16,629 | $ 10,276 |
Increase due to current year tax positions | 5,861 | 5,363 | 3,600 |
Increase due to prior year tax positions | 629 | 0 | 2,753 |
Decrease due to prior year tax positions | 0 | (212) | 0 |
Settlements | 0 | 0 | 0 |
Ending of the period | 28,270 | 21,780 | 16,629 |
Federal | |||
Expense (benefit) for income taxes | |||
Current expense (benefit): | 0 | 0 | (3) |
Deferred tax expense (benefit): | (3,292) | (222,693) | (3,050) |
State | |||
Expense (benefit) for income taxes | |||
Current expense (benefit): | 2,170 | 1,388 | 802 |
Deferred tax expense (benefit): | (8,926) | (30,528) | (4,260) |
Foreign | |||
Expense (benefit) for income taxes | |||
Current expense (benefit): | 1,131 | 4,898 | 933 |
Deferred tax expense (benefit): | $ (147) | $ 54 | $ 120 |
INCOME TAXES - Deferred Tax Ass
INCOME TAXES - Deferred Tax Asset, Valuation Allowance RollForward (Details) - Deferred tax asset - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] | |||
Beginning balance | $ (262,238) | $ (293,397) | $ (195,401) |
Valuation allowances established | (159,919) | (206,574) | (94,589) |
Changes to existing valuation allowances | 2,780 | (1,500) | 2,151 |
Acquisition and purchase accounting | 21 | 239,233 | (5,558) |
Ending balance | $ (419,356) | $ (262,238) | $ (293,397) |